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The cost of bringing a drug to market is astounding and the failure rate is intimidating. 
Drug discovery has been of limited success under the conventional reductionist model of one-
drug-one-gene-one-disease paradigm, where a single disease-associated gene is identified and a 
molecular binder to the specific target is subsequently designed. Under the simplistic paradigm of 
drug discovery, a drug molecule is assumed to interact only with the intended on-target. However, 
small molecular drugs often interact with multiple targets, and those off-target interactions are not 
considered under the conventional paradigm. As a result, drug-induced side effects and adverse 
reactions are often neglected until a very late stage of the drug discovery, where the discovery of 
drug-induced side effects and potential drug resistance can decrease the value of the drug and even 
completely invalidate the use of the drug. Thus, a new paradigm in drug discovery is needed.  
Structural systems pharmacology is a new paradigm in drug discovery that the drug 
activities are studied by data-driven large-scale models with considerations of the structures and 
drugs. Structural systems pharmacology will model, on a genome scale, the energetic and dynamic 
modifications of protein targets by drug molecules as well as the subsequent collective effects of 
drug-target interactions on the phenotypic drug responses. To date, however, few experimental 
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and computational methods can determine genome-wide protein-ligand interaction networks and 
the clinical outcomes mediated by them. As a result, the majority of proteins have not been charted 
for their small molecular ligands; we have a limited understanding of drug actions.  To address the 
challenge, this dissertation seeks to develop and experimentally validate innovative computational 
methods to infer genome-wide protein-ligand interactions and multi-scale drug-phenotype 
associations, including drug-induced side effects. The hypothesis is that the integration of data-
driven bioinformatics tools with structure-and-mechanism-based molecular modeling methods 
will lead to an optimal tool for accurately predicting drug actions and drug associated phenotypic 
responses, such as side effects.  
This dissertation starts by reviewing the current status of computational drug discovery for 
complex diseases in Chapter 1. In Chapter 2, we present REMAP, a one-class collaborative 
filtering method to predict off-target interactions from protein-ligand interaction network. In our 
later work, REMAP was integrated with structural genomics and statistical machine learning 
methods to design a dual-indication polypharmacological anticancer therapy. In Chapter 3, we 
extend REMAP, the core method in Chapter 2, into a multi-ranked collaborative filtering 
algorithm, WINTF, and present relevant mathematical justifications. Chapter 4 is an application 
of WINTF to repurpose an FDA-approved drug diazoxide as a potential treatment for triple 
negative breast cancer, a deadly subtype of breast cancer. In Chapter 5, we present a multilayer 
extension of REMAP, applied to predict drug-induced side effects and the associated biological 
pathways. In Chapter 6, we close this dissertation by presenting a deep learning application to 
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The 2018 Nobel Prize in Physiology or Medicine was awarded to two researchers for their 
revolutionary discovery of proteins that inhibit immune responses to cancers [1]. Although the 
discovery of the checkpoint proteins initiated the development of targeted immunotherapies, 
critical challenges remain to be addressed [2]. Limitations have been well known for 
chemotherapies, where cytotoxic compounds are administered to directly kill tumor cells and slow 
the progression of cancers [3]. Targeted therapies, where drug molecules interfere with tumor-
specific molecular abnormalities also has been actively studied for over half a century and used in 
parallel with other types of anticancer therapies. Although advancements in our understanding of 
cancer biology and the treatment options have made some types of cancers manageable, challenges 
remain in all types of anticancer therapies. First, the efficacy of treatment is often limited to a 
minor group of patients, leaving an important, but difficult task to stratify patients prior to 
treatment [4]. Moreover, many anticancer drugs, including both immunotherapeutic and other 
targeted therapeutic agents cause serious side effects [5-7]. Biological complexity makes it even 
more difficult to identify the targets that are critical for cancer development and progression due 
to natural redundancy and diversity in biological network, such as feedback mechanisms, which 
enhance robustness of phenotypical outcomes against perturbations. Multidrug resistance develops 
over time, making the tumors immortal against the previously effective treatments [8-10]. Better 
therapeutic options are needed to battle against and eventually conquer cancers. 
Despite the urgent need, drug discovery is a time-consuming and costly process with low 
success rate. A variety of risk factors delay new drugs entering the market and increase the chance 
of withdrawal, increasing the overall cost of drug development [11]. Drug-induced side effects and 
toxicity are one of the key issues relevant to the high rate of drug attrition [12]. The limited success 
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of drug development suggests flaws in the long-standing paradigm: one-drug-one-target-one-
disease, where the goal is to design a molecule that inhibits a biological target (e.g. protein) known 
to be crucial for the disease. Under the paradigm, drug candidate molecules are optimized to 
interact with the intended target (on-target), without proactively understanding off-target 
interactions and leaving safety and toxicity tests to the later stage of pipeline. Off-target 
interactions, most of time unexpected, may cause undesirable outcomes, even fatal ones in extreme 
cases, leaving irreparable damages to the business and patients [13]. On the other hand, the 
treatment of complex diseases may benefit from off-target interactions if both on- and off-target 
synergistically reverse the pathological processes. Indeed, it is now known that many approved 
drugs interact with more than one biological targets [14, 15], and the importance of understanding 
the complex biological interactions for such multitargeting drug molecules is emphasized as a new 
paradigm of drug discovery, polypharmacology [15, 16]. Instead of suffering from unexpected 
outcomes caused by off-target interactions, polypharmacology is an attempt to understand drug 
actions as results of multiple different interactions involving the drug molecule and maximize the 
benefit from the interactions. Indeed, the superiority of multitargeting drugs over highly selective 
single-target drugs is suggested [15]. Under the new paradigm, off-target interactions of existing 
drugs can be used to repurpose them for new indications. Protein-ligand interaction profiles for 
new ligands can be computationally predicted, and the chemical scaffolds active for multiple 
targets of interest can be integrated into a single molecule to maximize therapeutic effects and 
minimize adverse events [17]. New discoveries in biological studies reveal previously unattended 
anticancer targets, and new drugs can be designed to play multiple roles in the biological network 
[18, 19]. Therefore, early understanding of drug-target interaction profile across whole genome 
space is essential for development of new, more effective and safer drugs. However, our 
 4 
knowledge of intermolecular interactions drug molecules cause is limited. It is prohibitive to 
experimentally evaluate all possible drug interactions. Drugs and drug candidate molecules are 
typically screened against a subset of potential biological targets, resulting in biased, noisy, sparse, 
and incomplete interaction profiles. At present, no experimental techniques are affordable and 




Figure 1.1 Illustration of a general workflow for computational protein-ligand interaction 
prediction projects  
*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press) 
 
Although not scalable yet to the whole human genome space, high-throughput 
experimental methods have produced tremendous amount of compound bioactivity data, providing 
rich resources for data-driven knowledge discovery. To rapidly and systematically explore the data 
and discover hidden knowledge, various types of computational methods have been developed and 
applied to predict potential interactions of drug molecules. Among many classes of computational 
methods applicable for drug discovery, those specifically designed to predict unknown protein-
ligand interactions are particularly suitable to fill in the sparse knowledge in bioactivity. This 
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chapter aims to discuss the recent advancements in machine learning methods for the prediction 
of protein ligand interactions as well as the efforts to collect and curate experimental data. 
Although many different computational methods have been developed to fight against various 
diseases, we focus in this chapter on the methods that are at least partially relevant to the 
development of anticancer therapies. While some methods directly aim to discover new anticancer 
therapies, other methods also provide opportunities to discover anticancer therapies when 
appropriate data sets and validation steps are incorporated. Also, the strategies and methodologies 
introduced in this chapter can be applied to important diseases other than cancers with appropriate 
data preparation and evaluation strategies.  We try to guide readers who are interested in computer-
aided drug discovery by providing information about collecting data, preprocessing the data, and 
methods that can take the preprocessed data for inference. We discuss the major sources of 
biopharmaceutical databases that are frequently used to train and evaluate computational methods. 
Throughout this chapter, different types of computational approaches to predict intermolecular 
interactions are discussed with examples, including the main methods that we present in later 
chapters. Figure 1.1 illustrates a general workflow for computational protein-ligand interaction 
prediction projects. 
It should be emphasized that drug action is a complex process. The genome-wide protein-
ligand interaction alone may be insufficient to predict clinical end-points, such as therapeutic 
efficacies and side effects. A systems biology approach is needed to model the collective behavior 
of biomolecular interactions (e.g. DNA, RNAD, protein, metabolite, drug, etc.), which is beyond 
the scope of this dissertation. Interested readers are referred to other publications [20-25]. 
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Table 1.1 Commonly used databases for artificial intelligence-based drug discovery projects 
 










ZINC [27] Large-scale compound library, compound 3D structures ready for docking https://zinc.docking.org 
ChEMBL [28] Continuous-valued bioactivities, large-scale bioassays from publications https://www.ebi.ac.uk/chembl 
PubChem [29] Large-scale compound library with activities https://pubchem.ncbi.nlm.nih.gov 
BindingDB [30] Continuous-valued bioactivities with focus on potential drug targets 
https://www.bindingdb.org/bind/inde
x.jsp 
LINCS [31] Kinase-specific bioactivities https://lincs.hms.harvard.edu 
STITCH [32] Protein-ligand and ligand-ligand interaction data, including predicted activities http://stitch.embl.de 
BioGRID [33] Protein-ligand and protein-protein interaction data from publications https://thebiogrid.org 
SIDER [34] Drug-induced side effect data http://sideeffects.embl.de 
KEGG [35] Bioactivity and biological pathway data https://www.genome.jp/kegg/kegg1.html 
DrugBank [36] Drug-protein interactions for approved and investigational drugs https://www.drugbank.ca 
ExCAPE-DB [37] Example of systematic data integration https://doi.org/10.5281/zenodo.2543724 
MUV [43] Example of systematic data split https://omictools.com/muv-tool 







UniProt [38] Primary amino acid sequences and functional domain information https://www.uniprot.org 
PDB [39] Largest existing protein 3D structure database to date https://www.rcsb.org 
Pfam [40] Curated protein families with sequence homology https://pfam.xfam.org/ 
STRING [41] Protein-protein interaction with functional annotations, including predictions https://string-db.org 
The Human Protein 
Atlas [42] 
Human protein classifications based on functions and 
phenotypes 
https://www.proteinatlas.org 
Harmonizome [43] Multiple categories of data relevant to genes, proteins, cell lines, and pathways 
http://amp.pharm.mssm.edu/Harmoni
zome 
*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press) 
1.2 Open-access databases for computational drug discovery projects 
High-quality and large-scale compound activity data (e.g. protein-ligand binding affinity) 
are indispensable in artificial intelligence and machine learning-based drug development projects. 
To train a computational prediction method, often called a computational model, known protein-
ligand associations are preprocessed in the way the model can take. Many publicly available 
databases curating experimentally measured protein-ligand interactions can be used for such 
purposes. The protein-ligand pairs are numerically represented using techniques called molecular 
fingerprints, which is discussed below. The model is trained and evaluated on the numerically 
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preprocessed data sets. Therefore, it is critical to appropriately choose and utilize the databases. 
Databases that provide compound bioactivity data or proteomic information are especially useful 
for protein-ligand interaction prediction projects. While they are roughly divided into bioactivity-
centric and proteomic databases, many current databases are actively maintained and updated to 
integrate data from multiple sources, providing more rich and comprehensive data sets. Also, 
biological network data can be integrated into computational models to help better prediction. The 
following sections are to describe some of the commonly used bioactivity and proteomic databases 
for artificial intelligence-based drug discovery projects (Table 1.1). Other types of large-scale 
omics data include genomics, transcriptomics, metabolomics and biological pathway information, 
and relevant databases are discussed elsewhere [26]. 
Bioactivity-centric databases 
Bioactivity-centric databases provide rich resources for protein-ligand interaction data, 
which can be used as the known protein-ligand association for computational models. While these 
provide large-scale data sets, the interaction profiles are incomplete, and computational models 
are used to partially complete the empty space in the profiles. The databases introduced here are 
not comprehensive, but these are frequently updated to maintain the state-of-the-art quality and 
quantity. The bioactivity data that these provide may overlap, so special care is necessary when 
integrating them for a large-scale project. We introduce a few bioactivity centric databases in the 
next paragraph. 
ZINC is a free database of commercially available compounds, especially suitable for 
virtual screening projects [27]. As of this writing, it contains over 700 million purchasable 
compounds, among which over 200 million are available for 3D structures, which is essential for 
structure-based projects, such as protein-ligand docking. ChEMBL, a part of the European 
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Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI), is a publicly 
available database of bioactivities from multiple sources [28]. ChEMBL database (version 27) 
contains approximately 16 million bioactivity values from more than 1.2 million assays, covering 
over 1.9 million unique compounds and 13000 proteins. While major sources of its bioactivity 
samples are from over 76000 scientific publications, it also contains samples from both nonprofit 
and commercial organizations deposited data sets. PubChem, a chemical information database at 
the U.S. National Center for Biotechnology Information, contains about 250 million bioactivities 
for over 200 million substances and 17000 protein targets from over 30 million publications and 3 
million patents [29]. BindingDB contains over 1.7 million protein-ligand binding affinities, which 
mainly focuses on small, drug-like molecules and potential druggable target proteins [30]. The 
Library of Integrated Network-based Cellular Signatures (LINCS) is a database of cell-based 
perturbation-response signatures, which contains data samples for small molecules, cells, genes, 
and proteins categorized by the assay types [31]. STITCH is a protein-ligand interaction database 
containing over 400000 chemicals and their interacting protein targets [32]. Its protein-ligand 
interaction data contains computationally predicted samples as well as samples from other 
databases. BioGRID contains protein and genetic interactions as well as chemical interactions with 
post-translational modification information [33]. SIDER, which is also a part of EMBL, is a 
database containing known drug-side effect associations [34]. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) contains a large-spectrum biochemical and biomedical data sets, including 
protein-ligand interactions for approved drugs, gene-biological pathway associations, and 
biomolecular functions named KEGG Orthology [35]. DrugBank provides rich resources for 
approved and investigational drugs with their known associations with protein targets [36]. 
DrugBank is also a great resource for drug-drug interactions. ExCAPE-DB is a relatively new 
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database providing open-access to the integrated bioactivies from ChEMBL and PubChem [37]. 
While its contents are from existing databases, ExCAPE-DB provides a unified set of samples 
from the databases with appropriate, reproducible data integration steps. 
Proteomic databases 
UniProt is a large-scale database as a part of EMBL-EBI, containing over 120 million 
proteins across all branches of life, with their primary sequences [38]. RCSB Protein Data Bank 
(RCSB PDB, PDB) is a database containing 3D structures of biomolecules, including proteins and 
protein-ligand complexes [39]. Pfam is a database of curated protein families, which contains over 
18,000 families, each of which contains up to 676,776 protein sequences with homology search 
information [40].  STRING database allows researchers to connect these proteins to build a large-
scale protein-protein interaction network [41]. The Human Protein Atlas project aims to map all 
human proteins in cells, tissues, and organs using various experimental and computational 
techniques, which provides category information for genes and proteins based on their functions, 
compartments, and relevant diseases and drugs [42]. Harmonizome contains data sets for genes 
and proteins with their associations with other biomolecules, expressions in cells and tissues, and 
knockout phenotypes [43]. Harmonizome is a collection of data sets from multiple sources, so 
users may also obtain other types of data sets according to the design of the project. 
1.3 Data preparation for training and evaluating computational models 
Data preparation 
The databases described above are rich data sources regarding chemical compound 
structures, properties and their biomolecular activities with relevant target information. The 
differences and variety of data sets make it an important step to prepare samples appropriately for 
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the artificial intelligence and machine learning-based drug discovery projects. It often gives too 
optimistic results when a computational model is trained on one database and evaluated another 
without properly integrating multiple data sources, due to suboptimal coverage or overlapping 
samples. The above-mentioned databases are updated on a regular basis to maintain the quality 
and coverage as new samples become available. As a result, databases of similar kinds often 
present samples from the same sources, making parts of database overlapping each other. 
Therefore, a care is necessary when integrating multiple databases into a single data set. ExCAPE-
DB presents an example for integrating and quality-filtering steps for bioactivity databases [37]. 
Once databases are integrated, a proper data split strategy must be used to separate samples for 
training and evaluating the model. It is essential to split a data set into training and evaluation sets 
so that the samples in evaluation set has never been used to train the model. While a commonly 
used procedure is to integrate multiple data sets with quality-filters and to randomly split into 
training and evaluation sets, the random split is too simplistic, especially when there are many of 
distinct, but highly similar compounds or targets in the integrated data set. Many samples in 
evaluation set will have highly similar compounds or targets to those in training set, and they will 
still be considered unique, non-overlapping samples. 
A better approach is to consider properties of entities in the samples when splitting a data 
set. For instance, when molecular structural similarity scores are available for chemical molecules, 
it is possible to set a similarity threshold such that the maximum similarity between a molecule in 
training set and a molecule in evaluation set is below the threshold. This strategy can enhance the 
computational model in that the model better generalizes over larger spectrum of molecular 
structures and prevent overfitting. Maximum Unbiased Validation (MUV) [44] and Directory of 
Useful Decoys-Enhanced (DUD-E) [45] are two important data splitting schemes applied to 
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provide well-prepared data sets for computational drug discovery projects. MUV was designed to 
overcome artificial enrichment and analogue bias, two major biases in virtual screening data sets. 
Artificial enrichment is the bias when some simple molecular properties, such as molecular weight, 
separates the active and inactive compounds. Computational models suffer from analogue bias 
when they are trained with data sets having some sub-structures overrepresented in the active sets. 
A computational model well-trained on such data sets is likely to make biased predictions based 
on the simple molecular features or overrepresented substructures. DUD-E adopts similar idea to 
the two biases while it focuses on protein-ligand pairs with 3D structures available, making it 
especially useful for virtual docking or structure-based models. The two data sets, however, are 
not perfect for all kinds of projects. MUV excludes frequent hitters, the compounds that are active 
in most tested assays, making it less suitable for projects where the aim is to predict all unknown 
associations for drugs. DUD-E samples include activities for non-human homologs and exclude 
targets with mutations, making it be subjective to species-specific or mutant-specific activities. 
Furthermore, despite the efforts, DUD-E samples are still not free from the biases as shown in a 
recent study regarding 3D structure-based protein-ligand binding prediction methods [46]. Both 
data sets are relatively small as well, partly because of the developed date and the structural 
coverage. As a result, the data sets and split strategies are often study-specific, and performances 
may be provided on these data sets for comparison. A gold-standard data set for artificial 
intelligence and machine learning-based protein-ligand association projects is needed. 
Performance evaluation 
Performance evaluation is an essential step during a computational modeling of drug 
activities. Classification models output discrete values (e.g. binding/nonbinding, or stages of 
cancer), whereas regression models output continuous values (e.g. strength of protein-ligand 
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binding as pKd). As they have different predictive tasks, different metrics are used to evaluate the 
models. A simple classification metric is accuracy, where the count of correct predictions is 
divided by the count of total predictions. It is called zero-one-loss for binary classification tasks 
(e.g. true/false). Especially when the classes are unbalanced, it is easy for a model to reach high 
accuracy without capturing meaningful pattern in samples. For example, if there are 95 negative 
samples out of 100 samples, a meaningless all-negative prediction model can reach 95% accuracy. 
Other frequently used classification metrics are based on the confusion matrix, which is defined 
as an 𝑛 × 𝑛 matrix C, where Ci,j is the number of observations known to be in the class i, but 
predicted to be class j. For binary classification tasks, the diagonal elements of the confusion 
matrix are true positives (TP) and true negatives (TN) while the off-diagonal elements are false 
positives (FP) and false negatives (FN), where the names stand for the correctness and predicted 
labels. For example, TN is the number of observations correctly predicted as negative. FP is for 
observations wrongly predicted as positive (i.e. known to be negatives but predicted positive). 
Precision and recall are the ratio of TP to all predicted positives and all known positives, 
respectively, and the harmonic mean of the two is called F1 score. When the model output is a 
probability value of an observation being positive and hence a predefined threshold 𝛼 is used (i.e. 
prediction is positive only if probability ≥ 𝛼), the ratio values can be a function of probability 
threshold. As 𝛼 increases, more predictions are treated as positives, gradually increasing FP. Area 
Under Receiver Operating Characteristic curve (AUROC) measures how early a model reaches 
high TP while maintaining low FP by plotting TP versus FP with gradually increasing 𝛼 [47]. An 
ideal AUROC value is 1.0 while AUROC of 0.5 means random prediction in balanced cases. 
Precision and recall can also be plotted with increasing 𝛼. It is called Area Under Precision-Recall 
curve (AUPR).  
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Regression metrics evaluate how close or consistent the predicted values are to the true 
values. Two simple regression metrics are mean squared error (MSE) and mean absolute error 
(MAE), where the differences between predictions and labels are averaged after squared or 
unsigned. Prediction consistency is often evaluated by correlation coefficients, where higher 
coefficients are obtained if higher (or lower) observation is consistently predicted to be higher (or 
lower). Correlation coefficient values range from -1 to 1, from perfect anti-correlation to perfect 
correlation. Although it is ideal to use a model that performs better in all metrics, it is common 
that a model is better only in certain metrics. Thus, one or more performance metrics of interest 
that are more important to the given problem should be defined for projects. For example, 
correlation coefficients may provide better evaluation scores if the goal is to prioritize ligands with 
high potential. Nevertheless, no one metric is a perfect measure for model performances in all 
cases. Thus, it is common and highly recommended to present and compare multiple performance 
metrics together. 
1.4 Representation of molecules for a computational drug discovery project 
Machine learning and artificial intelligence methods, including deep learning methods, 
take numerical inputs. Thus, molecules, such as small molecular compounds and protein targets 
must be represented as numeric vectors or tensors to be used as inputs. Since the inputs are the 
information passed to the computational models, they should be meaningful, not just arbitrary or 
sequential numbers. Many different approaches have been proposed to numerically represent the 
molecules. The methods to numerically represent biochemical molecules are often called 
molecular fingerprints or descriptors, and the numerical representations may be used to train 
computational models or calculate similarity scores (or distances) between molecules. 
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Chemical molecular fingerprints 
Chemical molecular fingerprints are a class of methods that capture some information – 
commonly the atom types, bond types, topological distances and chemical substructures – about 
the input molecules. Atom pair descriptor [48] and topological torsion descriptor [49] are both 
molecular fingerprint methods developed early in 1980s. While both of them take atom types, 
heavy atom neighbors, and 𝜋-electrons to numerically represent molecules, they differ in that atom 
pair descriptor takes topological distances (e.g. how many bonds are in the shortest path between 
two atoms) while topological torsion descriptor does not. 2D-pharmacophore fingerprint [50] is 
another method that takes the topological distances in addition to the appearance of the 9 
predefined classes of pharmacophores (e.g. hydrogen bond donor, halogen atoms, etc.). While 
these fingerprint methods consider some atomic points in a molecule to form graphs connecting 
them, Extended Connectivity Fingerprint (ECFP) [51] is another method that focuses on the 
appearance of substructures. ECFP is often used in two different versions; count vectors which 
counts the appearances of substructures, and hashed bits with ‘1’s for appeared substructures and 
‘0’s for the rest. While 3D fingerprint methods exist, little to no benefit over ECFP is reported in 
virtual screening experiments [52]. Thus, ECFP has often been used to numerically represent small 
molecules. Many software tools exist for these conventional fingerprinting techniques, including 
a few open-source tools, such as PaDEL descriptor [53], OpenBabel [54], and RDKit [55]. Users 
can choose appropriate methods for their use cases. 
Despite the extensive studies, there is no one consensus for the best molecular 
representation technique for all computational drug discovery projects. Ligand-based virtual 
screening studies suggest that the best-performing molecular fingerprint is dependent on the 
method and data [56-59]. Moreover, the conventional fingerprints introduced above are very 
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sparse, containing mostly zeros, wasting the computational resources. It is also known that 
although with very low probability, bit collision may occur, where two different substructures are 
represented as the same bit information. Importantly, they are “not learnable” from the given tasks. 
In other words, the vector representation of a molecule will always be the same and are not adjusted 
during model training. Thus, ongoing efforts are to develop innovative, novel, yet systematic and 
efficient descriptors that are learnable and adjustable to the tasks. Several newer molecular 
fingerprint techniques have been developed using more advanced artificial intelligence algorithms. 
Mol2vec is a natural language processing (NLP)-based approach to represent small 
molecular ligands into vectors of continuous values, overcoming the sparsity and bit collision 
issues [60]. Ligands are first represented as an ordered list of small substructures, like a sentence 
of words in NLP, which are fed into the word2vec model [61]. Word2vec is known to preserve the 
semantic similarity of the input words, which is also the case in mol2vec. In other words, the 
outputs of two similar ligands are closer than those of less similar ones. The output vectors can 
then be used to train downstream tasks, such as molecular property prediction or protein-ligand 
interaction prediction. Molecular dynamics fingerprint is a 3D-structure-based descriptor of small 
molecules [62]. Molecular dynamics fingerprint, as the name suggests, describes the statistics of 
biophysical molecular properties, such as free energy, from simulations of the molecules in various 
solvent environment. This information-rich molecular descriptor can be combined with other 
molecular descriptors to predict the behaviors of molecules. Neural molecular fingerprint (NeuMF) 
method is one of the newest chemical molecular fingerprint techniques that uses convolutional 
neural network (CNN) to represent small molecules [63]. NeuMF considers a molecule as a graph 
of atoms and substructures that are connected by varying degree of topological distances. Then, 
fully. Connected linear layers are applied to a set of atoms or substructures having certain degree 
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of connectivity. NeuMF is technically similar to ECFP as they both split a molecule into a set of 
substructures comprising it according to the topological distances. The weights for NeuMF are, 
however, tuned particularly for the given tasks (e.g. solubility prediction, or binding affinity 
prediction), and the output vectors contain continuous values, instead of binary digits. Coley et al. 
demonstrated that incorporation of additional atomic and molecular features to the NeuMF can 
improve the performance in molecular property prediction tasks [64]. It is noted that although these 
newer fingerprinting techniques alleviate aforementioned issues, stereochemistry is mostly 
ignored. To date, only a limited number of ligands have known 3D conformation linked to 
activities and readily available in databases. While there are ways to obtain the lowest-energy 
conformers, the lowest-energy conformation may be different from the conformation when the 
ligands are in action (e.g. binding to a target protein). Also, a novel algorithm that learns accurate 
representation from 3D graph is needed. 
Representation of protein sequences and structures 
Representing proteins as numeric vectors is often a critical step in data-driven drug activity 
modeling. Proteins are in general, however, larger and more complex than drug molecules: they 
are polymers of amino acids forming distinct folds and structures to perform biochemical activities. 
As a result, there are many ways to represent proteins at different scales and depth from whole 
primary sequence composition to more complex 3D interactions among atoms within binding 
pockets. Simple protein descriptors can be built based on the composition of amino acids. For 
example, how many times a particular amino acid appears in a protein can be counted and used as 
a descriptor for the protein. In the same way, the appearance of doublets or triplets of amino acids 
may be counted, which increases the complexity of the descriptor. These composition-based 
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descriptors are however too simplistic to capture different properties of amino acids or positional 
dependencies. 
Physicochemical properties of amino acids have been studied, recorded, and continuously 
refined as more data and techniques become available [65, 66]. Such physicochemical properties 
are called amino acid index, which have been utilized to design various protein descriptors. For 
instance, conjoint triad descriptor is a type of the composition-based descriptor for amino acid 
triplets [67]. It categorizes amino acids into 7 distinct classes based on polarity and volume, which 
reduces the dimension of the descriptor as well as takes some physicochemical properties into 
account. Moreau-Broto autocorrelation descriptor is the average of the product of a selected amino 
acid index between the 𝑖!" and (𝑖 + 𝑑)!" amino acids along the sequence, where 𝑑 is called the 
lag of the autocorrelation [68]. Other variants of the autocorrelation descriptor can be obtained by 
using another type of descriptive statistics or amino acid index. Scale-based protein descriptors are 
a class of statistical methods that attempt to capture the variability of amino acid features. A 
pioneering effort in the scale-based descriptors was to use a large number of physicochemical 
properties of the 20 natural amino acid and compress the features by principal component analysis 
[69]. Further efforts to improve the quality of scale-based descriptors have been made by adjusting 
the number of amino acid properties and/or including unnatural amino acids [70-72]. Various kinds 
of these protein descriptors are available [73]. 
Two key properties are desired for an efficient protein descriptor for computational drug 
discovery projects: position-dependency and long-range dependency. An amino acid may play 
completely different roles in terms of biomolecular activities when its environment is changed, 
and two sequentially distant amino acids may closely interact with each other to render important 
functions (e.g. binding pocket). While the lag of autocorrelation partially accounts for the long-
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range dependency, it does not differentiate the amino acids that do interact from the rest. Moreover, 
above mentioned methods consider little, if any, about the positional differences. Profile-based 
descriptor is a position-dependent protein descriptor based on multiple sequence alignment [74]. 
Such a descriptor uses the observed and expected frequencies of amino acids at particular positions 
of aligned sequences, which instead focuses less on the long-range dependency. A recent 
advancement in natural language processing methods provide new opportunities to design protein 
descriptors that account for both of the important dependencies. Based on the successful natural 
language processing model, Bidirectional Encoder Representations from Transformers (BERT) 
[75], Rives et al. showed that the model can learn biochemical properties of amino acids and 
proteins, such as charge, size, secondary structures, and residue-residue contacts [76]. Briefly, a 
large amount of protein sequence data from UniProt [38] is used to train the BERT model in a self-
supervised manner (i.e. some amino acids are hidden and the task is to predict the hidden ones) 
without preprocessing the sequences. This step is called pre-training of BERT, which is followed 
by fine-tuning steps with labeled data, such as protein family prediction, binding site prediction, 
using the BERT-calculated protein vectors as descriptors. The BERT-based protein descriptor is 
position-dependent and captures long-range dependency by design. BERT uses positional 
embedding that differentiates the representation of a word by its position. The long-range 
dependency is captured by one of the key components of BERT, the self-attention mechanism, 
which aligns the input embedding vectors by their impacts on each output embedding [77]. One 
drawback of BERT is the computational cost for training. A recent development of a light version 
of BERT, called ALBERT, attempts to significantly reduce the computational costs by improving 
the efficiency of parameters in BERT without compromising performance [78]. Computational 
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costs can also be alleviated by using more powerful devices or down-sampling the input data by 
preprocessing (e.g. multiple sequence alignment and sequence identity-based clustering). 
1.5 Computational methods for protein-ligand interaction prediction 
In this chapter, we divide computational protein-ligand interaction prediction methods into 
four categories: ligand-based, structure-based, network-based, and deep learning-based methods 
(Table 1.2). Please note that many deep learning-based methods can also be regarded as one of the 
other three categories. Ligand-based methods rely on the assumption that the differences in 
chemical molecular structures can explain their different bioactivities. Small molecular 
compounds are numerically represented using molecular fingerprint techniques, and the 
fingerprint vectors are mathematically compared to other compounds having known protein targets. 
The closer the two fingerprint vectors are, the more likely that they share the same target proteins. 
Though sounds simple, many ligand-based methods show high predictive performances, 
suggesting that the assumption is indeed valuable. However, limitations exist. They cannot explain 
the activity cliff [79], and their performances are suboptimal for novel molecules. Structure-based 
methods, also called protein-ligand docking methods, take structural information for both proteins 
and ligands and can partially overcome the drawbacks. The physicochemical interactions between 
atoms comprising the ligands and the binding pockets of proteins are calculated, and the predefined 
energy functions are used to score the protein-ligand pairs of interest. While they can provide 
detailed pictures of how the given pair of molecules may interact, they suffer from high false 
positives. Also, high computational burden makes them inappropriate for screening protein-ligand 
interactions at a large scale. In network-based methods, protein-ligand interactions are treated as a 
bipartite graph where nodes are proteins and ligands, and edges are known protein-ligand 
associations. Nodes and edges may possess attributes, representing the characteristics of the 
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molecules or interactions. The missing edges (e.g. unknown interactions) are predicted using 
various kinds of mathematical models. Network-based methods often enjoy high scalability due to 
the design of the models. However, they. Rely on high-level features (e.g. only a few numbers 
representing a whole protein target) to represent the network, limiting their accuracy and 
interpretability. Deep learning-based methods use artificial neural networks to replace the 
mathematical models used in the methods of other kinds. With the great success and explosive 
interest in deep learning, artificial neural networks, such as convolutional neural network have 
been applied to computational protein-ligand interaction predictions. Deep learning-based 
fingerprints introduced above can be used to represent molecules. The flexibility of deep learning 
architectures makes the number of possible models virtually infinite, and larger and more complex 
models are being developed. The field of deep learning is fast-evolving in both its software and 
hardware, continuously improving the performances on various tasks. While they enjoy the 
greatest flexibility and high performances, their interpretability has been criticized due to the 
“black-box” nature of complex artificial neural networks. Deep learning-based methods can also 
be classified into the other categories listed above. 
Table 1.2. Strengths and weaknesses of protein-ligand interaction prediction methods 
 
Method type Strength Weakness 
Ligand-based 
Computational cost is generally low, high 
performance on some well-studied 
targets, simple to implement 
Lack of high-resolution details in predicted 
interaction, performance limited for 
screening against targets with many known 
ligands 
Structure-based 
High-resolution details can be obtained, 
can make predictions for new targets 
(with structure available) 
High computational cost, scalability also 
limited by structural coverage, often suffer 
from high false positive 
Network-based 
Systematically integrates knowledge from 
large amount of data across multiple 
aspects (multi-omics)  
Lack of high-resolution details, scalability 
depends on core algorithms and data 
requirement, comparing performances of 
multiple methods is not trivial 
Deep learning-
based 
Often achieve higher performance 
compared to other types of methods, 
model flexibility to integrate assumptions 
from multiple types of methods 
Computational cost is usually high, low 
interpretability of models, require large 
amount of data to train models 
*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press) 
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Ligand-based virtual screening 
A traditional assumption in ligand-based virtual screening is that ligands that are similar to 
each other are more likely to share common targets. For a given target protein, if a query ligand 
turns out to be very similar to a known active ligand, it is likely that the query ligand will also be 
active. A systematic approach of this is to decide the numerical representation of ligands (e.g. 
molecular fingerprints), define a similarity metric (e.g. Tanimoto coefficient or cosine distance), 
and evaluate the pairwise ligand similarity scores for each query ligand against each known 
active/inactive ligand. Then, the predicted protein-ligand interaction for the query ligand can be 
made simply based on the nearest neighbors [59] or based on the statistical significance of the 
similarity [56, 58]. It was shown that with proper measurement, a set of weak ligand similarities 
(with statistical significance) may be an indication of common target. Moreover, the similarities 
between ligand pairs contain information relevant to the target proteins [56, 80]. Due to the 
underlying assumption in the ligand-based virtual screening, however, an adequate number of 
known active/inactive ligands must be provided for each target protein. This makes ligand-based 
virtual screening inappropriate for cases where insufficient amount of data is available. For 
instance, a suboptimal performance is expected if predictions are made for novel mutant target 
proteins, where the known active/inactive ligands are available only for the wild-type proteins. An 
approach taking advantage of more detailed target features, such as physicochemical interactions 
in 3D space, should be considered in such cases. 
Riniker et al. performed an extensive comparison of 12 commonly used molecular 
fingerprints on DUD, MUV and ChEMBL data sets [59]. For each test compound, its similarity 
score to all active molecules in training set were measured. The maximum similarity scores for 
each test compound are then used to rank them, and the efficiency of each fingerprint is evaluated 
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using the rank. Circular fingerprints performed better when evaluated by early recognition metrics, 
whereas path-based fingerprints were better for AUC. It was also found that the performance varies 
more cross-target-same-fingerprint than the cross-fingerprint-same-target evaluations.  
A popular method in ligand-based virtual screening is Similarity Ensemble Approach, 
(SEA) which applies statistical tests on top of the fingerprint-based pairwise ligand similarity 
search methods to rank the target proteins [56]. In SEA, each target protein is represented as a set 
of its known active ligands. For each query ligand, similarity to the known actives for each target 
are calculated, and the sum of the similarity scores above certain threshold are summed to derive 
raw scores for the query ligand-target protein association. The raw scores are then statistically 
evaluated against randomly populated set of ligands, and the statistical significance is used to rank 
the target proteins. In a later study, it was shown that the performance can be improved by using 
multiple SEA models, each with different types of fingerprints and by preparing for target-specific 
data sets (e.g. kinase dataset) [57]. 
The SEA method is important in a few aspects. First, it uses all active ligands for a given 
target, instead of closest neighbors. The high performance of this method suggests that a set of 
weak similarities may indicate significant overall relatedness. Koutsoukas et al. proposed a 
probabilistic machine learning model, Parzen-Rosenblaat Window (PRW) method with similar 
ideas [81]. Each target protein is represented as a set of ECFP fingerprint features for the active 
ligands, and the probability of the query ligand being active is obtained by comparing how many 
of the fingerprint features they share. In other words, a target protein is a bag of fingerprint bits 
from its active ligands, and the query ligand may have many of the bits-in-bag if it is active. Second, 
the similarity scores are statistically tested against randomly populated set of ligands, instead of 
simply using the best similarity scores. Awale et al. measured pairwise ligand similarity scores 
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based on multiple types of fingerprints, and the statistical significance of the distances between 
query and the closest neighbor in the active ligands for a target protein is used to rank the target 
proteins [58]. 
Lauria et al. developed DRUDIT, a ligand-based drug discovery tool that is freely 
accessible via web service [82]. Similar to an earlier work by Riniker et al. [59], ligands are 
represented as chemical molecular descriptor vectors, which are then used to build templates for 
target proteins. Here the chemical descriptors contain not only the presence/absence of certain 
substructures but also some other physicochemical properties, such as the autocorrelation values. 
The target template represents the distribution of each descriptor from the active ligands. The input 
ligand’s descriptors are then compared to the target template, where the score is higher if the input 
ligand’s descriptor values are within a small range of the target template distribution. DRUDIT is 
strictly based on the ligand property and the known protein-ligand associations, and the easy-to-
use web service (www.drudit.com) is freely available at the time of writing this review. Such a 
user-friendly service of computational drug discovery tool is rare and valuable. 
Yang et al. used extreme gradient boost to predict the inhibition strength of compounds 
against JAK2. The authors collected active and inactive compounds for JAK2 from PubChem, 
BindingDB, and ZINC databases. Molecular fingerprints for the compounds were calculated using 
RDKit and fed into extreme gradient boost classification and regression models. It was shown that 
models using ECFP4 performed consistently better, and the extreme gradient boost classification 
model performed better than virtual docking methods in terms of early enrichment of active 
compounds [83].  
Sadawi et al. reported that their multi-task regression algorithm outperformed the single-
task counterpart, and incorporation of evolutionary distances among protein targets further 
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improved the performances in majority of the tasks [84]. In the multi-task regression method, each 
target protein is a task, where the protein-ligand affinity data with IC50 measurements were 
obtained from ChEMBL. Using 1024-bit pharmacophore fingerprint (FCFP) as ligand 
representation, Random Forest regressor was used as the baseline single-task method, and two 
types of multi-task methods, namely feature-based and instance-based methods were compared. 
In feature-based multi-task method, FCFP was used to represent ligand, and the target proteins are 
simply grouped by their family hierarchy manually curated by ChEMBL, forming multi-task data 
sets for related tasks. In addition to the feature-based method, instance-based method takes the 
target-target similarity profile as an additional input, where the similarity scores are based on 
amino acid sequence similarity. While the single-task baseline method has a flaw in that it does 
not include any target features, the study clearly showed that the target-target similarity scores help 
improve the predictive performances, i.e. instance-based performed better than feature-based 
multi-task method. It is important to note that in the study, the evaluation data set contained same 
targets that were appeared in the training set. 
Ligand 3D feature-based virtual screening 
The limited success of ligand-based virtual screening may be partially attributed to the 
abstraction of chemical molecular features that cannot fully represent 3D structures of molecules. 
Therefore, virtual screening methods that utilize ligand 3D features have been studied to more 
accurately predict protein-ligand interactions. For the additional details in molecular representation, 
ligand 3D feature-based methods may provide more accurate predictions but may also suffer from 
higher computational costs. The requirement of ligand 3D structure also limits the scalability of 
models to chemical space. 
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Grisoni et al. used ligand 3D features, such as partial charges and 3D shape of compounds 
to select a handful of ligands that are likely to show similar interaction profile to (-)-galantamine, 
a natural product approved for Alzheimer’s Disease [85]. Potential target proteins for these 
selected ligands were predicted and some of them were experimentally validated. Although the 
proposed target is not cancer, it is a computational approach to discover multitarget drugs.  
Hernandez et al. developed a 3D graph-based molecular similarity search method, which 
performed better than conventional fingerprints for classifying active ligands in DUD-E data set 
[86]. The ligand molecules are represented as a graph of atoms and ring structures containing 
physical and pharmacophore features as node attributes. Then, maximum common substructures 
for pair of ligands were heuristically calculated to obtain ligand-ligand similarity scores. The 
similarity scores are then used to rank ligands in DUD-E data sets to classify active and inactive 
ligands and the early enrichment performances were generally higher than the conventional 
fingerprint-based methods. While the gain of performances in early enrichment is noticeable, the 
proposed 3D graph-based method did not outperform ECFP for all target classes. This may be due 
to that there are many ligands without known 3D conformation specific to the binding targets. As 
done in this study, the available standard conformers need to be used for the algorithm, which may 
not correctly represent the binding poses of the ligands. In cases where the ligands of interest are 
topologically similar but showing different activities, requiring high-resolution comparisons, such 
a 3D structure-based method can be more accurate than the 2D topology-based fingerprints. 
Fan et al. proposed DStruBTarget, a ligand-based virtual screening method that utilizes 2D 
and 3D ligand information as well as protein-ligand binding affinity information [87]. In 
DStrubTarget, the prediction scores are calculated by finding a reference ligand that maximizes a 
combination of three values: 2D similarity between query and reference ligands, 3D similarity, 
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and scaled binding affinity between the reference ligand and the target of interest. The evaluation 
demonstrated that incorporation of 3D similarity scores is helpful to improve the predictive 
performances. 
Structure-based virtual screening 
Structure-based virtual screening methods are a class of methods that uses 3D structures of 
the ligands and target proteins as input. Using the physicochemical properties of the 3D structures, 
the alignment between proteins and ligands are searched and scored. To date, molecular docking 
simulation methods are actively developed and applied to predict protein-ligand binding activities. 
Molecular docking simulation methods are frequently used to search for such binding poses by 
optimizing method-specific scoring functions. Scoring functions are metrics evaluating the 
protein-ligand docking poses based on physicochemical interactions (force field), statistics of atom 
pairs from known protein-ligand interactions, or some other types of variables designed to 
correlate with known binding affinities [88]. A usual workflow in studies based on molecular 
docking simulation is first to find the 3D structures for the ligands and targets of interest, where 
ligands often outnumbers the targets. Using the structures as input, various molecular docking 
simulation approaches can be used to rank the ligands against each target with favorable (e.g. low-
energy) protein-ligand binding complexes. Some of high-ranked binding complexes are obtained 
and filtered (e.g. discarding molecules predicted to interact with too many targets). Eventually, a 
handful of protein-ligand pairs are considered candidates and may be evaluated in vivo or in vitro 
for experimental validation of predicted activities [89, 90]. A number of user-friendly graphic 
interfaces are available for molecular docking experiments, including AutoDock [91], UCSF Dock 
[92], MTiOpenScreen [93], HADDOCK [94], and SwissDock [95]. 
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While traditional molecular docking experiments aim to screen a large library of ligands 
against a few particular targets of interest, inverse docking methods aim to screen a few ligands of 
interest against a large number of target proteins and therefore is “target-fishing.” Inverse docking 
is a useful scheme when a ligand with unknown targets is known for certain phenotypes. A 
potential target of a known tumor growth inhibitor was suggested by using an inverse docking 
method [96]. A general inverse docking approach was presented for multitargeting antibacterial 
drug design [97]. Recently, Wang et al. proposed a consensus inverse docking model by utilizing 
multiple different docking methods to predict consensus docking conformations [98]. It is 
available for web access (http://chemyang.ccnu.edu.cn/ccb/server/ACID/).  
One of the key strengths of molecular docking methods is that the simulated protein-ligand 
complexes can be used to provide atom-level insights on how the binding occurs, generating 
hypotheses about the mechanism of action. For this reason, molecular docking methods can be 
used as a supplementary method for other classes of methods to enhance the predictions by 
providing finer-resolution view of the interactions [85, 99, 100]. However, due to the requirement 
of 3D structures and atom-level detailed computations, molecular docking methods suffer from 
computational cost and relatively low scalability. Thus, to date, such methods alone cannot fully 
exploit the abundance of archived data from high-throughput biochemical and biomedical 
experiments. When appropriate, other 3D structural features with lower resolution may be used to 
reduce the computational costs and thus increase scalability of the model [101]. More details of 
the strengths and drawbacks of molecular docking methods can be found in the reference [88].  
Network-based virtual screening 
In network-based virtual screening methods, protein-ligand interactions are viewed as a 
network, where proteins and ligands are nodes, and protein-ligand associations are edges 
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connecting the nodes. A protein-ligand association network can be represented as an m-by-n 
rectangular matrix, where m and n are the number of unique proteins and ligands. In the matrix 
form, typically ‘1’ indicates known protein-ligand associations and ‘0’ indicates unknown ones, 
thereby representing the adjacency (or connectivity) between one type of nodes to another. While 
many databases can be integrated to build a large-scale protein-ligand association network, the 
protein-ligand adjacency matrix is usually sparse, noisy, biased, and incomplete. Due to the 
incomplete coverage of experiments, many interacting protein-ligand pairs have not been 
evaluated and thus are hidden in the ocean of ‘0’s in the adjacency matrix. Thus, the aim of many 
network-based virtual screening methods is to predict the hidden associations based on the known 
information. For example, the missing links between proteins and ligands can be predicted by 
evaluating the degree of shared neighbors within the protein-ligand interaction network [102]. 
Without using any other information than known protein-ligand associations, the assumption here 
is similar to that of ligand-based methods: similar nodes (in terms of shared neighbors) are likely 
to interact. 
As drug activities, including protein-ligand interactions happen within a complex and 
heterogeneous biological environment, many biological features are frequently used to help the 
protein-ligand interaction prediction, and the capability to utilize such side information is one of 
the key strengths of network-based methods. To be compatible with protein-ligand interaction data, 
side information may also be encoded in the form of adjacency matrix or similarity matrix. For 
example, drug-induced side effects may be in an n-by-s matrix, where n and s are the number of 
unique drugs and side effects, respectively. When a network consists of multiple types of nodes 
(e.g. proteins, ligands, diseases, side effects in one network), it is called heterogeneous network, 
where special treatments are often required to integrate and process the network for prediction. 
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Also, similarities between nodes of same type can be measured and used as features, such as 
ligand-ligand similarity or protein-protein similarity. Within a network, the groups of nodes of 
same type are often referred as layers (e.g. ligand layer is a group of ligands in the network), edges 
connecting nodes of same type are intra-layer (or within-layer) edges, and edges connecting nodes 
of different types are inter-layer (or cross-layer) edges. The following examples are heterogeneous 
network-based protein-ligand interaction prediction methods.  
BANDIT utilizes multiple biochemical and biomedical properties of compounds to identify 
target proteins of an orphan ligand [80]. BANDIT takes ligand chemical structure, gene expression 
profile upon chemical perturbation, cellular growth inhibition profile, drug-induced side effects, 
and other types of biochemical assay results to compare large number of ligands. Each pair of 
ligands are represented as a set of similarity scores, where each score is based on the 
aforementioned ligand properties. Then, a Bayesian statistic model is used to calculate the 
likelihood that two ligands share a target protein given the pieces of evidence. Using BANDIT, 
the researchers were able to predict the target protein of ONC201, an anticancer compound in 
clinical development whose biological target and mechanisms remained unknown. In addition to 
high performance and utility in clinical development, the performance of BANDIT suggests that 
it is beneficial to integrate multiple types of large-scale data sets to predict protein-ligand 
interactions. While the prediction procedure – that is to compare ligands based on their properties 
and shared targets are assumed for similar ligands – is similar to that of many ligand-based virtual 
screening methods introduced above, BANDIT is also capable of separating drugs based on their 
mechanisms of action, demonstrating its unique strength as a network-based method.  
Chu et al. developed DTI-CDF, a network-based machine learning model that uses network 
representation of protein-ligand associations with intra-layer similarity information to predict 
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unknown drug-target associations [103]. In DTI-CDF, protein-protein and ligand-ligand similarity 
scores are used to train different numbers of Random Forest [104] and XGBoost [105] models 
stacked multiple times to make final predictions. For each stack of the models, the input contains 
the multiple types of similarity information. From the second stack, the output from previous stack 
is additionally used as input. The model architecture resembles that of residual network, a popular 
CNN architecture that has been very successful in image recognition. DTI-CDF, however, is 
trained and evaluated only on KEGG data set [35], which contains a small subset of proteins and 
ligands, thus limiting the generalizability of the method to a larger protein-ligand space. 
Luo et al. developed a computational framework to repurpose drugs by integrating 
heterogeneous network of drugs, diseases, side effects, and target proteins [106]. The 
heterogeneous network consists of both cross-layer (drug-protein, drug-side effect, drug-disease, 
and protein-disease associations) and within-layer (drug-drug interactions, drug-drug similarities, 
protein-protein interactions, and protein-protein similarities) edges, and Random Walk with 
Restart (RWR) [107], a popular network propagation method was used to extract the feature 
vectors for each nodes. A feature reduction technique was used to compress the size of the node 
vectors, and the drug vectors are projected to the target protein space, such that the projection 
approximates the known drug-protein interaction matrix. The method identified three drugs as 
potential cyclooxygenase inhibitors, and experimental validation confirmed the inhibitory 
activities of the drugs. The potential binding modes of the drugs were also predicted using a 
molecular docking simulation method. 
Utilizing a convenient feature of adjacency matrices, Fu et al. attempted to computationally 
parse through the pathways that link proteins with ligands [108]. They first built more than 50 
different semantic network relationships represented by commuting matrices – a kind of adjacency 
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matrix representing the number of length-n pathways between nodes – from adjacency matrices of 
ligands, ligand substructures, side effects, diseases, protein targets, protein functional annotations, 
and biological pathways. The commuting matrices can be obtained by matrix multiplication of 
adjacency matrices. For example, if matrix A and B represent protein-ligand and ligand-disease 
associations, the matrix dot product of A and B (i.e. A∙B) represents the number of unique 
pathways connecting proteins and diseases after one intermediate ligand node. The commuting 
matrices represent the meta-paths between proteins and ligands, which are used to train Random 
Forest and Support Vector Machine models to predict binary protein-ligand associations. While 
the report did not include a repositioning of drugs, the high performance suggests that the 
incorporation of heterogeneous biological data sets is beneficial for computational predictions.  
Notably, the ‘0’s in protein-ligand interaction network do not necessarily indicate non-
interacting pairs. Zheng et al. showed that systematically sampling the true negative pairs can 
significantly improve performances of many machine learning algorithms for protein-ligand 
interaction prediction [109]. On a heterogeneous network of proteins, ligands, side effects, and 
protein functions, they applied guilt-by-association assumption – where protein-ligand pairs are 
likely negative if they are dissimilar to most of known positives – to obtain high-confidence 
negative protein-ligand interactions. The improved performances of machine learning models with 
the imputed negative data suggest that it is overly simplistic to use all ‘0’s as negative samples. 
Nonnegative matrix factorization (NMF) is also a popular network modeling method that 
has been applied to computational drug discovery. REMAP takes protein-ligand interaction 
network as well as the intra-layer similarity networks to obtain compressed feature representations 
for all proteins and ligands in the network [110]. Liu et al. separately developed a similar method, 
called NRLMF [111], where the main difference from REMAP is that REMAP explicitly consider 
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the possibility that some of ‘0’s are actually positives. A major restriction in REMAP is that the 
compressed feature vectors for proteins and ligands must be of the same dimension. To overcome 
the drawback, a tri-factorization version of REMAP, WINTF, was developed [99, 112].  In both 
REMAP and WINTF, ligand-ligand and protein-protein similarities can be calculated based on the 
2D molecular structures and primary sequence comparisons, respectively. By the design of 
REMAP algorithm, once optimized, two structurally similar ligands are assigned similar 
compressed feature vectors, and so for proteins. This property of the algorithm provides a useful 
way to represent ligand molecules in a way that contains both its chemical structure and its global 
target profile in compressed vectors. Wang et al. used the compressed vectors from WINTF to 
cluster ligands and applied RWR algorithm to repurpose diazoxide for triple-negative breast cancer 
[99]. Ayed et al. used the compressed vectors from REMAP to predict drug sensitivity of cancer 
cell lines, which showed superior performances compared to features based only on ligand 
structures [113]. A multilayered version of REMAP, FASCINATE method was applied to predict 
drug-induced side effects and side-effect-pathway relationships from heterogeneous biological 
network data [22]. These methods will be introduced in more detail throughout later chapters. 
Deep learning-based biochemical activity prediction 
Zakharov et al. proposed a deep learning-based multitask protein-ligand interaction 
prediction model, named deep learning consensus architecture (DLCA) [114]. DLCA takes 
multiple types of molecular descriptors as inputs, each of which are processed separately by layers 
of fully connected artificial neurons, also known as feed-forward neural network, and the outputs 
from each of the separate layers are averaged to provide consensus predictions. The authors 
adopted both random split and scaffold out validation (i.e. training and test compounds do not 
share some predefined chemical substructures). The performance dropped significantly when 
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scaffold out validation was performed. However, the consensus model performed better than every 
individual component model for both random split and scaffold out validation. DLCA is an 
example where the consensus models (or ensemble models) performing better than the individual 
component models. It was also shown no single type of molecular fingerprint is superior than the 
others in general.  
Lee et al. developed DeepConv-DTI, a CNN-based binary classification tool for drug-
target interaction prediction [115]. DeepConv-DTI takes compound 2D structure and target protein 
primary sequence as inputs, which are vectorized by ECFP and a simple lookup table (i.e. each 
amino acid has a unique integer identifier), respectively. The protein lookup values are then 
projected into embedding vectors, which are then pooled by convolutional layers before being 
concatenated with the compound vectors. The model was trained on a collection of binary protein-
ligand associations in some of the databases mentioned above. Importantly, the convolutional 
filters applied to the protein sequences seem to highlight the parts of proteins interacting with the 
compound, suggesting the capability of convolutional neural network to capture the local features 
relevant to the physicochemical interactions. 
Moridi et al. applied variational autoencoder and principal component analysis to extract 
features for small molecule drugs and diseases to repurpose approved drugs [116]. A small 
molecule drug is represented by its chemical structure, target protein sequences, relevant enzyme 
sequences, and gene expression profile under the treatment. These features are processed by 
variational autoencoders to reduce dimension and extract salient features, and then used to measure 
drug-drug similarity scores using cosine distance. On the other hand, a disease is represented by 
its phenotypes and genotypes (i.e. disease characteristics and involved genes), compressed by 
principal component analysis, which are used to measure disease-disease similarity scores. The 
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predicted drug-disease association scores are then calculated by taking the square root of the 
maximum product of similarity scores within the drug-drug and disease-disease similarity network. 
When evaluated for each distinct disease, the model achieved high AUC values for most of the 
reported diseases. One shortcoming is that the model requires the target genes and relevant 
enzymes for the input drugs. While it is likely for an approved drug to have known target genes 
and enzymes, they are not necessarily the key players for the new indications, limiting the 
interpretability and applicability of the method. 
Torng and Altman proposed a two-stage graph-CNN method to predict protein-ligand 
binding affinity [117]. They first built an unsupervised deep autoencoder to represent the binding 
site pockets for druggable proteins. Each protein pocket is a graph of amino acid residues having 
any atoms within 6 Å to the bound ligands from PDB co-crystal structures. Residues within 7 Å 
are connected to form a binding pocket graph. The second stage comprises two separate graph 
CNN models that learns features from proteins and ligands, supervised by the binding 
classification labels. Ligand molecules are represented in the second stage using NeuMF graph 
CNN [63]. Since the two supervised graph CNNs run in parallel to predict the binding activity, the 
model does not require the co-complex structure information. They applied negative sampling 
strategy to include both negative binding pockets and negative ligands. From DUD-E database, 
randomly chosen binding pockets dissimilar to the active pockets are included as negative pockets. 
From ChEMBL database, ligands having measured IC50 is greater than 50 𝜇M are used as negative 
ligands. Such negative sampling technique can be critical for successful modeling as the 
benchmark data sets are often incomplete, sparse and biased. Zhang et al. developed a deep 
learning-based protein-ligand binding affinity predictor, DeepBindRG [118]. DeepBindRG 
extracts interacting atom pairs from protein-ligand co-crystal structures similarly to the Torng and 
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Altman method. The atom pairs are then featurized based on their chemical and force-field-based 
atomic categories to prepare 2D picture-like input data. The popular ResNet architecture [119] was 
then trained to predict the protein-ligand affinity values in pKd or pKi.  
Karimi et al. developed DeepAffinity, a protein-ligand affinity prediction tool based on 
RNN and CNN [120]. The inputs for DeepAffinity are the protein primary sequence and ligand 
2D structures in SMILES string format, which are then processed by Recurrent Neural Network 
(RNN)-based encoder [121] and pairwise attention mechanism. Before feeding into RNN, protein 
primary sequences are used to represent their structural properties, such as secondary structure 
elements and physicochemical properties, while SMILES strings are k-hot encoded (i.e. binary bit 
vector indicating the individual characters). The RNN-encoded protein and ligand vectors are then 
further processed by pairwise attention mechanism, followed by CNN layers and fully connected 
layers to predict pIC50 values. It is noted that the authors split the protein-ligand affinity data for 
novel protein family prediction cases. In other words, the model performances were measured for 
protein targets that were not included in the training data. Also, it was shown that the attention 
mechanism assigned higher scores for protein segments that are closer to the binding sites although 
the input did not contain 3D structures. DeepAffinity does not require 3D structure data, making 
it more appropriate for larger-scale, early-stage predictions, where limited information is available 
for the proteins and ligands of interest. 
Wan et al. proposed NeoDTI, a prediction tool for binary protein-ligand interactions based 
on graph convolutional neural network that is designed to learn from heterogeneous network, 
which showed superior performances compared to multiple types of methods [122]. Using the 
same datasets as Luo et al. [106], heterogeneous network was built to consist of intra-layer and 
inter-layer relationship edges between drugs, proteins, side effects, and diseases (nodes). Using 
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graph convolutional neural network, similar to that of NeuMF [63], the information about nodes 
are collected to reflect the nodes themselves and their neighbor nodes connected by different edge 
types. The update of node information is governed by a loss function that is specially designed to 
drive the feature vectors of related nodes can be correctly identified after appropriate projection. 
The idea of the loss function is similar to that of matrix factorization methods – that is, the feature 
vectors of proteins and ligands reproduce the protein-ligand network. NeoDTI integrates graph-
based neural network and matrix factorization to predict protein-ligand interactions.  
Other computational drug repurposing methods 
 The methods mentioned above are mainly for predicting protein-ligand or drug-target 
interactions and thereby proposing new indications of existing drugs. While such methods are 
critical, computational drug repurposing in general includes other classes of methods that do not 
necessarily predict protein-ligand interactions. Computational methods that directly predict drug-
side effect or drug-disease associations are useful tools for drug repurposing, where the core 
assumption is that similar drugs are likely to share therapeutic effects [123-125]. Gene expression 
perturbations have also been used to predict therapeutic effects where a drug is assumed to be 
efficient if the gene expression signatures under treatment are in opposite direction of those from 
diseased states [126, 127]. Although relatively less explored and potentially raising questions 
regarding security and privacy, electronic health records are also useful resources to 
retrospectively explore clinical data to mine undiscovered opportunities [128]. These classes of 
methods are out of the scope of this dissertation. Interested readers are referred to the references 
[129-131]. 
1.6 Discussion 
We discussed a few important subtypes of computational drug discovery approaches with 
a focus on anticancer therapeutics. A typical workflow of artificial intelligence-based drug 
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discovery project contains a few steps, including problem definition, data set preparation, 
computational model building, training and evaluating the performance of the model, statistical 
analyses of the performance and predictions, and the inference and validation by assays. 
Depending on the problem definition, a project can be classified as ligand-based, (target) structure-
based, or network-based. As reviewed above, ligand-based models mostly rely on the ligand 
homophily effect – ligands that are similar to each other are likely to share targets, which makes 
the ligand-ligand similarity measurement a key component for the models. Structure-based models 
consider more about the physicochemical interface of protein-ligand binding, often containing a 
sub-model to represent binding pockets or interacting residues extracted from the 3D structures of 
protein-ligand interaction complexes. Network-based models treat protein-ligand binding as a 
network with edges (binding) connecting vertices (proteins and ligands) and aim to predict the 
unknown edges based on known edges. It is noted that these strategies are applicable to diseases 
other than cancers when appropriate inputs pertinent to the diseases of interest are available. 
There is no one size fits all solution in computational drug discovery. Ligand-based models 
are often simple and scalable, but their dependency to the ligand-ligand similarity measure make 
them less suitable to predict and overcome the activity cliff – a small change in ligand structure 
leading to dramatic differences in bioactivity [79]. Structure-based methods can perform better for 
the activity cliff as they consider the physicochemical properties of both protein and ligand. 
However, they require the 3D structure of the target and suffer from higher computational 
complexity. Network-based models often integrate information from both proteins and ligands by 
building protein-protein and ligand-ligand intra-layer networks in addition to the protein-ligand 
inter-layer network. They are designed to overcome the high computational complexity and the 
requirement of protein 3D structures by using sequence-based features. Nevertheless, network-
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based models suffer from the sparsity, incompleteness, biases, and noises in the known protein-
ligand interaction network, and they are prone to the loss of information. For instance, it is not 
guaranteed that the solely sequence-based protein features are sufficient to accurately predict the 
physical interactions between proteins and ligands. Thus, it is desirable to combine multiple types 
of models to overcome the drawbacks for each class of methods as in a recent drug repositioning 
study [100]. 
To date, most cancer therapies focused on directly removing or killing the tumor cells. 
While such removal of growing seeds may exert some therapeutic effects, it is noted that less 
attention has been paid to the soil, called the tumor microenvironment (TME) [132]. So far, the 
inhibitors of aforementioned immune checkpoint proteins are one of few available TME-based 
therapeutic options whose inefficiency have not yet been fully understood [2]. Although 
incomplete, extensive biological research has revealed that there are subtypes of TMEs that either 
promote or inhibit tumor progression [133]. While the majority of computational drug discovery 
research in cancer therapies have focused on discovering molecules that can kill or inhibit the 
growth of cancer cells, a shift to target the specific subtypes of TMEs may result in novel 
therapeutic agents. The potential therapeutic targets that can possibly enhance quantity and quality 
of neutrophils – the most abundant circulating leukocytes that are responsible for innate immune 
response – have been recently reviewed [134]. It is also discussed that a variety of cells in TME, 
such as stromal, endothelial, and myeloid cells, can prevent T cells from exerting their antitumor 
immunity by either physically blocking T cells around solid tumors or biochemically depriving 
their activities [135]. Reported cases of drugs targeting cancer associated fibroblasts (CAFs), a 
major stromal component of TME in pancreatic cancer have been discussed in a recent review 
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[136]. While individual therapies have been of limited success, a number of potential CAF-related 
targeted therapies have been proposed.  
Polypharmacology theorizes that inhibiting two or more of the intended targets will be 
more beneficial than single-targeting drugs. A dual-action agent inhibiting both mevalonate 
pathway and sterol regulatory element-binding protein activity may provide unprecedently 
efficient antitumor effects by avoiding the resistance mechanism, as suggested in reference [18]. 
A recent study demonstrated that PD-1 proteins on myeloid cells may have different roles from 
those on T-cells [137], partially explaining the limited success of the immunotherapies. A 
hypothetical dual-action drug can be designed to inhibit both CAF-tumor crosstalk (e.g. TGF-𝛽 
inhibitor [138]) and CAF-produced tumor-promoting signals (e.g. Interleukin-33, which induces 
tumor-promoting M2 macrophages [139]). An existing CAF-derived extracellular matrix-targeting 
drug, sonidegib [140], can be optimized to also intervene the above mentioned TME biological 
networks or cellular metabolic pathways. Another hypothetical, multi-targeting drug that 
efficiently inhibits BCL-XL and MCL-1 (BCL-2 family multidomain anti-apoptotic proteins) may 
enjoy maximum benefits by reverting the adaptive resistance-based tumor cell survival with low 
toxicity [9]. Ligand-based screening methods can help identify chemical scaffolds that are potent 
against the multiple targets of interest, structure-based methods can help iteratively optimize the 
scaffolds, and network-based methods can identify the global bioactivity profiles at early stage. 
Biological interaction networks within and across cells have been actively revisited to reveal more 
potential therapeutic targets. Computational approaches should also be newly developed, revised, 
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 Drug discovery has been of limited success under the conventional one-drug-one-gene-
one-disease paradigm. It suffers from high attrition rate and possible unexpected post-market 
withdrawal [11]. It has been recognized that drug off-target interactions (i.e. interactions between 
the drug and unintended targets) frequently occur [141], which may lead to adverse drug reactions 
(ADRs) [142], as demonstrated by the deadly adverse reaction of a Fatty Acid Amide Hydrolase 
(FAAH) inhibitor in a clinical trial [13]. On the other hand, off-target interactions may be of 
therapeutic values, thus providing new opportunities for drug repurposing and polypharmacology 
[141]. Therefore, identifying off-target interactions is a critical step in drug discovery, which can 
reduce the drug attrition rate and to accelerate the drug development process, and ultimately to 
provide safer and more affordable therapeutic options. 
 A more recent paradigm in drug discovery is called polypharmacology, where multi-
targeted therapies through either drug combination or a single polypharmacological agent are 
developed to better treat diseases. It has been suggested that a single polypharmacological agent 
has advantages over the combination of multiple drugs [16]. Although there have been 
serendipitous success cases in polypharmacology, target selection and lead compound 
identification are two major challenges in the rational design of polypharmacological therapeutics. 
Existing efforts mainly focus on one-drug-multi-target-one-disease paradigm, selecting multiple 
targets involved in a single disease. It is not trivial, however, to choose the right target combination 
for the disease of interest due to the limited knowledge in gene-disease associations. In terms of 
lead compound identification, a typical approach is to merge two or more distinct molecular 
substructures each having a desired activity towards the targets of interest, designing a single 
molecule [143-145]. This approach may be too simplistic and often results in poor drug-likeness 
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properties, making subsequent lead optimization processes a serious bottleneck in the development 
of multi-targeting drugs [146]. Moreover, additional challenges in polypharmacology remain to be 
solved: the genome-wide drug-target interactions and multi-indications are rarely considered. 
 Many efforts have been made to develop statistical machine learning methods for the 
prediction of unknown drug-target associations by screening large-scale chemical and protein data 
sets [147]. The fundamental assumption in applying statistical machine learning methods to drug-
target interaction prediction is called similarity principle or homophily effect, where similar 
compounds tend to bind to similar protein targets, and vice versa. Based on the similarity principle, 
both semi-supervised and supervised machine learning techniques have been developed and 
applied. The semi-supervised learning methods either build statistical models for the k nearest 
neighbors (k-NN) of the query compound with similar compounds in the database (e.g. Parzen-
Rosenblatt Window (PRW) [81] and Similarity Ensemble Approach (SEA) [56] are examples). 
Although a large number of 2D and 3D molecular fingerprint representations of chemical 
compounds have been developed, molecular structure similarity that is measured by Tanimoto 
coefficient (TC) or other similarity metrics of fingerprints do not show continuous correlations 
with the binding activity. Activity cliff is known to exists in the chemical space, where a small 
modification of a compound structure can dramatically change its binding activity [148]. Thus, the 
chemical structural similarity alone is insufficient to capture genome-wide interaction profile, as 
protein-ligand interaction is determined by both protein and chemical structures. New deep 
learning techniques that can learn nonlinear, hierarchical relationships may provide new solutions 
for representing chemical space [149-152]. However, few works have been done to incorporate 
protein relationships into a deep learning framework. It remains to be seen whether deep neural 
networks are applicable to genome-wide target prediction. 
 43 
 A number of statistical machine learning techniques, such as Gaussian Interaction Profile 
(GIP), Weighted Nearest Neighbor (WNN), Regularized Least Squares (RLS) classifier [153, 154], 
and matrix factorization [155-157] have been developed to integrate chemical and genomic space. 
Neighborhood Regularized Logistic Matrix Factorization (NRLMF) [157] and Kernelized 
Bayesian Matrix Factorization (KBMF) [156] are two of the most successful methods among those 
methods. However, several drawbacks exist in these methods limiting their applications in 
genome-wide off-target predictions. First, several high-performing algorithms such as KBMF are 
computationally intensive, requiring prohibitive time and memory when applied to whole genome 
scale tasks. Second, these supervised learning methods require well-annotated negative samples. 
While publicly available biological and/or chemical databases (e.g. ZINC [27], ChEMBL [28], 
DrugBank [36], PubChem [29], and UniProt [38]) have enabled large-scale computational 
screening of chemical-protein interactions, the known interactions are sparse, and the number of 
reported negative samples (i.e. chemical-protein pairs do not interact with each other) is too small 
to optimally train a prediction algorithm [158]. Randomly generated negative cases will adversely 
impact the performance of these algorithms, and algorithmically derived negative cases are often 
unrealistic [158]. Finally, the performances of these methods have been mainly evaluated for the 
prediction of the off-targets within the same gene family (e.g. within GPCRs or protein kinases) 
using a small benchmark with hundreds of drugs and targets. Their performances in predicting off-
targets across different gene families on a large scale are not guaranteed. Indeed, drug cross-
reactivity is known to occur across protein fold spaces [159]. Thus, in silico prediction methods 
that are fast and accurate enough to explore the available large-scale data sets is urgently needed. 
 In this chapter, we describe our contributions to address the aforementioned issues. We 
present a scalable and efficient method, REMAP, which formulates the genome-wide off-target 
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predictions as a dual-regularized One Class Collaborative Filtering (OCCF) problem. By the 
design of the OCCF, negative data annotations are not required for the training, but can be used if 
available. We demonstrate that REMAP is highly scalable with promising accuracy; thus, it can 
be applied to large-scale off-target predictions. We introduce a new benchmark set to evaluate the 
performance of drug-target interactions across gene families, comparing performances of REMAP 
with other state-of-the-art methods. In our subsequent study, we apply REMAP to repurpose 
existing drugs for new indications [100]. We integrate REMAP with 3D structure-based prediction 
methods, thus naming it 3D-REMAP. Using 3D-REMAP, we design a dual-indication anti-cancer 
therapy by integrating multi-omics data with different classes of systems pharmacology algorithms. 
We repurpose levosimendan, an FDA-approved drug for heart failure, as an anticancer treatment. 
The kinase binding activity and anticancer activities of levosimendan were validated in subsequent 
experiments. The details about 3D-REMAP with experimentally validated drug repurposing 
outcomes are available in the reference [100]. Our findings present a new computational tool for 
drug repurposing and may shed a new light in the anti-cancer drug discovery and demonstrate the 
potential of genome-wide multi-target screening in precision medicine [160]. 
2.2 Methods and Materials 
Definition of off-target prediction method REMAP and its benchmark 
Problem formulation for REMAP method 
The problem we try to solve here is to predict how likely a pair of protein and ligand interact 
with each other, given a protein-ligand association network, protein sequences and chemical 
structures of the proteins and ligands. Note that we use the terms interactions and associations 
interchangeably. We define a bipartite network for protein-ligand associations as a sparse 𝑚 × 𝑛 
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matrix 𝑅, where m is the number of unique ligands and n is the number of unique protein targets. 
𝑅#,% = 1  if the 𝑖!"  and the 𝑗!"  protein are associated, and 𝑅#,% = 0 , otherwise. The chemical 
structural similarity scores are in an	𝑚 × 𝑚 square matrix 𝐶, with 𝐶#,% 		representing the similarity 
score between the 𝑖!"  and 𝑗!"  ligands 70 ≤ 𝐶#,% ≤ 19  for total m ligands. The target protein 
sequence similarity scores are in the same format for total n proteins 70 ≤ 𝑇#,% ≤ 19. We consider 
this problem analogous to the user-item purchase prediction, such that users and items represent 
ligands and proteins, respectively. Therefore, the problem is to provide an 𝑚 × 𝑛 matrix 𝑃, in 
which 𝑃#,%  indicates the score for the predicted association between the 𝑖!"  ligand and the 𝑗!" 
protein. 
Overview of off-target prediction method REMAP 
Our new method REMAP is based on a one-class collaborative filtering algorithm that 
recommends previously unknown user-item preferences based on the profiles of users and items 
[161]. The underlying assumption is that similar users tend to prefer similar items, and an unknown 
preference does not necessarily indicate a downvote. In our formulation, protein-ligand association 
prediction problem is analogous to the user-item preference prediction task. Assuming that a fairly 
low dimensional features (i.e. smaller number of features than the number of total ligands or 
protein targets) can sufficiently capture the characteristics determining the protein-ligand 
associations, two low-rank feature matrices, U (ligand side) and V (protein side), were 
approximated by minimizing ∑ ∑ 7𝑅 − (𝑈 ∙ 𝑉&)9'%(# , where R is the matrix for known protein-
ligand interactions, and 𝑉& is the transposition of the protein side low-rank matrix V. The two low-
rank feature matrices, 𝑈 and 𝑉  are optimized by iteratively minimizing the objective function 
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Figure 2.1 Overall process of the REMAP method. Known protein-ligand associations, protein sequence 
similarity, and ligand structural similarity information are incorporated in the matrices R, T, and C, 
respectively. After iterative updates, optimized low-rank matrices UUP and VUP are obtained, whose dot 
product forms the prediction score matrix, P. 
https://doi.org/10.1371/journal.pcbi.1005135.g001 
 
 All symbols used in this chapter are summarized in Table 2.1 Here, 𝑤 is the penalty weight 
on the observed and unobserved associations which indicates the reliability of the assigned 
probability of true associations, 𝑄 is the imputation matrix (i.e. the probability of unobserved 
associations as real associations for each entry), 𝛼  is the regularization parameter to prevent 
overfitting, 𝛽 is the importance parameter for the ligand structural similarity, 𝛾 is the importance 
parameter for the sequence-based protein similarity, and tr(A) is the trace of matrix A (Table 2.1). 
In this work, we use global weight and imputation values. However, the weight and imputation 
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values may be determined by a priori knowledge or from the prediction of other machine learning 
algorithms. In other words, 𝑤 can be a matrix with the same dimension as the matrix R, and the 
matrix 𝑄 can be filled by other predictive methods. For example, we used protein-ligand docking 
methods to partially fill in the matrix R. The weight values corresponding to the docking-predicted 
associations were set to a lower score, while the corresponding imputation values were set to zeros. 
This reflects our a priori knowledge that the predicted associations to be true with a lower 
confidence. Such an approach is the focus in the later parts of this chapter, which introduces 3D-
REMAP and its application to dual-action drug repurposing.  
The raw prediction score for the 𝑖!" ligand to bind the 𝑗!" protein are calculated by 𝑃(#,%) =
𝑈+,(#,:) ∙ 𝑉+,(%,:)
& . The raw scores, however, do not necessarily mean the probability or likelihood 
of the given associations. Moreover, the input matrix is significantly unbalanced in terms of 
positive/negative samples. Hence, the raw scores were adjusted based on the ratio of observed 
positive and negative cases when the negative data are available (explained in the prediction score 
adjustment section in this chapter). Also, the matrix 𝑈'×/ contains low-rank profiles for ligands 
since its 𝑖!"  row represents the ligand feature in the protein-ligand association network with 
consideration of the drug-drug similarity information. Analogously, the matrix 𝑉(×/ contains the 
low-rank features for each protein target, compressed into 𝑟-dimensional vectors. The REMAP 
code was originally written in Matlab and modified for the drug-target predictions. A python 
implementation of REMAP is also freely available at the same repository 
https://github.com/hansaimlim/REMAP/tree/master/scripts. We note that the python 
implementation shows comparable speed for processing moderately sized datasets. As data 
matrices get larger, the python implementation requires significantly more memory than Matlab 
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implementation due to the advantage of highly optimized sparse matrix operations in Matlab. The 
users may choose the right implementation for their use cases. 
Table 2.1. The symbols and the descriptions for numerical calculations 
 
Symbol Definition and Description 
𝑅 The adjacency matrix of the known drug-target associations, 𝑅 ∈ ℝ'×(. 
𝐶, 𝑇 The chemical-chemical and the target-target similarity matrices,  𝐶 ∈ ℝ'×', 𝑇 ∈ ℝ(×(. 
𝐶	(1.,1/) The chemical-chemical similarity score for the chemicals 𝑐2 and	𝑐3. 
𝑑&4(#	(1.,1/) The Tanimoto dissimilarity coefficient for the chemicals 𝑐2 and	𝑐3. 
𝑇(52,53) 
The target-target similarity score for the query protein 𝑝2 and the target 
protein	𝑝3. 
𝑑6#!	(52,53) The bit score for the query protein 𝑝2 and the target protein	𝑝3. 
𝐷7 , 𝐷&  The degree matrices of C and T, respectively, 𝐷7 ∈ ℝ'×', 𝐷& ∈ ℝ(×(. 
𝑈, 𝑉 The chemical-side and the target-side low-rank approximation matrices, 𝑈 ∈ ℝ'×/ , 𝑉 ∈ ℝ(×/. 
𝑅(#,%) The element of 𝑅 at its 𝑖!" row and 𝑗!" column. 
𝑅(#,:) The 𝑖!" row of 𝑅. 
𝑅(:,%) The 𝑗!" column of 𝑅. 
𝑅& The transpose matrix of 𝑅. 
𝑡𝑟(𝑅) The trace of matrix 𝑅. 
𝑄 The imputation matrix (i.e. the probability of unobserved associations as real associations for each entry in the matrix 𝑅), 𝑄 ∈ ℝ'×(. 
𝑚 The number of unique ligands. 
𝑛 The number of unique protein targets. 
𝑤 The penalty weight on observed and unobserved associations which indicate the reliability of assigned probability of true association. 
𝛼 The regularization parameter to prevent overfitting. 
𝛽 The importance parameter for chemical-chemical similarity. 
𝛾 The importance parameter for protein-protein similarity. 
𝑟 The rank of the low-rank approximation matrices, i.e. dimension of the compressed protein and ligand features. 
𝑝#!8/ The number of maximum iterations to minimize the objective function. 
𝑃(#,%) The raw prediction score by REMAP for the 𝑖!" chemical and the 𝑗!" protein. 






Ligand structural similarity calculation 
Ligand-ligand similarity score matrix is one of the required inputs of REMAP. We define 
the similarity between a pair of ligands based on their chemical molecular 2-dimensional 
structures. We first calculate chemical molecular fingerprints for each ligand and evaluate the 
similarity between the two molecular fingerprints using Tanimoto coefficient [162]. The 
fingerprint of choice in this study is the Extended Connectivity Fingerprint with maximum 
diameter of 4 (ECFP4), which has been successfully applied to ligand-based virtual screening 
method, PRW [81]. The use of the same fingerprint also allows for a fair comparison of REMAP 
with PRW. It is interesting to compare the different fingerprints in the future study. 
To calculate a similarity score between two ligands, c1 and c2, the Tanimoto distance 
𝑑&4(#(1.,1/) was obtained using JChem software from ChemAxon with the Tanimoto metric for the 
ECFP4 molecular descriptor type using the command in the Unix environment, 
“ChemAxon/JChem/bin/screenmd target_smi query_smi -k ECFP -g -c -
M Tanimoto” [163]. Then, the ligand structural similarity score, 𝐶(1.,1/) is simply 𝐶(1.,1/) = 1 −
𝑑&4(#(1.,1/). Briefly, two ligands have a higher structural similarity if they have more of the same 
chemical substructures (e.g. functional groups) at more similar relative positions. Ligand similarity 
scores below 0.5 were treated as noise and set to 0.  
Protein primary sequence similarity 
Protein-protein similarity matrix is also one of the required inputs for REMAP. The 
similarity of a pair of proteins was calculated by algorithmically comparing the primary sequences 
of the proteins. NCBI BLAST [164] with an e-value threshold of 1 × 109: and its default options 
(e.g. 11 for gap open penalty and 1 for its extension, BLOSUM62 for the scoring matrix, and so 
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on) are used to calculate the bit-scores for each pair of proteins. Based on our 10-fold cross 
validation (see below), e-value thresholds from 1 to 1 × 1093; did not significantly affect the 
performance (data can be found in Supplementary Figure 1 in [110]). Therefore, we decided to use 
a moderate e-value threshold of 1 × 109:. Note that the BLAST default is 1 × 109<. A similarity 
score for a pair of protein 𝑝2 and protein 𝑝3  was calculated by the ratio of the bit scores for the 
pair, 𝑑6#!(5.,5/) , compared to the bit score of the self-alignment, 𝑑6#!(5.,5.) . Specifically, the 




Benchmark test and data preparation 
We used ZINC dataset for the benchmark [27]. The protein-ligand associations were 
filtered at IC50 ≤ 10 µM, which yielded 31,735 unique protein-ligand associations for 3,500 
proteins and 12,384 ligands. Cell-based assay results or protein complex targets were excluded. 
As required for protein sequence similarity calculation, proteins whose primary sequence is 
unavailable were also excluded. Protein primary sequences were obtained from UniProt database 
[38]. The whole protein primary sequences were used to calculate protein-protein similarity scores 
as defined above. 
 To evaluate REMAP, we performed a 10-fold cross validation on the ZINC dataset 
described above. We set the hyperparameters as follows: 𝑤 = 𝛼 = 0.1, 𝑟 = 300, 𝛽 = 0.75, 𝛾 =
0.1, and	𝑝#!8/ = 400 . The optimized values determined by the 10-fold cross validation of 
benchmark are shown in Figure 2.2. Figure 2.2B indicates that the best performance is achieved 
when 𝛽 = 0.25 and 𝛾	 = 0.5. To further assess REMAP, we compared REMAP with several other 
methods on ZINC dataset: PRW [81], a ligand-based virtual screening method, NRLMF [111], a 
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matrix factorization-based method similar to REMAP, and KBMF with twin kernels (KBMF2K) 
[165], WNNGIP [154, 166], a combination of nearest neighbor and Gaussian interaction profile 
methods, and another new type of matrix factorization method (Collaborative Matrix Factorization 
(CMF) [167]) for different types of chemicals and proteins. 
 
 
Figure 2.2 Heatmap for REMAP hyperparameter grid search. 10-fold cross validation performances on 
ZINC dataset are shown with color bars.  Performances indicate the true positive rate at the top 1% 




 Next, we divided the ZINC dataset into different categories based on the connectivity of 
known protein-ligand associations and the degree of uniqueness of the ligands. First, all the ligands 
in the dataset were categorized based on the number of known target proteins into ligands having 
only one known target, two known targets, and three or more known targets. As a separate 
category, the ligands were clustered based on the structural similarity of the most similar ligand in 
the dataset with maximum similarity score increment of 0.1, starting from 0.5. Also, all protein 
targets in the dataset were categorized based on the number of known interacting ligands into 
 
100 200 300 400 500
100 0.76 0.7606 0.7615 0.7595 0.7623
200 0.7926 0.7938 0.7933 0.7934 0.7925
300 0.8002 0.7985 0.8005 0.7992 0.8
400 0.8008 0.8 0.8004 0.8009 0.8017





















0.6028 0.6343 0.624 0.6063 0.5809 3.0483
0.7713 0.7959 0.7774 0.7452 0.698 3.7878
0.7741 0.7967 0.7778 0.7442 0.6915 3.7843
0.7774 0.7961 0.7781 0.7424 0.6882 3.7822
0.7773 0.7956 0.7779 0.7427 0.6846 3.7781
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proteins having 1-5, 6-10, 11-15, 16-20, and 21 or more interacting ligands. The protein-ligand 
association samples were divided using at least one of the two ligand filters. Thus, samples were 
divided by number of targets and number of ligands filter, or number of targets and maximum 
structural similarity filter. The data categories were used to evaluate predictive performances of 
algorithms in various scenarios in drug discovery. Note the different numbers of known targets for 
ligands reflect novel and off-target prediction tasks. For example, samples for ligands having only 
one known target can be used to evaluate novel target prediction performances in cross validation 
settings. Samples for ligands having at least one known target can be used to evaluate performances 
in off-target predictions. Our focus is off-target prediction, and it is expected that REMAP is 
suboptimal in novel target prediction tasks. This is analogous to the new user or new item problem, 
also called cold start problem reviewed by Su et al. [168]. 
Evaluation of prediction accuracy of REMAP by TPR vs. Cutoff Rank 
Our benchmark dataset is heavily unbalanced with much smaller number of known 
associations than unknown ones. Moreover, the unknown ones are not necessarily negative. Thus, 
a typical metric, such as Receiver Operating Characteristic curve (ROC) cannot reliably evaluate 
the performance. Thus, we define a performance measurement that is analogous to ROC curve 
without dependencies to the true negatives. We evaluate the performances by the true positive rate 
( ∑&/?8	,@A#!#B8A∑7@(=#!#@(	,@A#!#B8A; TPR, Recall or Recovery) at the top 1% of predictions for each ligand. To be 
specific, the top 35 target proteins out of 3,500 for each ligand are considered positively predicted 
for our datasets. Thus, for instance, a TPR of 0.965 at the 35th cutoff rank (top 1%) means that 
96.5% of the total hidden positive pairs were ranked 35th or better for the ligands in test set. 
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Scalability of REMAP as a matrix factorization algorithm 
 In order for REMAP to be practically applied to whole genome-scale protein-ligand 
interaction prediction tasks, its speed on a reasonably sized dataset should be fast enough. We 
measured its running time by varying the rank parameter or the size of dataset for both Matlab and 
python implementation of REMAP. On the ZINC dataset (12,384 ligands and 3,500 proteins), 
from 𝑟 = 100	to	1000 with an increment of 100 and from 𝑟 = 1000	to	2000 with and increment 
of 250. 10 replicative tests were performed for each condition. Also, a synthetic protein-ligand 
interaction network containing 50,000 ligands and 20,000 proteins with 1% known interactions 
are built and used to evaluate the running time of REMAP. The maximum number of iterations 
(𝑝#!8/) was fixed to 100. A 15-inch MacBook Pro (2018) with 2.2 GHz Intel Core i7 and 32 GB 
memory was used to evaluate running time of REMAP in both Matlab and python implementation. 
We also compared the speed of different matrix factorization methods with ours. However, due to 
the large time complexity and memory requirement for other algorithms, we needed to use a larger 
machine. A multi-core node with up to 700 GB of shared memory system in CUNY HPCC for 
them on the ZINC dataset. It is noted that the main purpose of this experiment is to show that 
REMAP is scalable to whole genome-scale off-target predictions. 
Genome-wide chemical-protein association dataset for benchmark study 
For performance comparison, protein-ligand associations were obtained from the ZINC 
[27], ChEMBL [28] and DrugBank [36] databases and integrated into a larger set of association 
data. Assays with IC50 or pIC50 (negative log of IC50 in molarity) information available were 
extracted from the databases, and IC50 ≤ 10 𝜇M (equivalent to pIC50 ≥ 5.0) were considered the 
activity threshold. The lower IC50 value (greater pIC50), the more potent the association is. UniProt 
Accessions and InChI Keys were used to remove duplicate proteins and ligands, respectively. For 
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assay recorded with IC50 in µg/L (found in ChEMBL database), the full molecular weights of the 
compounds listed on ChEMBL database were used to convert µg/L to µM and applied the same 
threshold. After merging the databases, protein-ligand pairs were considered ambiguous if records 
exist in both ranges and unobserved otherwise. A total of 198,712 unique ligands and 3,549 unique 
target proteins were obtained from the combination of ChEMBL and ZINC with 228,725 unique 
protein-ligand active pairs, 76,643 inactive pairs, and 4,068 ambiguous pairs. Of the 198,712 
ligands, 722 were found to be FDA-approved small molecular drugs. Furthermore, drug-target 
relationships were extracted from the DrugBank database and integrated into the ZINC_ChEMBL 
dataset above. As a result, a total of 199,338 unique ligands and 6,277 unique proteins were 
obtained from the combination of the three databases with 233,378 unique active associations.  
3D-REMAP, integration of 3D structures into REMAP for drug repurposing 
REMAP method itself is scalable to genome scale off-target prediction. However, it lacks 
structural components, which is an important aspect for successful protein-ligand interaction 
prediction. Thus, ligand binding site similarity search across human structural proteome was 
performed and integrated into the REMAP method described above. The computational 
procedures have been reported in previous studies [23, 169-174]. Briefly, we used PDE3B (PDB 
ID 1SO2) as the template structure for the binding site analysis. PDE3B is a reported target for 
levosimendan, a candidate for dual-indication precision anticancer treatment in this study. The 
SMAP software [175-177] was applied to characterize ligand-binding potential from the 
geometric, physiochemical, and evolutionary characteristics of the binding pocket of PDE3B, and 
to computationally predict the binding site similarity between the template and 10,472 non-
redundant human protein structures in PDB database. The p-value of binding site similarity was 
normalized by structural classes (e.g. all-alpha, all-beta, and mixed alpha-beta). The structures 
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whose ligand binding sites were predicted to be similar to that of PDE3B with the p-value < 0.002 
were selected as the initial off-targets of PDE3B inhibitors. Autodock Vina was used to predict the 
binding energy between the selected off-targets and levosimendan, milrinone, anagrelide, 
amrinone, and enoximone. Drug-target interactions that had docking scores less than -7.5 were 
incorporated into the genome-wide chemical protein interactions network in the next step.  
Using REMAP method described above, we incorporated the 3D structure-based 
predictions into REMAP, and we further integrated the pipeline with other machine learning 
methods. Hence, we name the new pipeline, 3D-REMAP.  As described above, genome-wide 
drug-target interactions were predicted using 3D-REMAP. 3D-REMAP takes four network 
matrices as input: protein-ligand associations (matrix R), structurally predicted off-target 
associations (matrix Q), ligand structural similarity, and protein sequence similarity. Note that 3D-
REMAP takes the structurally predicted association matrix in addition to the other required inputs 
to REMAP method. The protein-ligand associations were obtained by integrating three publicly 
available resources: 1) large-scale databases, ChEMBL [28] (v23.1) and DrugBank [36] (v5.5.10), 
2) four data sets from recent publications about kinome assays [178-181], and 3) protein structure-
based off-target prediction from previous step. From ChEMBL, inhibition assays having 𝐼𝐶:; ≤
10	𝜇𝑀 were considered positive. Assays with suboptimal confidence scores (i.e. confidence < 9) 
were excluded. From DrugBank database, all available protein-ligand associations, including 
drug-target, drug-enzyme, drug-carrier, and drug-transporter associations were collected. The 
kinome assays datasets provide protein-ligand associations in different types of activity 
measurement. Christmann-Franck et al. collected kinase-ligand binding assays from multiple past 
publications and presented the activity standardization protocol in the manuscript, which assumed 
an activity with 𝐾# ≤ 5	𝜇𝑀 is active [178]. If the original publication reported percent inhibition 
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(or percent activity) at a given compound concentration, the corresponding Ki value was calculated 
as follows: 
𝐾# =
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 × (100 −%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛)
%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛  
    
If the original publication reported the pKi value, Ki is simply 𝐾# = 1095C1. For this study, 
we followed the above standardization protocol to consistently integrate kinome assays with the 
public databases. We considered kinase-ligand associations active if 𝐾# ≤ 5	𝜇𝑀	𝑜𝑟	𝑝𝐾# ≥ 	5.3. As 
done in REMAP benchmark study above, InChIKey and UniProt Accession are used to remove 
duplicate ligands and proteins, respectively. In case the dataset does not provide InChI Keys, we 
used OpenBabel to convert all chemical molecules to InChI Key. Assays for low confidence targets 
from reference [180] were excluded. Structure-based off-target network was obtained using the 
procedure described in the previous section. Ligand-ligand and protein-protein similarity scores 
were calculated as described above. MadFast software developed by ChemAxon (Budapest, 
Hungary. https://chemaxon.com/) was used to calculate ligand structural similarity matrix, and 
BLAST was used to calculate protein-protein similarity matrix. The integrated protein-ligand 
association network contains 650,581 positive associations for 1,656,274 unique ligands and 9,685 
unique target proteins. The ligand-ligand and protein-protein similarity score matrices contain 
122,421,717 and 31,266 nonzero scores, respectively. 
 
2.3 Results 
REMAP is highly effective in predicting off-targets even for novel chemicals 
 We evaluated the performances of algorithms for chemicals having one, two, or more than 
three known targets with varying maximum ligand structural similarity ranges or with proteins 
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having a certain number of known ligands in the databases (dataset prepared as explained in the 
methods and materials section). In general, the performances improve as the number of known 
ligands per protein or the maximum ligand structural similarity value increases. In product 
recommendation scenarios, it is easier to make better recommendations when there are more of 
previous purchase history or more users or items of similar kinds are known in the database. On 
the other hand, it is possible to see a decreased performance when there are more of correct answers 
to predict. It is important to note that, however, some methods may benefit more from the available 
information, reflecting the proper design of the methods for the given problem. 
 It was noticeable that REMAP performed significantly better than PRW and NRLMF when 
there was at least one known target for a chemical whose targets are predicted (Figure 2.3). 
REMAP consistently showed greater than 90% recall at the top 1% except in one category where 
REMAP is still the best. While PRW and NRLMF also reached reasonably high recall for some 
categories (e.g. more than 11 known ligands per proteins, or max7𝐶(1.,1/)9 > 0.7 ), REMAP 
showed that it can still perform well when there are limited structural similarities between training 
and test ligands (Figure 2.3B). In other words, REMAP is applicable to chemicals that are 
structurally distant to the ligands already in the dataset. In all cases with at least one known target 
for the tested chemicals, REMAP performed best among the three algorithms (Figure 2.3 and 
Figure 2.4). Therefore, in practice, REMAP can predict potential drug targets for chemicals with 
at least one known target as training data, even when the chemicals are structurally dissimilar to 




Figure 2.3 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having 
two known targets. L1to5 means 1-5 known ligands per target, and L21more means 21 or more known 
ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("!,""), < 0.6. Note that during cross-validation, the 
dataset is equivalent to off-target prediction problem, where there is only one known target, and the 





 As shown in Figure 2.3, REMAP outperforms the state-of-the-art NRLFM algorithm in 
most of the tested cases. As NRLMF is sensitive to the rank parameter, we carried out 
optimizations to determine optimal rank and iterations for NRLMF (Supplemental Figure S4). The 
optimal rank and iterations used in the evaluation were 100 and 300, respectively. Moreover, in 
the current implementation, REMAP is approximately 10 times faster and uses 50% less memory 
than NRLMF. Consistent with the results by Liu et al. [111], the accuracies of NRLFM are 
significantly higher than KBMF2K, CMF, and WNNGIP in all of ZINC benchmarks (data not 





Figure 2.4 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having 
three or more known targets. L1to5 means 1-5 known ligands per target, and L21more means 21 or 
more known ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("!,""), < 0.6. Note that during cross-
validation, the dataset is equivalent to off-target prediction problem, where there is only one known 
target, and the other is hidden. Asterisks represent statistical significance based on one-tail t-test (* 𝑝 <
0.05, ** 𝑝 < 0.001). 
https://doi.org/10.1371/journal.pcbi.1005135.g004 
 
Ligand structural similarity significantly improves REMAP performance, while protein 
sequence similarity information contains significant noise 
 To test whether the ligand structural similarity matrix helps prediction, we performed 10-
fold cross validation on the ZINC dataset with the contents of the ligand-ligand or the protein-
protein similarity matrix controlled. In other words, about half of the nonzero similarity scores in 
ligand similarity matrix were randomly chosen and set to zero for the “half-filled chemical 
similarity” matrix, and all entries are set to 0 for the “zero-filled chemical similarity” matrix. The 
predictive power of REMAP was noticeably improved when all available ligand similarity pairs 
were used, compared to the half-filled or the zero-filled similarity matrix (Figure 2.5A). Similarly, 
the contents of the protein similarity matrix were controlled (e.g. half-filled protein sequence 
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similarity, and zero-filled protein sequence similarity) while the full ligand similarity matrix was 
used. Unlike the ligand similarity experiment, the protein-protein similarity information did not 
necessarily improve the performance (Figure 2.5B). Best performance was achieved when a half 
of the protein-protein similarity information was used together with the full ligand similarity 
matrix, suggesting that there is significant noise in the protein sequence similarity matrix. It is note 
that the information is still helpful as seen in the Figure 2.5B compared to the zero-filled matrix 
curve. A careful examination of the BLAST-based protein sequence similarity matrix may give an 
insight for the design of a novel protein-protein similarity metric for drug-target binding activities. 
     
 
Figure 2.5 Impact of ligand and protein similarity information on the performance of REMAP, 
evaluated by true positive rate at a given cutoff prediction rank. A. Performances evaluated by varying 
degree of information in ligand structural similarity matrix. B. Performances evaluated by varying 
degree of information in protein sequence similarity matrix. 
https://doi.org/10.1371/journal.pcbi.1005135.g005 
 
We also performed grid searches for 𝛽 and 𝛾 on ZINC dataset. Although the performance 
was slightly better when the ligand structural similarity importance was maximum (Figure 2.6A), 
the difference was too small to conclude that it is best to fix 𝛽 = 1. Instead, the prediction may 
rely too much on the ligand structural similarity scores. Therefore, to allow flexibility on utilizing 
ligand similarity information, we set 𝛽 = 0.75 at which the performance was almost as accurate 
as 𝛽 = 1. On the other hand, the best performance was achieved when the protein sequence 
similarity importance, 𝛾, was set to 0.1 (Figure 2.6B), further supporting our claim that protein-
protein sequence similarity is not an optimal choice for the prediction of protein-ligand 
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interactions. When jointly optimizing 𝛽  and 𝛾 , their optimal values were 0.25 and 0.5, 
respectively, as seen in the 10-fold cross validation benchmark evaluation (Figure 2.2B).  
    
 
Figure 2.6 Impact of the importance weights for ligand and protein similarity on the performance of 
REMAP, evaluated by true positive rate at a given cutoff prediction rank. A. Performances evaluated 
by varying degree of importance score for ligand structural similarity. B. Performances evaluated by 




 Our result supports a recent study [162] which showed that Tanimoto coefficient is an 
efficient metric for ligand structural similarity calculation for virtual screening tasks. A chemical 
molecular fingerprint-based virtual screening method, PRW, was developed by Koutsoukas et al 
[81]. PRW defines protein targets as bins that can contain molecular fingerprint features for 
interacting ligands. While the fundamental idea of dissecting ligand molecules into functional 
fragments is similar to that of our method, it should be noted that PRW does not consider the 
information from proteins, as well as the interactome. 
REMAP is readily scalable for large-scale protein-ligand interaction networks 
 In our benchmark studies, REMAP showed great speed without losing its accuracy. On our 
benchmark dataset (ZINC; 12,384 chemicals and 3,500 proteins), it took approximately 260 
seconds and 380 seconds to run 100 iterations at the rank of 200 (𝑟 = 200, 𝑝#!8/ = 100) for Matlab 
and python implementations of REMAP, respectively. The time complexity is approximately 
linearly dependent on the rank in both Matlab and python implementation of REMAP (Figure 2.7). 
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The scalability of REMAP is superior when compared to KBMF2K, a state-of-the-art matrix 
factorization-based protein-ligand interaction prediction algorithm that is also implemented in 
Matlab [165]. It took more than 10 days for KBMF2K to run on the same-sized matrix using even 
more powerful, high-performance computer system with up to 24 cores and 700 GB shared 
memory for the ZINC benchmark (data not shown). Moreover, REMAP was capable of 
factorizations with higher ranks while KBMF was limited to rank of 200 in our system due to the 
high memory requirement (over 100 GB of memory). Even at a much higher rank (𝑟 = 2,000), 
less than one hour was required for REMAP on the same dataset (Figure 2.7).  
    
 
Figure 2.7 Scalability of REMAP method in both Matlab and python implementation. Running times 
for REMAP algorithm for ZINC dataset were recorded 5 times for each low-rank parameter (x-axis). 
Average running times for Matlab and python implementations are shown in seconds (y-axis). Error 
bars represent ± 7 times standard deviation. Intel Xeon E5-1603 v3 having 4-cores at 2.80 GHz CPU 
with 32 GB memory was used for both implementation. 
 
 
Low-rank profile-based ligand structural similarity analysis 
As expected, the percentage of pairs of ligands sharing common targets decreases with the 
decrease of the ligand structural similarity measured by the Tanimoto coefficient of ECFP 
fingerprints (𝐶(1.,1/)). The percentage of target-sharing ligand pairs drops below 50% and 20% 
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when the Tanimoto coefficient is between 0.5 and 0.6, and less than 0.5, respectively (Figure 2.8). 
Thus, a model is less likely reliably detect novel protein-ligand binding pairs by ligand structural 
similarity alone, especially when the structural similarity between ligands is limited.  It is 
interesting to see how REMAP performs when the ligand structural similarity fails.  
 
      
 
 
Figure 2.8 Percentage of ligand-ligand pairs sharing common targets with different types of similarity 
between them. A. Percentage of ligand-ligand pairs (y-axis) with varying ligand structural similarity (x-
axis). B. Percentage of structurally dissimilar ligand-ligand pairs (y-axis, 𝐶("!,"") < 0.5) with varying 
low-rank profile similarity (x-axis). Ligand chemical similarities are measured by Tanimoto coefficient. 
Ligand profile similarities are measured by 1 − 𝑆%&',(%!,%").	[0.5,0.6) means 0.5 ≤ 𝐶("!,"") < 0.6. 
https://doi.org/10.1371/journal.pcbi.1005135 
 
We analyzed the low-rank ligand profile (matrix UUP) to see whether it represented the 
target-binding behavior of the ligands. When filtered by low ligand structural similarity (𝐶(1.,1/) <
0.5), there are 899,871 ligand-ligand pairs. Among them, the cosine similarity between profiles 
(𝑆1@A,(1.,1/)) of 91,888 ligand-ligand pairs are higher than 0.3. With high profile similarity (0.99 ≤
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𝑆1@A,(1.,1/) ≤ 1), a total of 1,327 ligand-ligand pairs were found of which 1,033 pairs shared at least 
one commonly known target. Figure 2.8B shows the percentage of pairs that share the common 
target in different profile similarity bins for FDA-approved drugs. This suggests that REMAP can 
provide a protein-ligand binding profile that cannot be captured by ligand structural similarity 
alone. 
 When the ligand profile similarity is limited to 𝑆1@A,(1.,1/) ≤ 0.3, the percentage of ligand 
pairs that share a common target drops below 50% (Figure 2.8B). We constructed a ligand-ligand 
similarity network by filtering out ligand pairs with 𝑆1@A,(1.,1/) ≤ 0.3 , then applied the MCL 
algorithm on the ligand-ligand network to find clusters of similar ligands. The largest cluster of 
ligands contained a total of 313 ligands, and their relationships to diseases were examined based 
on the known associations annotated in CTD database [182]. As a result, we found ligands are 
drug molecules that are related to mental disorders, including hyperkinesis, dystonia, catalepsy, 
schizophrenia and basal ganglia diseases as the mostly related diseases. The most frequent known 
protein targets by the ligands were GPCRs. It is comparable that GPCRs were targeted 1,924 times 
while kinases were targeted only 55 times. While it is interesting to further examine the cluster, 
validating all possible protein-ligand pairs in the largest cluster is inefficient. 
A smaller cluster of drugs consists of a total of 31 FDA-approved drugs 26 of which are 
known to target kinases or interact with microtubule (Table 2.2). Seven drugs in the cluster have 
not been used for anticancer treatment and were found to be closely related to the anticancer drugs 
(Figure 2.9 and Table 2.2). Interestingly, several of them have been tested for their anticancer 
activity. For instance, colchicine (also known as colchine), an FDA-approved drug for gout 
treatment, has been shown to have anti-proliferative effects on several human liver cancer cell 
lines at clinically acceptable concentrations [183]. Griseofulvin is an antifungal antibiotic drug, 
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which appears to be effective as an anticancer drug when used together with other anticancer 
treatments [184]. The three anthelmintic drugs, albendazole, mebendazole and niclosamide, have 
been studied and repurposed for their anticancer therapeutic effects on different types of cancers. 
Albendazole has been shown to be effective in suppression of liver cancer cells both in vitro and 
in vivo [185], and recently has been repurposed for ovarian cancer treatment with a bovine serum 
albumin-based nanoparticle drug delivery system [186]. Mebendazole showed anticancer activities 
in human lung cancer cell lines [187] and human adrenocortical cancer cell lines [188], and it has 
been repurposed as a treatment for colon cancer [189]. Niclosamide and mebendazole showed 
beneficial effects in glioblastoma in different studies [190, 191]. Use of aprepitant was proposed 
in combination with other compounds to improve the efficiency of temozolomide, the current 
standard treatment for glioblastoma [192]. Anticancer activity of carbidopa hydrate has not yet 
been reported. These literature evidence support the utility of REMAP to repurpose existing drugs 
for another uses, especially as an anticancer treatment. Experimental validations of predicted 





Figure 2.9 Clusters of ligands based on the low-rank profile similarity A. Overview of the ligand 
clusters with the anticancer drug cluster highlighted. B. Inset of the anticancer drug cluster highlighted 
in A. 25 known anticancer drugs are in light blue boxes, and 7 other FDA-approved that are closely 




Table 2.2 The known uses and target information for the anticancer drug cluster in Figure 2.9 obtained 
from DrugBank. The known targets are in UniProt Accession.  
 
Drug name Approved treatment(s) Known binding target(s) Principal mode of action 
Albendazole Parenchymal neurocysticercosis F1L7U3, Q71U36, P68371, P83223 Tubulin polymerization inhibitor 
Aprepitant Antiemetic P25103 Substance P/Neurokinin NK1 receptor antagonist 
Carbidopa 
hydrate 
Reduce adverse effects of levodopa in Parkinson 
disease treatment P20711 DOPA decarboxylase inhibitor 
Colchine Gout Q9H4B7, P07437 N/A (depolymerize microtubule) 
Griseofulvin Ringworm infection P10875, P87066, Q99456 N/A 
Mebendazole Anthelmintic Q71U36, P68371 Tubulin polymerization inhibitor 
Niclosamide Anthelmintic against tapeworm infections P40763, O60674, P12931 disrupt oxidative phosphorylation 
Aza-epothilone B Breast cancer Q13509 Microtubule stabilizer 
Bosutinib Chronic Myelogenous Leukemia 
P11274, P00519, P07948, P08631, P12931, 
P24941, Q02750, P36507, Q9Y2U5, 
Q13555 
Tyrosin kinase inhibitor 
Cabazitaxel Prostate cancer P68366, Q9H4B7 Microtubule stabilizer 
Crizotinib Non-small cell lung cancer Q9UM73, P08581 Anaplastic lymphoma kinase inhibitor 
Dabrafenib Metastatic melanoma P15056, P04049, P57059, Q8NG66, P53667 
Inhibitor of some mutant BRAF 
kinases 
Dasatinib Chronic myeloid leukemia P00519, P12931, P29317, P06239, P07947, P10721, P09619, P51692, P24684, P06241 
BRC/ABL and Src family tyrosine 
kinase inhibitor 
Docetaxel Breast, ovarian and non-small cell lung cancer Q9H4B7, P10415, P11137, P27816, P10636, O75469 Microtubule stabilizer 
Erlotinib Non-small cell lung cancer, pancreatic cancer P00533, O75469 N/A (EGFR inhibitor) 
Gefitinib Non-small cell lung cancer P00533 EGFR inhibitor 
Imatinib Chronic myelogenous leukemia A9UF02, P10721, O43519, P04629, P07333, P16234, Q08345, P00519, P09619 Tyrosine kinase inhibitor 
Nilotinib Various leukemias (investigational) P00519, P10721 Tyrosine kinase inhibitor 
Paclitaxel Lung, ovarian and breast cancers P10415, Q9H4B7, O75469, P27816, P11137, P10636 Microtubule stabilizer 
Pazopanib Renal cell cancer and soft tissue sarcoma 
P17948, P35968, P35916, P16234, P09619, 
P10721, P22607, Q08881, P05230, 
Q9UQQ2 
Tyrosine kinase inhibitor 
Ponatinib Chronic myeloid leukemia 
P00519, P11274, P10721, P07949, 
Q02763, P36888, P11362, P21802, 
P22607, P22455, P06239, P12931, 
P07948, P35968, P16234 
Bcr-Abl tyrosine kinase inhibitor 
Regorafenib Metastatic colorectal cancer and gastrointestinal stromal tumors 
P07949, P17948, P35968, P35916, P10721, 
P16234, P09619, P11362, P21802, 
Q02763, Q16832, P04629, P29317, 
P04049, P15056, P15759, P42685, P00519 
Multiple kinases inhibitor 
Ruxolitinib Myelofibrosis P23458, O60674 Janus Associated Kinases (JAK) 1 and 2 inhibitor 
Sorafenib Renal cell carcinoma P15056, P04049, P35916, P35968, P36888, P09619, P10721, P11362, P07949, P17948 
Inhibitor of Raf kinase, PDGF, 
VEGFR 2 and 3 
Sunitinib Renal cell carcinoma and gastrointestinal stromal tumor 
P09619, P17948, P10721, P35968, P35916, 
P36888, P07333, P16234 
Multi-targeted receptor tyrosine kinase 
inhibitor 
Trametinib Metastatic melanoma Q02750, P36507 
Allosteric inhibitor of mitogen-
activated extracellular signal regulated 
kinase 1 and 2 
Vandetanib Broad range tumor types P15692, P00533, Q13882, Q02763 Inhibitor of VEGFR 
Vinblastine Breast, testicular cancers, lymphomas, neuroblastoma 
Q71U36, P07437, Q9UJT1, P23258, 
Q9UJT0, P05412 N/A (mitosis inhibition, metaphase) 
Vincristine Acute lymphocytic leukemia, lymphomas, neuroblastoma, rhabdomyosarcoma P07437, P68366 N/A (mitosis inhibition, metaphase) 
Vindesine 
Acute leukemia, malignant 
lymphoma, Hodgkin’s disease, acute 
erythraemia, acute panmyelosis 
Q9H4B7 mitosis inhibition, metaphase 





Rational polypharmacology strategy for discovering dual-indication cross-gene family multi-
target agents 
With the promising utility of REMAP method for protein-ligand off-target prediction, we 
propose a new strategy that can systematically utilize off-targets to maximally benefit from multi-
targeting drug molecules. The rationale of our multi-target drug repurposing strategy is that the 
serious side effect caused by therapeutic target(s) (i.e. on-target effect) or anti-target(s) (i.e. off-
target effect) of a drug can be mitigated by its or another drug’s interaction with an off-target, 
which is against the side effect, as shown in Figure 2.10. The drug-off-target interaction can come 
from a single polypharmacological agent or multiple drug combination. In this chapter, we focus 
on searching for marketed drugs that may act as a dual-indication agent that can mitigate the 
cardiotoxicity of anticancer therapy and present anticancer potency at the same time. 
Contemporary anticancer therapeutics, such as tyrosine kinase inhibitors, anthracycline 
chemotherapy, and immunotherapy, are all known to be associated with cardiotoxicity [193]. 
       
 
Figure 2.10 Illustration of our rational design of dual-action drug repurposing. A. Concept figure for 
dual-action drug levosimendan, which targets both RIOK1 and PDE3 for therapeutic and mitigating side 
effects. B. Our 3D-REMAP pipeline that integrates structural systems pharmacology with chemical 






Hypothesis generation using 3D-REMAP, a genome-scale multi-target screening platform 
The rational discovery of the dual-indication drug was performed using a novel genome-
scale multi-target screening platform, 3D-REMAP, as illustrated in Figure 2.10B. In our 
subsequent study, we introduce 3D-REMAP framework, which integrates diverse data from 
structural genomics and chemical genomics, as well as synthesized tools from bioinformatics, 
cheminformatics, biophysics, and machine learning [100]. We briefly introduce the 3D-REMAP 
framework in this chapter. Interested readers are referred to the published manuscript [100].  Since 
each data set alone is biased, incomplete, and noisy, and a single computational or experimental 
tool has its inherited advantages and limitations, the integrative analysis may provide more 
comprehensive and reliable outcomes. 3D-REMAP takes four networks as input: a protein-ligand 
interaction network, represented by the matrix R in Eq. 2.1. In this study, the matrix R contains 
650,581 positive protein-ligand pairs for 1,656,274 unique ligands and 9,685 unique target 
proteins. In addition to R, two other input networks are a ligand structural similarity network and 
a protein sequence similarity network (Figure 2.1). The details in the construction of protein-ligand 
association, chemical-chemical similarity, and protein-protein similarity networks are described in 
the Materials and Methods section. 
Since observed protein-ligand interaction matrix from chemical genomics databases is 
highly sparse, one of the unique features of 3D-REMAP is to apply ligand-binding site similarity 
search and protein-ligand docking to screen off-targets of given ligands across human structural 
proteome [23, 169-174].  The putative ligand-off-target interactions are predicted by structural 
comparisons for the binding pockets (SMAP software [175-177]) and protein-ligand docking 
[194]. The predicted ligand-off-target interactions serve as imputations to fill in the unobserved 
entries in the matrix R. The structural genomics data are complementary with the chemical 
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genomics data and may provide additional information on genome-wide protein-ligand 
interactions.  
Using the matrix R and Q along with ligand-ligand and protein-protein similarity networks 
as input, 3D-REMAP algorithm described above was then applied to predict the binding profiles 
of the given drugs against the 9,685 targets. To reduce the impact of the potential false positives 
from the off-target prediction, a confidence weight can be supplied to quantify the uncertainty of 
the prediction, making 3D-REMAP robust to noisy data. Finally, atomic-level details of the 
prioritized drug-off-target interactions are analyzed for lead optimization using flexible protein-
ligand docking. Because 3D-REMAP integrates cheminformatics, SMAP, protein-ligand docking, 
and machine learning and is scalable to tens of thousands of protein targets on genome-scale tasks, 
it may predict off-targets that are overlooked by protein structure-based approaches and other 
cheminformatics methods alone. The integrated 3D-REMAP pipeline showed unmatched accuracy 
in predicting drug-off-target interactions compared to the accuracy of each component method 
without integration. The potential of such combinational framework is strongly supported by the 
experimental validations of our predicted drug-off-target interactions between levosimendan and 
multiple kinases. The proprietary KinomeScan assay confirmed the strong binding affinity of 
levosimendan against RIOK1 (Kd = 0.82 𝜇M) and several other kinases. Downstream analyses 
using statistical machine learning methods predicted the use of levosimendan as an anticancer 








REMAP improves the predictive power of off-target prediction and drug repurposing 
In this chapter, we first developed REMAP, a one-class collaborative filtering application 
to predict off-target interactions from protein-ligand association network. Our extensive 
benchmark studies show that REMAP outperforms existing methods in most of the cases for the 
off-target prediction. Compared with other state-of-the-art matrix factorization algorithms, the 
performance of REMAP comes from several improvements. First, we formulated the protein-
ligand interaction prediction as a one-class collaborative filtering problem; thus, the negative data 
are not required for the training. Second, a priori knowledge including known negative data can 
be incorporated into the matrix factorization framework with imputation and weight matrices. 
Finally, the imputation and weight values can be either simplified as scalars or detailed to 
incorporated a priori knowledge from other methods. REMAP boasts unmatched computational 
scalability when the imputation and weight values are simplified, and its performance can be 
significantly improved when they are carefully filled based on other classes of data sets and 
computational methods as shown in 3D-REMAP. 
The efficiency and effectiveness of REMAP allows us to predict proteome-wide target 
binding profiles of hundreds of thousands of ligands. As the proteome-wide target binding profile 
is more correlated with phenotypic response than a single target-binding activity, REMAP can 
facilitate linking molecular interactions in the test tube with in vivo drug activities. When using a 
multitarget binding profile predicted by REMAP as the signature of a ligand molecule, 7 drugs 
were found to be associated with anticancer therapeutics, although they do not have detectable 
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ligand structural similarity. Among them, the anticancer activities of 6 drugs were supported by 
literature evidence. Thus, REMAP itself could be a great tool for drug repurposing.  
Using our new systems structural polypharmacology pipeline, 3D-REMAP, we 
computationally predicted and experimentally validated that levosimendan – a marketed drug for 
heart failure – can inhibit the growth of multiple cancer cell lines, notably, lymphoma. The 
anticancer activity of levosimendan mainly comes from the modulation of RNA processing 
pathway through the inhibition of atypical kinase RIOK1. RIOK1 represents a new anticancer 
target [195, 196], and the chemical space of its inhibitors has just emerged. Tyrosine kinase 
inhibitors have been previously approved for treatment of lymphoma [197, 198]. Our findings 
suggest that levosimendan could be used as a combination therapy or a potential lead compound 
for new multitarget drugs for lymphoma. On one hand, levosimendan may be combined with other 
tyrosine kinase inhibitors that are associated with cardiotoxicity. Different from inhibitors 
generated from high-throughput screening or de novo design from a single target, it is known that 
levosimendan interacts with other protein targets for therapeutic effects than RIOK1. The 
combination of levosimendan and tyrosine kinase inhibitors may not only reduce the cardiotoxicity 
of tyrosine kinase inhibitors but also enhance the anticancer efficacy since they act on different 
cancer-associated pathways. On the other hand, levosimendan interacts with multiple kinases that 
are associated with cancers as well as proteins that are responsible for heart failure. The 
promiscuity of levosimendan may allow us to utilize it as a lead compound to design a new type 
of dual-action agent by modulating multiple targets that are involved in both side effects and 
disease mechanisms. In many cases, disease-causing genes have pleiotropic effects on biological 
systems, thereby making on-target side effect(s) unavoidable. In contrast to the conventional drug 
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discovery processes that design highly selective ligands, it is possible to mitigate the side effect by 
designing a drug molecule that binds to an off-target that is against the side effect [199].  
Remaining issues and future directions 
Although REMAP showed its great potential on genome-wide off-target predictions as 
discussed above, two issues remain: the cold start problem and suboptimal protein similarity 
metrics. Similar to other matrix factorization algorithms such as NRLMF, REMAP suffers from 
cold start problem, also known as new user or new item problem. In other words, difficulty is 
expected when recommending a product for a new user if the new user has never purchased or 
reviewed a product in the database [168]. For novel ligands that do not have any known targets in 
the dataset, REMAP did not show better performance than PRW. Moreover, if the target of a novel 
ligand has 10 or fewer known ligands, the recovery of REMAP drops below 0.5 (Figure 2.11A). 
When the novel ligand is similar to those ligands in the database, the recovery of REMAP reached 
above 90% (Figure 2.11B). These suggest that, in practice, existing matrix factorization-based 
methods, including REMAP, are suboptimal if the ligands of interest do not have any known 
interactions. To resolve, it is possible to design an algorithm that combines the benefits of PRW 
or other algorithms with REMAP. The use of confidence weights and a priori imputation makes 
it straightforward yet powerful for REMAP to incorporate additional information, as shown in our 
3D-REMAP pipeline. In addition, the computational efficiency of REMAP makes it possible to 




Figure 2.11 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having 
only one known target in the network. L1to5 means 1-5 known ligands per target, and L21more means 
21 or more known ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("!,""), < 0.6. Note that during 
cross-validation, the dataset is equivalent to cold start problem, where the ligands are new in the dataset. 
Asterisks represent statistical significance based on one-tail t-test (* 𝑝 < 0.05, ** 𝑝 < 0.001). 
https://doi.org/10.1371/journal.pcbi.1005135 
 
The suboptimal performance of REMAP may arise from the lack of molecular-level 
biochemical details in deriving the protein similarity metrics. When testing the ZINC dataset, we 
found that REMAP performs better as lower weight was assigned for protein-protein sequence 
similarity data (Figure 2.6B). In addition, the predictive power of REMAP improved when about 
half of the randomly selected protein-protein similarity scores were set to zero, further confirming 
that the noisy metric confounds relating global sequence similarity to ligand binding activities 
(Figure 2.5B). It is not surprising that proteins with similar sequences do not necessarily bind to 
similar ligands, as protein-ligand interaction is governed by the spatial organization of amino acid 
residues in the 3D protein structure [203]. Amino acid mutations/post-translational modifications 
and conformational dynamics may alter the ligand-binding activity through direct modification of 






















































that can accommodate different types of ligands. Thus, two proteins with high sequence similarity 
do not necessarily share ligands because the they may possess different 3D conformations, 
especially in their binding sites [203]. In contrast, two proteins with low sequence similarity can 
still bind to the same ligands if their binding pockets are similar [176, 204]. The binding site 
similarity can be a more biologically sensitive measure of protein-protein similarity for the off-
target prediction [169-174]. While such work is on-going, it also inspired the development of our 
new pipeline, 3D-REMAP, which integrates structural genomics into the REMAP algorithm. 
In our subsequent work, we published our new pipeline, 3D-REMAP, which integrates 
structural genomics and other types of methods into REMAP to repurpose levosimendan, a heart 
failure treatment as an anticancer treatment [100]. To further improve the potential of 
levosimendan in cancer treatment, several points remain to be investigated. First, the anticancer 
potency of levosimendan can be further enhanced by designing personalized derivatives. The 
binding pose analysis may provide valuable clues to the molecular design. Second, a patent has 
shown that PDE3 inhibitors may be active against HeLa cell line [205]. It will be interesting to test 
the sensitivity of levosimendan and other PDE3 inhibitors on more cancer types. Finally, in vivo 
anticancer activity of levosimendan need to be verified.  
Despite the promising results, the rational design of multi-indication multitarget drugs is 
an extremely challenging task. It requires modeling drug actions on a multi-scale, from genome-
wide protein-ligand associations to system-level drug responses. We showcase that 3D-REMAP 
is a promising tool towards designing polypharmacological agents and drug repurposing. 3D-
REMAP provides a framework to integrate heterogeneous data from chemical genomics, structural 
genomics, and functional genomics, and synthesize a variety of computational biology tools from 
bioinformatics, machine learning, biophysics, and systems biology for the multi-scale modeling of 
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drug actions. An emerging paradigm of systems pharmacology enables the understanding of 
cellular mechanism of drug action at organismal resolutions, but it lacks the potential to screen 
and design new chemical entities. Structure-based drug discovery has been successful in 
identifying novel drug molecules with fine-tuned binding properties to specific targets. However, 
the designed protein-ligand interactions may not transform well into the desired organismal level 
drug response. 3D-REMAP may bridge the structure-based drug design and systems 
pharmacology; thus, it facilitates drug development for complex diseases. Nevertheless, many 
aspects of 3D-REMAP could be improved. First, the performance of each individual algorithm, 
such as protein-ligand docking and protein-ligand interaction prediction in the computational 
pipeline needs to be improved.  Second, we use REMAP to integrate different experimental data 
sets and computational predictions into one pipeline. Other machine learning techniques such as 
deep learning could provide more powerful integration. Third, there still exists a big gap between 
in vitro drug activity and clinical phenotype. More data types and modeling techniques, such as 
quantitative systems pharmacology and pharmacokinetics modeling as well as data mining of 
electronic health records should be incorporated into the pipeline for more comprehensive 
prediction pipeline. With the knowledge of genome-wide protein-ligand interaction profiles and 
their associations with diseases, significant time and cost could be saved in the lead optimization, 
pharmacokinetics, pre-clinical, and other downstream research activities using pro-target strategy 











WINTF: An Extension of REMAP Using Matrix Tri-factorization for Target Gene 
Prediction for Transcription Factors 
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3.1 Introduction  
Transcription factors (TFs) regulate gene expression via complex interactions with the 
target genes, and the regulations are critical for cellular organizations and development. TFs can 
activate or deactivate their target genes by binding to the recognition DNA sequences, also known 
as motifs. In addition, TFs can interact with each other or recruit other protein components to form 
a protein complex to perform transcriptional regulations [206]. Such complex regulations explain 
the relative complexity of higher metazoans compared to lower organisms, such as unicellular 
eukaryotes or prokaryotes, where the organismal complexity cannot be fully explained by the 
number of distinct genes alone. It is established that the human genome contains only about twice 
as many genes as Drosophila, and the difference is largely from the duplication of the same genes 
rather than new ones [207]. Thus, the incredibly high complexity of humans cannot be understood 
without considering that human genome contains approximately one TF per every ten genes [208]. 
The complicated transcriptional regulations by TFs seems to play an important role in development. 
In Drosophila, for example, deletion of one TF gene (Antennapedia) cause a serious phenotypic 
defect – legs are on the head where antennae is supposed to be [209]. Thus, understanding the 
associations between TFs and target genes is an important research topic in the biological and 
biomedical sciences. 
Recent advancement of sequencing and molecular biology technology has led to 
developments of laboratory techniques to identify TF-gene associations on a large scale, and the 
output data have been utilized for computational studies to integrate results from different 
experiments [210]. Chromatin immunoprecipitation (ChIP)-based techniques include ChIP-chip 
[211], ChIP-seq [212], and ChIP-PET [213]. The sequences from ChIP techniques are enriched 
around the binding sites for the TFs. Therefore, the target genes can be inferred by mapping the 
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sequence read peaks to the genome. Several studies have focused on identifying the true 
associations from the ChIP data by statistical comparison with the sequence peaks to the 
background signal [214-216]. DamID is an alternative technique to ChIP techniques to identify 
TF-DNA interactions [217]. ChIP Enrichment Analysis (ChEA) [218] is a freely available tool 
that combines TF-DNA associations manually curated and automatically collected from 115 
publications for the ChIP-X experiments, including the three ChIP techniques and DamID. ChEA 
takes a set of genes (whose expression levels are significantly altered) and finds the potential TFs 
that are predicted to interact with most of the genes. ChEA represents a reliable but incomplete 
resource for known TF-target gene associations; thus, it can serve as a benchmark for algorithm 
development. 
Although the laboratory techniques mentioned above are essential for studying TF-DNA 
associations, they are imperfect. Sequencing data from experiments contain noisy reads that are 
not necessarily indications of the corresponding TF-DNA interactions. In addition, ChIP protocols 
are often dependent on the quality of the antibody used in the experiments [219]. The antibody 
may not be specific enough, or it could even block successive interactions between TFs, making 
it difficult to observe indirect interactions. DamID is largely limited by its resolution as the GATC 
motifs are required, although the use of antibodies is not required and therefore has advantages 
over the ChIP protocols [220]. Thus, the currently known TF-gene associations represent 
incomplete, biased, and noisy dataset due to the limitations of experimental techniques. 
Computational methods to infer missing TF-gene associations are needed to reveal a 
comprehensive picture of the gene regulations. 
Collaborative filtering methods are a group of computational algorithms that have been 
widely used in a broad range of areas to infer unobserved associations based on the observed ones 
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with or without additional information [168]. The early generations of collaborative filtering 
methods are based on probabilistic models and aimed for business concerns, such as 
recommending products for users in commercial platforms, such as Amazon.com and Barnes and 
Noble [221, 222]. First proposed by Paatero and Tapper in 1994, nonnegative matrix factorization 
(NMF) [223] has been adopted for recommendation problems, especially after the development of 
the fast multiplicative update rules by Lee and Seung [224]. One of the most successful 
applications is the popular Netflix challenge, where unknown user-video preferences are predicted 
using the past activities of the users [225]. The early collaborative filtering methods heavily rely 
on the availability of the information about the users’ past activities, and it is difficult to make 
predictions for new users, called cold start problem. To overcome the drawback, more advanced 
collaborative filtering methods attempt to utilize additional information, including user-user or 
item-item similarities [168]. Recently, Yao et al. developed a one-class collaborative filtering 
algorithm, wiZAN-dual, that utilizes both user-user and item-item similarity information as well 
as regularization and imputation techniques applied to improve prediction accuracy [161]. 
FASCINATE is an extension of wiZAN-dual on a multilayered network [226]. REMAP is an 
application of wiZAN-dual for biomedical problems introduced in Chapter 2. REMAP predicts 
off-targets of ligands based on the ligand structural similarity and protein sequence similarity as 
well as the information about the known protein-ligand interactions. In the comprehensive 
benchmark studies shown in Chapter 2, REMAP outperforms other state-of-the-art methods. Thus, 
we will only use REMAP as a baseline for the performance evaluation in this chapter. 
As shown in Chapter 2, biomedical and biochemical association predictions can be 
modeled as collaborative filtering problems by replacing users with ligands and items with proteins. 
Similarly, the unobserved TF-gene associations can be inferred using REMAP. However, one 
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limitation of REMAP is that the factorized low-rank matrices for both ligands and proteins must 
have the same rank. That is, the TF-side and gene-side latent features must be in the same 
dimensional latent space, which is unrealistic, particularly if the number of TFs and genes are very 
different. Moreover, the relationship between the TF and the gene will be modeled by the inner 
product between two latent features. The inner product could be too simple to capture complex 
nonlinear relationships between TFs and genes. In this chapter, we present a new weighted imputed 
neighborhood-regularized tri-factorization algorithm (WINTF), an extension of REMAP, which 
allows us to set different feature sizes for TFs and genes as well as increase the power of modeling 
complex relationships among them.  We apply WINTF to the target gene prediction of TFs, in 
which the latent features of TFs and genes have different ranks. In the benchmark, WINTF 
achieves better prediction accuracy for TF-gene association prediction, compared with REMAP 
and vanilla tri-factorization method that do not use the advanced features of REMAP and WINTF, 
such as weight, imputation, and neighborhood-regularization. Many of our inferred novel 
associations are supported by literature evidence. Further applications to tissue-specific TF-gene 
association prediction will significantly enhance our knowledge in transcriptional regulation.  
3.2 Related Works and Contributions 
Here we review the existing methods for target gene identification tools and relevant 
databases, followed by methods in the similar mathematical framework. Existing TF-related 
studies mainly focus on prioritizing the TF-DNA binding peaks to collect the putative TF-gene 
associations from ChIP-X experiments and the databases for the known TF-gene associations. To 
the best of our knowledge, there are few artificial intelligence and machine learning-based TF-
gene prediction tools that take known TF-gene associations as input to infer unknown ones. 
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Therefore, WINTF is the first machine learning algorithm for the target gene prediction of 
transcription factors. 
Target identification from profile (TIP) is a probabilistic model that ranks target genes for 
TFs based on the relative strengths of binding signals from ChIP experiments, with an assumption 
that the binding signal is normally distributed [227]. Identifying target genes (iTAR) is an online 
server, which is designed to overcome the limitation from the normality assumption in TIP by 
applying a Gaussian mixture model to estimate p-values [228]. Covariance based extraction of 
regulatory targets using multiple time series, CERMT, infers TF target genes based on an 
assumption that the true target genes for TFs will show similar response pattern to the TFs [229]. 
Targetfinder is a computational tool to predict target genes with an assumption that the genes with 
similar expression profiles are likely to be regulated by the same TFs [230]. These methods either 
take ChIP experimental data as input or rely on the gene expression data to compare the input 
genes. A recent study combining these ideas infers functional TF-gene associations by correlating 
ChIP data and gene expression profiles [231].  
TRANSFAC is a database for TF-gene interactions from experimental data, which has been 
managed and updated to adopt new data across different organisms as well as tissue-specific 
regulations [232, 233]. In addition to the information about TFs, their binding sites, and target 
genes, the new TRANSFAC database contains information about the control of gene expressions, 
the source cell line for TFs, and binding sites for different experimental conditions, if available 
[234]. JASPAR is another TF-gene association database for matrix-based TF binding sites from 
published experiments [235]. The updated version of JASPAR includes multiple species in six 
taxonomic groups [236]. The famous encyclopedia of DNA elements (ENCODE) project, initiated 
in 2004, aimed to identify all functional elements in the human genome, which includes TF-gene 
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associations [237]. ChEA presents a large collection of TF-gene associations that are manually 
curated and computationally extracted from over 100 published ChIP-X experiments [218]. 
TRRUST is a more recent database for human TF-gene associations by text-mining a large volume 
of literature abstracts [238]. TRRUST version 2 includes TF-gene interactions in mice as well as 
more for humans [239]. TRANSFAC, JASPAR, ENCODE project and ChEA databases are also 
available in Harmonizome, an integrated knowledgebase about genes and proteins, developed to 
facilitate easy and reproducible access to and learning from a large amount of biomedical data [43]. 
Human transcriptional regulation interactions database (HTRIdb) is a publicly available database 
containing experimentally validated human TF-gene associations [240]. 
As mentioned in the introduction, NMF-based models have been applied to predict 
unknown associations such as unobserved protein-ligand binding. SymNMF is an NMF-based 
method to integrate and infer missing similarity information between proteins and ligands from 
multiple sources [241]. Matrix Tri-factorization (MTF) differs from NMF in that the input matrix 
is factorized into three latent feature matrices (e.g. matrices 𝐹, 𝐺, and 𝑆 in Table 3.1), instead of 
two (e.g. matrices 𝐹 and 𝐺 where 𝑟 = 𝑠). Unlike aforementioned NMF or MTF-based ranking 
methods that heuristically optimize the feature sizes (e.g. 𝑟  and 𝑠  in Table 3.1), MTF-based 
supervised clustering requires prior knowledge to determine the feature sizes. Hwang et al. 
developed an MTF-based supervised clustering method (R-NMTF) for disease phenotypes and 
genes regularized by phenotype similarity and protein-protein interaction network [242]. Park et 
al. developed NTriPath to cluster cancer types and genes regularized by protein-protein interaction 
data [243]. While the output clusters may be utilized for certain ranking tasks, these methods 
require prior knowledge in the number of clusters and correct cluster labels in addition to the 
 83 
regular inputs for NMF- or MTF-based ranking methods. MTF has been applied to gene function 
prediction, patient stratification, and disease module detection in other studies [244, 245].  
Our contributions in this chapter are mainly threefold. First, we develop a new algorithm WINTF, 
which incorporates sample weight, imputation, and side information into the existing tri-
factorization frameworks for the first time [244, 245], making it better handle noisy and sparse 
data. Second, we present an efficient optimization algorithm based on the multiplicative update 
rule. Finally, we develop an accurate machine learning method for the target gene prediction of 
TFs for the first time.  
3.3 Methods 
Prediction Method Description 
We first present in this section a mathematical formulation of the one-class collaborative 
filtering problem. The optimization function for our prediction algorithm, weighted and imputed 
neighborhood-regularized tri-factorization (WINTF) in Eq. 3.1 with the symbols described in 
Table 3.1. Then, we describe how WINTF differs from REMAP, a single-ranked counterpart of 
WINTF.  We also present the update rules for our algorithm, based on the multiplicative update 
rule by Lee and Seung [224].  
𝐽 = i𝑊⨀7𝑅 + 𝑃 − (𝐹𝑆𝐺&)9i3 + 𝛼(‖𝐹‖3 + ‖𝑆‖3 + ‖𝐺‖3) 
+𝛽𝑡𝑟(𝐹&(𝐷D −𝑀)𝐹) + 𝛾𝑡𝑟(𝐺&(𝐷E − 𝑁)𝐺) 
(3.1) 
 
WINTF algorithm is designed to find the nonnegative low-rank feature matrices 𝐹, 𝑆, and 
𝐺 that minimizes the optimization function in Eq 3.1. The optimization function 𝐽 consists of four 
terms as shown in Eq. 3.1. Although the formula is slightly different from that for REMAP, most 
ideas remain the same. The shared ideas are described in the following paragraph. 
As mentioned, WINTF is an extension of REMAP in Chapter 2.  REMAP was applied to 
predict off-target protein-ligand associations based on the wiZAN-dual algorithm, which was 
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originally designed to predict user-item preferences [161].  REMAP and WINTF share several 
design ideas. They both take the known user-item (protein-ligand in REMAP application) 
associations with user-user similarity scores and item-item similarity scores. The inputs are 
therefore three network matrices: user-item association, user-user similarity, and item-item 
similarity network matrices. The core MF algorithm attempts to find the latent matrices containing 
the feature vector representations of users and items, such that the dot product of the matrices 
reconstructs the known association network. Both WINTF and REMAP also commonly take a 
penalty weight, an imputation value, a regularization parameter, and importance weights for user-
user and item-item similarity information as user-defined parameters. The penalty weight is to 
indicate the reliability of the known associations, and the imputation value indicates the probability 
of unknown associations to be positive. They can be either obtained from a priori knowledge, such 
as the false positive rate of high-throughput experiments or tuned as hyperparameters, or as 
described in the Chapter 2 for 3D-REMAP. The last two terms in Eq. 3.1 accounts for the similarity 
principle (i.e. similar users prefer similar items, also called homophily effect). The two importance 
parameters control how much the corresponding similarity scores should affect the optimization. 
In both WINTF and REMAP the similarity principle is critical. The similarity scores, which can 
be measured by external methods (e.g. ligand structural similarity for different drugs introduced 
in Chapter 2), are used to reflect the similarity principle by updating the low-rank matrices so that 
the feature vectors for two similar users or items are closer in Euclidean space. Further details 
about the design of the optimization function are available in Chapter 2.  
The key difference between WINTF and REMAP is that WINTF is designed to calculate 
three low-rank matrices to approximate the known association matrix, as opposed to only two 
matrices for REMAP and other traditional NMF methods. The optimization function for REMAP 
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can be obtained by removing the matrix 𝑆 in the Eq. 3.1. Without the matrix 𝑆, however, one can 
easily see that the matrix inner product 𝐹𝐺&  must be in the same dimension as the known 
interaction matrix 𝑅. Therefore, the matrices 𝐹 and 𝐺 must have the same rank. In other words, 
the feature sizes for both users and items must be the same. This single-rank constraint is 
undesirable unless the actual feature sizes are coincidentally identical. The feature interaction 
matrix 𝑆 alleviates the single-rank constraint, making it possible to set the rank of 𝐹 different from 
that of 𝐺 . With an additional matrix 𝑆  into traditional NMF methods, better predictive 
performances are expected due to more flexible choices for feature sizes. Introduction of an 
additional feature interaction matrix inevitably increases the running time for the algorithm. We 
also show that the increased computational cost is affordable in most modern computers. 
Table 3.1 Symbols and definitions 
 
Symbols Definition 
𝑚, 𝑛 Number of unique genes and TFs. 
𝑟, 𝑠 Feature sizes for genes and transcription factors, respectively. 𝑟 < 𝑚, and 𝑠 < 𝑛. 
𝑤 Scalar reliability weight. 𝑤 ∈ [0, 1] 
𝑝 Scalar imputation score. 𝑝 ∈ [0, 1] 
Θ, Θ1 Set of observed and unobserved associations. 
  Element atrow andcolumn of matrix 𝑅. 
𝑅 Known association matrix.  𝑅(#,%) = 1	𝑖𝑓	(𝑖, 𝑗) ∈ Θ, 0	𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑅 ∈ ℝ'×( 
𝐹 Low-rank feature matrix for genes. 𝐹 ∈ ℝ'×/ 
𝐺 Low-rank feature matrix for TFs. 𝐺 ∈ ℝ(×A 
𝑆 Low-rank feature interaction matrix. 𝑆 ∈ ℝ/×A 
𝑀 Gene-gene similarity score matrix. It is a symmetric, positive matrix.  𝑀 ∈ ℝ'×' 
𝑁 TF similarity score matrix, defined similarly to 𝑀.  𝑁 ∈ ℝ(×(  
𝐷D , 𝐷E Degree matrices for 𝑀 and 𝑁, respectively. 𝐷D and 𝐷E are diagonal, positive matrices. 
𝑊 Weight matrix. 𝑊(#,%) = 1	𝑖𝑓	(𝑖, 𝑗) ∈ Θ, 𝑤	𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑊 ∈ ℝ'×( 
𝑃 Imputation matrix. 𝑃(#,%) = 0	𝑖𝑓	(𝑖, 𝑗) ∈ Θ,			𝑝	𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑃 ∈ ℝ'×( 
𝟏'×( Indicator matrix containing 1 at every position. 𝟏'×( ∈ ℝ'×( 
α Regularization parameter. 𝜆/ ∈ [0, 1] 
𝛽, 𝛾 Importance weights for genes and TFs, respectively. 
𝑡𝑟(𝑀) Trace of matrix 𝑀. 
‖𝑀‖3 Frobenius norm of matrix 𝑀. 
Matrices are capitalized and italicized, and scalars are in lower cases 
 86 
 The optimization algorithm for WINTF is based on the multiplicative update rule [224], 
similar to that of REMAP algorithm described in Chapter 2. As in other NMF problems, the 
optimization problem in Eq. 3.1 is not convex due to the coupling of 𝐹, 𝑆, and 𝐺. Therefore, the 
multiplicative update rule is to find a fixed-point solution for a local optimum of the problem with 
nonnegativity constraint. The update rules for each of the three low-rank matrices are below. 
𝐹(?,/) ← 𝐹(?,/)v
[(1 − 𝑤𝑝)𝑅𝐺𝑆& +𝑤𝑝1'×(𝐺𝑆& + 𝜆F𝑀𝐹](?,/)
w(1 − 𝑤)	𝑅xG𝐺𝑆& +𝑤𝐹(𝑆𝐺&𝐺𝑆&) + 𝜆/𝐹 + 𝜆F𝐷D𝐹y(?,/)
	 (3.2) 
𝐺(#,A) ← 𝐺(#,A)v
[(1 − 𝑤𝑝)𝑅&𝐹𝑆 + 𝑤𝑝1'×(𝐹𝑆 + 𝜆H𝑁𝐺](#,A)
w(1 − 𝑤)𝑅xG𝐹𝑆 + 𝑤𝐺(𝑆&𝐹&𝐹𝑆) + 𝜆/𝐺 + 𝜆H𝐷E𝐺y(#,A)
 (3.3) 
𝑆(/,A) ← 𝑆(/,A)v
[(1 − 𝑤𝑝)𝐹&𝑅𝐺 + 𝑤𝑝(𝐹&1'×(𝐺)](/,A)
w(1 − 𝑤)𝐹&𝑅xG𝐺 + 𝑤𝐹&(𝐹𝑆𝐺&)𝐺 + 𝜆/𝑆y(/,A)
 (3.4) 
The predicted score matrix for known associations, 𝑅xG, is defined as follows. 
𝑅xG	(?,#) = z




Algorithm 3.1 WINTF 
1. Input matrices: M, N, and R 
Input scalars: Ω = {𝑟, 𝑠, 𝑤, 𝑝, 𝛼, 𝛽, 𝛾} and max_iter 
2. Define: 𝑓3, 𝑓<, 𝑓I, 𝑓: from equations 3.2, 3.3, 3.4, and 3.5 above  
3. Initialize: 𝐹;, 𝑆;, 𝐺; = 𝑅𝑎𝑛𝑑𝑜𝑚𝑈𝑛𝑖𝑓𝑜𝑟𝑚𝑀𝑎𝑡𝑟𝑖𝑥 ∈ [0,1] 
4. for 𝑖 = 0 to (max_iter −1) 
5.       𝑅xJ,#	 = 𝑓:(𝑅, 𝐹# , 𝑆# , 𝐺#) 
6.       𝐹#K2 = 𝑓37𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9 
7.       𝐺#K2 = 𝑓<7𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9 
8.       𝑆#K2 = 𝑓I7𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9 
9.       replace NaNs in 𝐹#K2, 𝐺#K2, 𝑆#K2 with 0 
10. Return: real-valued matrices 𝐹#K2, 𝐺#K2, 𝑆#K2 
 
The update rules are derived by taking the partial derivatives with regard to each low-rank 
matrix, while fixing the other two low-rank matrices as constant. Thus, we update one low-rank 
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matrices at a time, while fixing the other two. The update process under the multiplicative update 
rules can also be described as a gradient descent method with specially tailored learning rates. The 
pseudocode for our method is below in Algorithm 3.1. Note the use of a global scalar weight 𝑤 
and a global scalar imputation 𝑝, instead of position-specific weight matrix 𝑊 and imputation 
matrix 𝑃. With a priori knowledge, it is possible to use position-specific matrices as shown in our 
3D-REMAP pipeline in Chapter 2. 
Once the updates are completed, 𝑅x , the prediction matrix for all TF-gene associations can 
be obtained by the inner product of the three low-rank matrices. The prediction score matrix for 
unknown interactions, 𝑅xG4,  can be obtained by 𝑅xJ4 = 𝑅x − 𝑅xJ, which contains prediction scores 
for both known and unknown associations. 
𝑅xG4 = 𝑅x − 𝑅xG,  where   𝑅x = 𝐹𝑆𝐺& 
Figure 3.1 summarizes the process of WINTF for predicting an unknown gene-TF 
association (Gene3 and TF1 in the figure). The mathematical justifications, including derivation 
and proof of the update rules with the use of scalar weight and imputation values are in the 
following section. 
 
Figure. 3.1 WINTF process for gene-TF association prediction. WINTF takes gene-TF, gene-gene, and 
TF-TF networks as input, and updates the three low-rank feature matrices, F, S, and G. Once WINTF 
update process is completed (Algorithm 1), the prediction score for an unknown gene-TF association 
(Gene3-TF1) is obtained by a dot product of the corresponding low-rank features. Blue and yellow 
rectangles represent the feature vectors for the gene and TF, respectively. In other words, blue rectangle 












Theorems and Proofs 
In the section above, we proposed the update rules for the three low-rank matrices to 
calculate a local minimum of the cost function 𝐽,	defined in Eq. 3.1. As mentioned, 𝐽 is nonconvex. 
Thus, we update one low-rank feature matrix at a time, while fixing the others as constant. When 
𝑆 and 𝐺 are fixed, the cost function can be simplified into 𝐽F.   
𝐽F = i𝑊⨀7(𝑅 + 𝑃) − 𝐹𝑆𝐺&9i
3 + 𝛼‖𝐹‖3 + 𝛽𝑡𝑟(𝐹&(𝐷D −𝑀)𝐹),							𝑠. 𝑡. 𝐹 ≥ 0 (3.6) 







(𝑅 + 𝑃)𝐺𝑆& − 𝛽𝑀𝐹 +𝑊⨀𝑊⨀𝐹𝑆𝐺&𝐺𝑆& + 𝛼𝐹 + 𝛽𝐷D𝐹 (3.7) 
Based on the multiplicative update rule developed by Lee and Seung [224], we derive the update 
rule for F as follows. 
𝐹(?,/) ← 𝐹(?,/)v
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆& + 𝛽𝑀𝐹](?,/)
[𝑊⨀𝑊⨀(𝐹𝑆𝐺&)𝐺𝑆& + 𝛼𝐹 + 𝛽𝐷D𝐹](?,/)
 (3.8) 
In the section 3.1, we showed simplified update rules that reduce the computational 
complexity by replacing the large dimension of the weight and imputation matrices with scalar 
values. The simplified update rule for Eq. 3.8 is the Eq. 3.2.  
In the remainder of this section, we first show that the fixed-point solution of Eq. 3.8 
satisfies the KKT condition, and that Eq. 3.2 and Eq. 3.8 are mathematically equivalent. Then, we 
show that the cost function, 𝐽F in Eq. 3.6 monotonically decreases under the update rule in Eq. 3.8. 
THEOREM 1. The fixed-point solution of Eq. 8 satisfies the KKT condition. 
PROOF. The Lagrangian of Eq. 3.6 is the following, where Λ is the Lagrange multiplier. 
𝐿L5 = i𝑊⨀7(𝑅 + 𝑃) − 𝐹𝑆𝐺




𝐿L5 = 0, we get the following. 
2(−𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆& +𝑊⨀𝑊⨀𝐹𝑆𝐺&𝐺𝑆& + 𝛼𝐹 + 𝛽𝐷D𝐹 − 𝛽𝑀𝐹) = Λ (3.10) 
From the KKT complementary slackness condition, we derive the following. 
[−𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆& +𝑊⨀𝑊⨀𝐹𝑆𝐺&𝐺𝑆& + 𝜆/𝐹 + 𝜆F𝐷D𝐹 − 𝜆F𝑀𝐹](?,/) ∙ 𝐹(?,/)
= 0 
(3.11) 
Eq. 3.12 is the fixed-point solution of Eq. 3.8. It is trivial to show that Eq. 3.12 satisfies Eq. 3.11. 
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆& + 𝛽𝑀𝐹](?,/) = [𝑊⨀𝑊⨀(𝐹𝑆𝐺&)𝐺𝑆& + 𝛼𝐹 + 𝛽𝐷D𝐹](?,/) (3.12) 
Next, we show that Eq. 3.2 is mathematically equivalent to Eq. 3.8. We use 𝟏N, 𝟏G, and 
𝟏G4 as the indicator matrices for all, observed, and unobserved associations, respectively, so that 
1'×( = 𝟏N = 𝟏G + 𝟏G
4, and 𝟏G = 𝑅. Note that the weight and imputation values are applied only 
for unobserved associations, the equations below turn the weight matrix W and imputation matrix 
P into scalar weight w and scalar imputation value p, respectively, significantly reducing the 
computational costs. Note that the weight matrix W contains the square root of the global weight 
w, on unobserved positions and zero on observed ones. 
𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆&  
= 7𝟏J⨀𝑅 +𝑤𝑝 ∙ 𝟏J69𝐺𝑆& = (𝑅 + 𝑤𝑝 ∙ 𝟏N −𝑤𝑝 ∙ 𝟏J)𝐺𝑆&  





= 𝑊⨀𝑊⨀7𝑅xJ + 𝑅xJ49𝐺𝑆& = 7𝑅xJ +𝑤 ∙ 𝟏J
4⨀𝑅xJ𝒄9𝐺𝑆&  
= (1 − 𝑤) ∙ 𝑅xJ𝐺𝑆& +𝑤 ∙ 𝐹𝑆𝐺&𝐺𝑆&  
Substituting the two equations above into Eq. 3.8 completes the proof that Eq. 3.2 is 
mathematically equivalent to Eq. 3.8.  
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THEOREM 2. The cost function in Eq. 3.6 monotonically decreases under the update rule 
proposed in Eq. 3.8. 
PROOF. To prove the theorem 2, we start from the cost function Eq. 3.6. 
Based on the auxiliary function strategy [246], 𝐻7𝐹, 𝐹9 is an auxiliary function of J(F) if 
it satisfies the following conditions. 
𝐻(𝐹, 𝐹) = 𝐽(𝐹),   and   𝐻7𝐹, 𝐹9 ≥ 𝐽(𝐹) (3.13) 
Defining 𝐹(!K2) = 𝑎𝑟𝑔𝑚𝑖𝑛
F
𝐻7𝐹, 𝐹(!)9  proves that 𝐽7𝐹(!)9  monotonically decreases since the 
following condition is satisfied by the design of the auxiliary function. 
𝐽7𝐹(!)9 = 𝐻7𝐹(!), 𝐹(!)9 ≥ 𝐻7𝐹(!K2), 𝐹(!)9 ≥ 𝐽7𝐹(!K2)9 (3.14) 
We first define an auxiliary function that satisfies the conditions in Eq. 3.13, and solve for the 
auxiliary function, which is the global minimum of the auxiliary function. 
𝐻7𝐹, 𝐹9 	= −2w7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺𝑆&y(?,O)𝐹







































It is trivial to show that 𝐻(𝐹, 𝐹) = 𝐽(𝐹). To show 𝐻7𝐹, 𝐹9 ≥ 𝐽(𝐹), we name the five terms 
in Eq. 3.15 as H1, H2, H3, H4, and H5, respectively. Then, using the inequality 𝑥 ≥ 1 + 𝑙𝑜𝑔	(𝑥), 
the H1 becomes the following. 
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= −2𝑡𝑟w7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺𝑆&𝐹y 
 
 





























































We derive Eq. 3.20 with the use of the following inequality , where 𝐴(×(, 𝐵O×O, 𝑆(×O, and 𝑆(×O∗  
















≥ 𝛽𝑡𝑟(𝐹&𝐷D𝐹)	 (3.20) 
Substituting Eq. 3.16 – Eq. 3.20 into Eq. 3.15 shows that the auxiliary function satisfies the second 








= −𝛽𝑡𝑟(𝐹&𝑀𝐹) (3.17) 
 
Then, for H3 we obtain 𝐻3 = 𝛼 ∙ 𝑡𝑟(𝐹𝐹&) (3.18) 
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The Hessian of 𝐻7𝐹, 𝐹9 is a diagonal matrix with positive diagonal elements. Therefore, we obtain 
the global minimum by setting Eq. 3.21 to be zero, which results in the following solution. 
𝐹(?,O)3 = 𝐹(?,O)3 ∙
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆& + 𝛽𝑀𝐹](?,O)
[𝑊⨀𝑊⨀7𝐹𝑆𝐺&𝐺𝑆& + 𝛼𝐹 + 𝛽𝐷D𝐹](?,O)
 (3.22) 
Setting 𝐹(!K2) = 𝐹 and 𝐹(!) = 𝐹 proves that the update rule Eq. 3.8 monotonically decreases the 
cost function. With the equivalence between Eq. 3.2 and Eq. 3.8, Eq. 3.6 monotonically decreases 
under the update rule Eq. 3.2. 
The proof for the update rule for G can be derived analogously to the proof above. The 
matrix S-equivalent of the cost function Eq. 3.6 is the following. 
𝐽(𝑆) = 𝑡𝑟(−2𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆&𝐹&) + 𝑡𝑟(𝑊⨀𝑊⨀(𝐹𝑆𝐺&)𝐺𝑆&𝐹&) + 𝛼𝑡𝑟(𝑆&𝑆) 
Therefore, we choose an auxiliary function for the matrix S, which is missing two terms 
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Setting the gradient to zero, we obtain the global minimum solution. 
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Combining the theorems 1 and 2, we proved that the proposed update rules satisfy the KKT 
condition and converge to the solution. We use the proposed update rules to iteratively update the 
low-rank matrices in alternating manner to find the solution. 
Experimental Setup 
We use the TF-gene interaction data from ChEA, which contains manually curated as well 
as computationally extracted associations from more than 100 publications for ChIP-X 
experiments [218]. The ChEA dataset contains 386,776 TF-gene interactions for 21,585 genes and 
199 TFs for human. Since the density is approximately 9%, it is expected that a random guess 
would have a 9% chance to correctly pick a true interaction. The gene-gene and TF-TF similarity 
matrices are prepared by assuming two interacting proteins are related to each other. The protein-
protein interaction (PPI) data is obtained from the STRING database, which contains 
experimentally known and computationally predicted protein-protein physical interactions and 
functional associations (e.g. co-expressed genes) with reliability scores [248]. The similarity score 
between the and genes (or TFs) is calculated by the PPI reliability score divided by the maximum 
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available score (1,000). If multiple reliability scores exist for a pair of proteins, average value is 
used. This makes all similarity scores in between 0 and 1, for minimum and maximum similarity, 
respectively. Sequence-based protein-protein similarity scores can be used as it was done in the 
REMAP application as described in Chapter 2. Two proteins will have a high similarity score if 
their BLAST [249] alignment returns a high score. As a result, 9,207,162 and 12,775 PPI-based 
nonzero similarity scores are obtained for gene-gene and TF-TF networks, respectively. 
To compare WINTF with REMAP, we evaluated the performances of them for the ChEA 
dataset described above. We conducted 5-fold cross validations to measure four different 
performance metrics: area under receiver operating characteristic curve (AUROC, or AUC), mean 
average precision (MAP), half-life utility (HLU), and mean percentile rank (MPR). AUROC is 
one of the most frequently used performance measurements that measures how quickly an 
algorithm achieves a high true positive rate while keeping low false positive rates. HLU measures 
the likelihood that a user accepts recommendation assuming that the likelihood decreases 
exponentially with the ranking of the recommended items [250]. MAP measures the average 
precision for all users at varying true positive rates [251]. MPR is the average percentile rank of 
positive associations in the test samples [252]. The higher AUC, MAP, HLU, and the lower MPR, 
the better performance. We compared the performances with and without the PPI-derived 







Compared to REMAP, WINTF has an additional feature interaction matrix, necessarily 
requiring longer computational time.  As we describe in Chapter 4 and in our previous application 
using WINTF algorithm [253], we measured computational time of WINTF using the ChEA data 
set. Figure 2 shows the average running time as increasing number of total elements in the matrices 
F, S, and G. The empirical time complexity of WINTF suggests that the running time 
approximately linearly dependent on the number of matrix elements. It also shows that WINTF on 
ChEA data set takes approximately 1,100 seconds at the default rank parameters (𝑟 = 1000, 𝑠 =
100). 
 
Figure. 3.2 Time complexity of WINTF using ChEA dataset. Average running time (blue squares) from five 
runs of WINTF are plotted according to the total number of elements in the three low-rank matrices, F, S, 
and G. The x-axis is the total number of elements in the three matrices in millions (i.e.	𝑚 × 𝑟 + 𝑟 × 𝑠 +
𝑛 × 𝑠). Within the tested range of elements, WINTF shows approximately linear time complexity (green 
dashed line). Error bars represent ± five times the standard deviations. 
Benchmark evaluation of prediction accuracy 
Our benchmarks under different conditions (e.g. different hyperparameters and 
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conditions (Table 3.2 and Table 3.3). Table 3.2 shows that WINTF performs significantly better 
than REMAP in all four metrics, regardless of the use of similarity matrices. Table 3.3 shows that 
the rank parameters affect the performances of both methods, and that WINTF outperforms 
REMAP under all tested hyperparameters. Due to the number of hyperparameters for both 
algorithms, it is impractical to compare them with all possible combinations. Thus, we tested a 
limited number of combinations, evaluating the potentials of different similarity measurements, 
and the effect of the additional low-rank matrix in WINTF. In our previous study with REMAP as 
described in Chapter 2, we performed extensive grid searches on the hyperparameter space, where 
we found that the optimal parameters are 𝑤 = 𝑝 = 𝛼 = 0.1, and max_iter=100. In our previous 
study, alterations on these hyperparameters did not significantly affect the performance, unless w 
is set to 1.0 and p, or 𝛼 is set to 0, respectively (Table 3.2, Condition E), or max_iter is fewer than 
50. We found similar trends from grid searches on WINTF hyperparameter space. Similar to our 
benchmarks in Chapter 2, small, nonzero w, p, and 𝛼 values showed reliable performances with 
max_iter=100. The dimension of the feature interaction matrix (e.g. r, s) are important 
hyperparameters and known to be data-dependent. Our experiments suggest that it is best to keep 
𝑟 ≥ 500  and 𝑠 ≤ 150, further supporting the power of our new algorithm for setting the ranks 
differently (Figure 3.3). Therefore, we set the default hyperparameters as 𝑤 = 𝑝 = 𝛼 = 0.1 , 
max_iter=100, 𝑟 = 1000, and 𝑠 = 100. With these default parameters, we observed that 𝛽 ≅
0.01 works best, and 𝛾  has less impact on performances compared to other hyperparameters. 
Therefore, we set 𝛽 = 0.01 and 𝛾 = 0.7 as the default hyperparameters. Both of the gene-gene 
and TF-TF similarity matrices used for our WINTF application are based on protein-protein 
interactions from STRING, as described in the method section.  
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 Figure. 3.3 Low-rank parameters and performances of WINTF. The two low-rank parameters, r and s, were adjusted 
together and the average AUC values were evaluated while the other hyperparameters were set to default. X-axis 
represents the pair of r and s, and y-axis represents the average AUC from 5-fold cross validation. Error bars represent 
± 5 times the standard deviation. 
 
Table 3.2 Performance comparison for WINTF and REMAP with different similarity information 
 
1Con. Algorithm AUC HLU MAP MPR 
A WINTF 0.763(8.0e-4) 40.7(0.394) 0.295(0.003) 0.259(5.0e-4) REMAP 0.717(0.001) 31.1(0.667) 0.231(0.002) 0.300(0.001) 
B WINTF 0.766(6.0e-4) 40.7(0.23) 0.295(2.6e-3) 0.259(4.6e-4) REMAP 0.726(1.7e-3) 32.0(1.7) 0.237(7.4e-3) 0.294(1.5e-3) 
C WINTF 0.762(7.8e-4) 40.7(0.394) 0.295(0.003) 0.259(5.0e-4) REMAP 0.727(0.002) 33.6(0.150) 0.243(0.001) 0.291(0.002) 
D WINTF 0.762(7.8e-4) 40.7(0.394) 0.295(0.003) 0.259(5.0e-4) REMAP 0.717(0.001) 30.1(0.672) 0.231(0.002) 0.300(0.001) 
E Vanilla MTF 0.500(0.0) 5.96(0.06) 0.155(5.0e-4) 0.320(6.6e-4) 
Values are mean and (standard deviation) for 5-fold cross validation 
1Condition A: TF similarity scores are based on sequence similarity only, and gene similarity scores are not used. Condition B: TF similarity scores 
are the average of sequence-based and protein-protein interaction-based scores, and gene similarity scores are based on PPIs only. Condition C: 
TF similarity scores are based on PPIs only, and gene similarity scores are not used. Condition D: No similarity information used.  Condition E: 








































































































w = 1.0, p = λr = λF = λG = 0
Table 3.3 Performance comparison for WINTF and REMAP with different hyperparameters 
 
1Con. Algorithm AUC HLU MAP MPR 
A WINTF 0.766(6.0e-4) 40.7(0.23) 0.295(2.6e-3) 0.259(4.6e-4) 
REMAP 0.726(1.7e-3) 32.0(1.7) 0.237(7.4e-3) 0.294(1.5e-3) 
B WINTF 0.764(5.1e-6) 40.7(0.09) 0.295(1.6e-3) 0.259(1.1e-6) 
REMAP 0.726(2.9e-3) 32.2(1.6) 0.238(3.7e-3) 0.294(2.7e-4) 
C WINTF 0.765(7.6e-4) 40.7(0.10) 0.295(1.5e-3) 0.259(6.4e-4) 
REMAP 0.730(1.8e-3) 29.8(0.30) 0.233(1.6e-3) 0.292(1.6e-3) 
D WINTF 0.762(6.6e-4) 40.7(0.09) 0.295(1.6e-3) 0.259(6.4e-4) 
REMAP 0.717(3.2e-3) 30.9(1.7) 0.231(4.2e-3) 0.300(3.0e-3) 
Values are mean and (standard deviation) for 5-fold cross validation 
1Condition A: Default parameters. Condition B: WINTF ranks=(100,100), REMAP rank=100. Condition C: WINTF ranks=(100,50), REMAP 
rank=50. Condition D: 𝜆! = 𝜆" = 0.   
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The results in Table 3.2 further demonstrates that the novelty and strength of our method 
comes from the weight, regularization, imputation, and side information parameters. It is noted 
that when  𝑤 = 1, 𝑝 = 𝛼 = 𝛽 = 𝛾 = 0, the optimization problem in Eq. 3.1 is equivalent to that 
of the plain matrix tri-factorization (vanilla MTF), 𝐽 = ∑(𝑅 − 𝐹𝑆𝐺&)3 . We observe clearly 
improved performances when the weight, regularization, imputation, and side information 
parameters are introduced into the vanilla MTF.  
Evaluation on independent test data 
With the choice of hyperparameters and similarity score matrices described above, we 
performed WINTF on the full ChEA TF-gene dataset. We first calculated the predicted score 
matrix 𝑅x  as described in the method section. To evaluate the statistical significance of the 
predicted scores, we randomly picked 1,000,000 scores in 𝑅x . Removing the scores for 90,076 
known interactions, we plotted a histogram of the 909,924 predicted scores, which suggested that 
the predicted scores are not following a simple distribution, such as Gaussian or exponential 
distribution (Fig. 3.4). Thus, we first removed the prediction scores for TF-gene interactions that 
were found in ChEA dataset, and we used Epanechnikov kernel to create a distribution that fits the 
sampled scores as shown in Figure 3.4. Then, we picked the predicted TF-gene pairs that ranked 
approximately within the top 2% (i.e. cumulative density above 0.9808 under the kernel 
distribution). Our prediction and filtering method returned 495 TF-gene interactions that were not 
included in ChEA dataset. We searched for TRANSFAC [234], ENCODE [237], and TRRUST2 
[239] databases to evaluate the final prediction accuracy. As a result, 187 of the 495 (37.8%) 
associations were found in at least one of the three databases (Appendix B in [112]). Recalling that 
the chance of correct prediction for a random guess is 9.0% based on the density of the ChEA data 
set, our enrichment factor is 4.19 (37.8% divided by 9.0%) for our prediction accuracy. 
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Table 3.4 Predicted TF-gene interactions by WINTF 
 
TF Gene 1CDF Database Reference 
MYC NOTCH2 0.99213 ENCODE [254, 255] 
MYC ZMIZ1 0.99906 ENCODE [256] 
MYC ARID5B 0.99928 ENCODE [257] 
MYC BCL6 0.99909 ENCODE, TRANSFAC [258, 259] 
MYC NDRG1 0.98982 ENCODE, TRRUST2 [260] 
MYC ST3GAL1 0.9992 ENCODE, TRRUST2 [261] 
MYC EFNA5 0.99607 ENCODE [262] 
SPI1 BCL6 0.99864 ENCODE, TRRUST2 [263] 
SOX2 HES1 0.99993 None [264, 265] 
SOX2 NOTCH2 0.99335 None [265] 
CREM MEIS1 0.99955 None [266] 
AR RUNX1 0.99837 None [267] 
1Cumulative distribution function of the Epanechnikov kernel fitted to the WINTF prediction scores 
 Among the 495 predicted novel associations that are not found in the ChEA training data, 
a number of them are strongly supported by published studies. The associations are listed in Table 
3.4. While the association between NOTCH1 and MYC was previously studied regarding T-cell 
acute lymphoblastic leukemia and included in ChEA dataset, NOTCH2-MYC association was not 
included. Our prediction suggests that NOTCH2 may also be associated with MYC. Indeed, it was 
suggested that NOTCH2 and MYC are related in terms of cellular proliferation in mouse thymic 
lymphoma without strong evidence to conclude their association [254]. More recently, a study 
 
 
Figure 3.4 Probability density of 909,924 randomly sampled WINTF prediction scores for TF-gene 




concerned with hypoxia-induced signaling pathway showed that NOTCH2-knockdown murine 
mesenchymal stem cells cannot properly proliferate, which can be reverted by overexpression of 
MYC [255]. The collaboration of ZMIZ1 and activated NOTCH1 was found to cause T-cell acute 
lymphoblastic leukemia in mouse models, which was proposed to be a result of the interaction 
between ZMIZ1 and MYC at downstream [256]. ARID5B gene, whose role in T-cell acute 
lymphoblastic leukemia has been unknown, was found to directly bind MYC enhancer to promote 
the MYC expression, which is a required step for the disease [257]. The concept of double protein 
lymphoma, characterized by the co-expression of MYC and BCL2 or BCL6, is known to be 
aggressive [258], although the MYC/BCL6 biomarker is of less prognostic value [259]. Possibly 
due to rarity of studies involving MYC/BCL6, the association was not included in the ChEA 
dataset, while the MYC-BCL2 association was included. NDRG1, whose overexpression in tumor 
cells decreases the proliferation rate [268], is known to be suppressed by MYC in embryonic cells 
[260]. In a study about the genetic linkage in colon cancer cells, upregulation of 
glycosyltransferase genes, including ST3GAL1 by MYC was observed [261]. It was also found 
that EFNA5 was upregulated along with other genes in MYC-knockout mice neural stem and 
precursor cells [262]. The physical interaction between SPI1 and BCL6 is reported. Interestingly, 
BCL6 acts as a repressor that binds to SPI1 in germinal center B cells [263]. Although the direct 
association is unknown and thus excluded from ChEA dataset, SOX2 and HES1 (with other genes) 
have been studied as markers of neural stem cells [264]. A more recent study added evidence that 
SOX2 and HES1 are at least members of the same regulatory pathway in rat anterior pituitary cells 
[265]. In the study, it was also found that SOX2-expressing cells have significantly lower levels 
of NOTCH2 expression, suggesting a potential repression of NOTCH2 by SOX2 [265]. The direct 
association between CREM and MEIS1 was not known although they are involved in the 
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myogenesis, the growth of skeletal muscle. A recent study suggests that although CREM and 
MEIS1 may not directly interact, they seem to regulate the growth process through another 
transcription factor, NF-Y [266]. In a recent ChIP-seq experiment, it was shown that RUNX1 is a 
target of AR, which is important for AR-dependent transcription and cell growth in androgen-
dependent prostate cancer [267]. These research activities support our claim that WINTF can 
predict unobserved, but positive associations based on the known associations. NOTCH2-MYC, 
ZMIZ1-MYC, BCL6-MYC, and EFNA5-MYC associations are in the ENCODE database [237], 
but not in the TRANSFAC [234] or TRRUST2 [239] database. MYC-NDRG1, MYC-ST3GAL1, 
and MYC-BCL6 associations are found in both ENCODE and TRRUST2 databases. ARID5B-
MYC, SOX2-HES1, and CREM-MEIS1 associations are not found in any of the three databases, 
suggesting that our method can predict novel TF-gene associations from known ones with proper 
TF-TF and gene-gene similarity measurements. 
3.5 Discussions 
It is suggested in Table 3.2 that TF-gene associations may be better modeled by using both 
protein-protein interaction network and sequence comparison. An important note is that using only 
one type of them (e.g. sequence-based similarity only) does not improve the predictive power of 
WINTF. In addition, the predictive performances were insensitive to the PPI-based TF-TF network 
importance weights, which implies that the canonical PPIs included in the database are insufficient 
to model gene regulation scenarios where multiple TFs form a complex to regulate a gene. A more 
comprehensive list of PPIs may address such issue. For better performance as well as 
interpretability, other types of gene-gene similarity scores may be used. The similarity may be 
based on the sequence alignment scores of the regulatory elements of the genes, which presumes 
that the DNA sequences of the regulatory elements have evolved to efficiently recruit the TFs. 
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Differential gene expression data can also be a way to measure similarities between genes with the 
hypothesis that two genes showing similar patterns of expression under the same conditions are 
likely to be regulated by the same TFs. A combination of these two types of similarity scores may 
improve the predictions. Other biological constraints, including the relative location of TF and 
gene in the genome can be incorporated into the weight and imputation matrices. However, many 
of such similarity measurements are tissue- and context-specific. Unfortunately, we do not have 
large-scale tissue-specific TF-gene association data yet. It is noted the canonical PPIs used in this 
study are mainly functional associations including the co-expressed genes. Although they are not 
perfect measurement for the gene-gene similarity, our benchmark studies and independent 
validations demonstrate their potential utility. 
Our benchmarks in Table 3.2 demonstrate that the weight, regularization, imputation, and 
side information parameters are critical for WINTF. Without these parameters, the vanilla MTF 
method shows no predictive power. Table 3.3 also suggest that the improved performance of 
WINTF compared to REMAP is from the introduction of the matrix S. While the main purpose of 
introducing the matrix S is to set different ranks for genes and TFs, it is not clear whether the ranks 
must be very different. The Condition B in Table 3.3 shows that WINTF performs better than 
REMAP even if all rank parameters are set to 100. In practice, the rank parameters are heuristically 
optimized. On the other hand, the matrix S can be viewed as a hidden layer introduced to REMAP. 
Thus, the matrix S may have worked similarly to the hidden layers for the popular deep learning 
methods, characterized by multiple layers of neural networks with activation functions and 
regularization steps. Increasing the number of low-rank matrices in WINTF to mimic deep learning 
may be an interesting future study. A more interesting combination is to integrate neural network 
techniques with matrix factorization, as shown in a recent study where the matrix inner product is 
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considered an additional layer to a multilayer neural network [269]. The time complexity due to 
the introduction of an additional low-rank matrix as well as large number of parameters from 
multilayer neural network can be overcome by factorizing smaller submatrices and projecting to 
the original feature space [270]. In addition, the algorithm to optimize the cost function of matrix 
factorization may be improved. Simultaneous perturbation stochastic approximation is a potential 
algorithm to improve the performance as well as the speed of optimization since it requires a 
dramatically low number of evaluations per iteration and randomness to potentially find the global 
minimum solution [271, 272]. Such work will enable larger scale applications of the association 











Application of WINTF for Targeted Anticancer Therapy 
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4.1 Introduction  
The cost of bringing a drug to the market has risen to approximately 2.6 billion dollars 
(Tufts Center for the Study of Drug Development, 2015), and the failure rate is intimidating: only 
about one third of drugs in phase III clinical trials reach the market. The limited success of the 
conventional drug discovery process is largely attributed to the wide adoption of a reductionist 
paradigm, “one-drug-one-gene-one-disease model” [273-275]. The onset and progress of many 
complex diseases such as cancer are systematic processes that involve multiple interacting genes 
in biological network. Therefore, it is important to design drugs that target gene interaction 
networks instead of a single gene. Furthermore, drug repurposing that reuses existing safe drugs 
for another indication has emerged as a new paradigm to accelerate drug discovery. As the safety 
profiles of existing drugs has already been well documented, the time and cost of clinical trials can 
be significantly reduced.  
Recent advancements in high-throughput laboratory techniques have generated abundant 
chemical genomics data on drug actions and disease genes. These big, complex, heterogeneous 
data sets provide unprecedented opportunities for identifying genome-wide drug-gene-disease 
associations, thereby facilitating multi-targeted drug design and drug repurposing. However, 
several challenges remain in successfully utilizing chemical genomics and disease association data 
for drug discovery. First, chemical genomics data from high-throughput screening experiments are 
not only extremely large but also highly noisy, biased, and incomplete. Many existing data mining 
algorithms are not directly applicable to build a reliable model for chemical genomics data. Second, 
drug action is a result of complex processes. Drug-gene interactions at the molecular level initiate 
the processes, and molecular interplay between biological network manifests the clinical outcomes. 
A single genomics data set can only capture a small part of the whole drug actions. Therefore, it 
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is critical to integrate multiple data sets for protein-ligand interactions, gene-disease associations, 
and ligand-disease associations to model the drug action on a multi-layer. Finally, one of the 
fundamental problems remaining in biomedical data mining: how to assess the reliability of a 
specific prediction from a data mining pipeline under a rigorous statistics framework. The reliable 
and unbiased assessment of the prediction for quality control is critical for cost-sensitive drug 
discovery projects. For instance, the selection of a novel ligand that is structurally different from 
patented drugs as a lead compound from a ranked list of candidate ligands is a billion-dollar 
decision.  Information on the reliability of individual prediction of a novel chemical entity based 
on its weak chemical similarity to existing drugs in terms of bioactivity is invaluable. Most existing 
data mining tools can only provide an averaged predictive accuracy based on the population of 
training data, but not reliability for a specific instance. For example, when using ranking-based 
predictive methods, it is not straightforward to determine what the threshold is to select top-ranked 
hits. The top ranked hit could be a false positive, or the top-N (N>1) ranked hits could all be true 
positives. 
To address aforementioned challenges in the predictive modeling of drug-gene-disease 
associations as well as unmet needs in the treatment of complex diseases such as cancer, our 
contributions in this work are in both methodology development and translational medicine.  
Our contribution in the methodological part starts from revisiting the WINTF method 
introduced in Chapter 3. In Chapter 3, we have developed a novel algorithm WINTF based on tri-
factorization to optimize matrix completion problem in which rows and columns have significantly 
different ranks. In this chapter, we formulate the protein-ligand interaction predictions as a multi-
rank dual-regularized weighted and imputed One Class Collaborative Filtering (OCCF) problem. 
Negative data, which are sparse and often unavailable, are not necessary for the training under the 
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OCCF problem formulation. By using element-specific weights and imputation values as in 
Chapter 2, WINTF can handle noisy chemical genomics data in which the label is often uncertain. 
Finally, unlike conventional OCCF algorithm that applies a single rank to all layers, WINTF 
assigns a different rank to a different layer. It is crucial since different layers can have dramatically 
different dimensions to optimally capture the layer-specific features. For example, the dimension 
of a ligand layer is in the order of millions, while the dimension of a protein layer is only thousands. 
Our benchmark in this chapter clearly show that WINTF outperforms its single-rank counterpart, 
REMAP, which is introduced in detail in Chapter 2. Second, to tailor the nature of protein-ligand-
disease association data sets where observed ligand-disease associations are far sparser than known 
protein-ligand interactions and few three-way protein-ligand-disease associations exist, we have 
developed a multi-rank, multi-layered framework, ANTENNA, for inferring novel protein-ligand-
disease associations. ANTENNA has three main components. (1) ANTENNA takes multiple 
chemical genomics and disease association data set, and integrate them as a multi-layered network 
[226], as shown in Figure 4.1. (2) ANTENNA uses WINTF algorithm to predict genome-wide 
novel protein-ligand associations. (3) Based on the genome-wide protein-ligand association 
network, ANTENNA applies Random Walk with Restart (RWR) and a statistical framework, 
Enrichment of Topological Similarity (ENTS) [276], to infer unobserved ligand-disease 
associations and assess their reliabilities.  
Arguably, the most important contribution of this work is to discover a potentially safe and 
effective targeted therapy for triple negative breast cancer (TBNC). Using ANTENNA, we 
predicted that an FDA-approved drug diazoxide may inhibit multiple kinases. Kinase malfunctions 
are known to be associated with many diseases such as cancer and Alzheimer’s disease. Among 
the kinases with the highest percentage of inhibition by diazoxide, TTK gene is specifically over-
 108 
expressed in TNBC patients [277, 278]. Therefore, we hypothesized that diazoxide may be 
cytotoxic against TNBC cells. We outsourced experimental validations, which are introduced in 
detail in our published work [99]. Multiple experimental evidence supports our prediction. TNBC 
is the most aggressive subtype of breast cancers. No targeted therapy is currently available for 
TNBC, supporting that our finding has a great potential toward developing an effective targeted 
therapy for TNBC.  
4.2 Relevant Works 
In principle, tensor factorization is a powerful method to predict three-way multilayer 
relationships. However, observed protein-ligand-disease triplet associations are extremely sparse. 
Majority of observed protein-ligand pairs are not associated with any diseases. Thus, tensor 
factorization may be an optimal solution. REMAP algorithm, a kind of OCCF has been applied to 
a bipartite graph for predicting protein-ligand interactions as introduced in Chapter 2, but not to 
inferring multiple protein-ligand-disease associations. Moreover, existing OCCF algorithm is 
mainly based on the formulization of matrix factorization that only allows a single rank for feature 
compression. FASCINATE is an algorithm that can jointly infer missing links from a multilayer 
network model, which is introduced in Chapter 5. However, FASCINATE is based on the 
formulation of a single-rank collective OCCF. Moreover, it can only rank predicted relations, 
 
 
Figure 4.1 Illustration of Multilayered network model that integrates multiple genomics data sets into a 
large protein-ligand-disease association network. 
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without providing any reliability measures. The WINTF algorithm, which is described in detail in 
Chapter 3, can address the drawbacks in matrix factorization, OCCF, and FASCINATE when 
applied to inferring protein-ligand-disease associations. 
 
4.3 Experimental and Computational Details 
Overview of Computational and Experimental Procedure 
Our primary purpose is to mine chemical genomics and disease association data to identify 
novel targeted therapies for unmet biomedical problems such as the treatment of TBNC. As shown 
in Figure 4.2, the input of ANTENNA is the association networks in chemical genomics, drug, and 
disease databases including DrugBank [36], ZINC [27], ChEMBL [28], and CTD [182]. We first 
integrate these data sets into a multilayered protein-ligand-disease network, MULAN. Then we 
apply WINTF, a multi-rank dual-regularized weighted and imputed OCCF algorithm introduced 
in Chapter 3, to infer novel protein-ligand associations. Next, we used ENTS to infer ligand-
disease associations and to assess the reliability for each predicted association. The output of 
ANTENNA is a list of predicted ligand-disease associations ranked by their statistical significance. 
Finally, we outsource to experimentally validate the top-ranked predictions. In this chapter, we 
discuss the construction of MULAN and application of WINTF algorithm. The full details about 
integration with ENTS and the experimental validations are described in our published work [99]. 
Construction of Multi-Layered Chemical-Gene-Disease Network (MULAN) 
We combined heterogeneous data sets from genomics into a multilayered network model, 
MULAN. Each node in MULAN is a chemical entity (ligands, drugs and other chemicals), a 
biological entity (genes or proteins that it encodes), or a phenotypic entity (disease and side effect). 
Nodes in the same entity class are linked together by within-layer similarities (e.g., ligand-ligand 
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structural similarity or protein-protein sequence similarity) or known interactions (e.g., protein-
protein interactions). Nodes that belong to different entity classes reside in different network layers 
and are linked by cross-layer associations (e.g., known drug-target interactions, disease-gene 
associations). Integration of genomics data into a bipartite graph is of a proven value [279]. 
MULAN can be regarded as the union of multiple bipartite graphs. Thus, our new method is likely 
to be more robust than traditional approaches. 
Protein-ligand associations including drug-target associations were obtained from the 
ZINC [27], ChEMBL [28] and DrugBank [36] databases as shown in Chapter 2. To obtain reliable 
protein-ligand association pairs, binding assays records with IC50 (concentration of the chemical 
needed to inhibit 50% of the activity of the target protein) information were extracted from the 
databases, and the cutoff IC50 value of 10 µM was used where applicable. Protein-ligand pairs 
were considered positively associated if IC50 ≤ 10 µM (active pairs), negatively associated if IC50 
>10 µM (inactive pairs), ambiguous if records exist in both ranges (ambiguous pairs), and 
unobserved otherwise (unknown pairs). A total of 198,712 unique ligands and 3,549 unique 
proteins were obtained from the combination of ChEMBL and ZINC with 228,725 unique active 
protein-ligand pairs, 76,643 inactive pairs, and 4,068 ambiguous pairs. Of the 198,712 ligands, 
722 were found to be FDA-approved drugs. Furthermore, drug-target relationships were extracted 
from the DrugBank and integrated into the ZINC_ChEMBL dataset above. A total of 199,338 
unique ligands and 6,277 unique proteins were obtained from the combination of ZINC, ChEMBL, 
and DrugBank with 233,378 unique active protein-ligand pairs. Ligand-disease and protein-
disease associations were obtained from the CTD database [182]. 
 We describe the required inputs to WINTF method first. As WINTF is a direct extension 
of REMAP, the same inputs are required as described in Chapter 2. Ligand structural similarity 
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scores are calculated based on Tanimoto coefficient of the radius-2 ECFP (ECFP4) for ligand 
molecules. Protein sequence similarity scores are calculated using BLAST sequence alignment 
scores as described in Chapter 2. 
  
In addition to the same inputs as REMAP, disease-disease similarity is also required for 
WINTF to infer ligand-disease associations, and can be calculated using distributed word 
representations [280]. In this chapter, we do not infer the ligand-disease associations directly using 
WINTF, since only less than 0.4% of ligands have observed associations with any diseases. Instead, 
we use ENTS and target binding profile of a ligand, which is derived from WINTF, to predict 
ligand-disease associations.  
WINTF Algorithm 
Our prediction method WINTF is described in detail with mathematical justifications in 
Chapter 3. We apply WINTF to predict unknown associations in protein-ligand interaction 
network in this Chapter. As introduced in earlier chapters, the prediction algorithm assumes that 
similar ligands are likely to share common target proteins. Also, unobserved associations do not 




Figure 4.2 Workflow of ANTENNA, a multilayer recommender system for drug repurposing. 
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necessary inputs, WINTF algorithm returns the two low-rank feature matrices F and G for ligands 
and proteins, respectively, based on the Eqs. 3.2, 3.3, 3.4, and 3.5, and Algorithm 3.1 in Chapter 
3. The predicted protein-ligand associations are obtained by removing scores for known 
associations from the dot product of the feature matrices. For benchmark purpose, we use the 
predicted protein-ligand associations to evaluate the performance of WINTF in comparison with 
REMAP. To combine WINTF into ANTENNA pipeline, we use the ligand-side low-rank feature 
matrix F to obtain feature vectors for each ligand. The feature vectors are used to build ligand-
ligand latent similarity network as described below. 
Combining WINTF and ENTS to Predict Drug-Disease Association 
In ANTENNA, we first use WINTF to generate ligand-side low-rank feature matrix F and 
protein side low-rank feature matrix G. The 𝑖!" row of F contains the protein association profile 
for the 𝑖!" ligand. Then, we calculated ligand-ligand cosine similarities based on the vectors in the 
matrix F and construct a ligand-ligand similarity graph. For each row of F for FDA-approved 




To search for possibly undiscovered uses of the FDA-approved drugs, we focus on drugs that are 
found to have high cosine similarity but low ligand structural similarity (< 0.5). Finally, we cluster 
drugs based on their directly or indirectly associated diseases found in CTD database [182], and 
use ENT to assess and rank the statistical significance of novel drug-disease associations. The final 
output of ANTENNA is a list of inferred drug-disease association based on the ranking of false 




4.4 Results and Discussions 
Performance evaluation of WINTF 
As shown in Chapter 2, single rank REMAP outperformed state-of-the-art methods: a 
chemical similarity-based method (PRW [81]), the best performed matrix factorization methods 
so far (NRLMF [111] and KBMF with twin kernels (KBMF2K) [165]), combination of WNN and 
GIP (WNNGIP [154]), and another type of matrix factorization-based collaborative filtering 
algorithm (Collaborative Matrix Factorization (CMF) [167]).  Here, we compare the performance 
of WINTF with that of REMAP using two benchmarks. The first benchmark includes 3,494 
chemicals, 25 G-protein coupled receptors (GPCRs), and 4,494 observed chemical-GPCR 
associations. The second benchmark includes 33,684 chemicals, 31 Cytochrome P450 enzymes 
(CYP450), and 51,699 observed chemical-CYP450 associations.  
As shown in Figure 4.3, WINTF clearly outperforms REMAP when evaluated by both 
benchmarks. WINTF identifies around 96% and 87% true associations ranked on the top 3 for 
GPCR and CYP450, respectively, while REMAP can only identify around 78% and 60% true hits 
at the same ranks, respectively. When evaluated by the application to sequence-structure similarity 
search, ENTS is shown to be superior to Hidden Markov Model and RWR [276].  
     
 
 
Figure 4.3 Performance evaluations for WINTF and REMAP on GPCR dataset (A) and CYP450 dataset 
(B). Performance measured by the recall at the top-K ranked predictions. 
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Time complexity of WINTF 
Our empirical result shows that the running time of WINTF is linearly dependent on the 
number of proteins and ligands, as shown in Figure 4.4. When evaluated in a machine with 2 cores 
of 2.18 GHz CPU. It takes around 1,000 seconds to converge for a matrix with 15,000 ligands, 200 
proteins, ligand-side rank of 1,000, and protein-side rank of 200. This demonstrates that WINTF 
algorithm is scalable to decent-sized protein-ligand association networks. 
ANTENNA Predictions 
By combining WINTF with ENTS, ANTENNA predicted a total of 21,921 novel drug-
disease associations with Benjamini-Hochberg adjusted false discovery rate (FDR) less than 0.02 
as described in [99]. Since it is impractical to experimentally evaluate all the predictions, we 
selected drug-disease pairs for further experimental evaluation based on the following criteria. 
First, predicted kinase-binders are preferred since the genome-wide binding assay for kinases is 
accessible. Second, the associated disease does not have effective therapy yet, so that the 
repurposed drug will have the maximal clinical impact. Third, cell-based disease models should 
be available, so that we can further evaluate the efficacy of the drug.  
     
 
 
Figure 4.4 Running time of WINTF according the number of items in the matrices. The computational 
time was measured using a 2-core 2.18 GHz CPU, for a matrix with 200 proteins and varying number of 




Based on above criteria, diazoxide, a safe FDA-approved drug for hypertension, was 
chosen for further evaluations. Diazoxide was predicted to interact with protein kinases. 
Furthermore, ANTENNA predicted that diazoxide was associated with Triple Negative Breast 
Cancer (TNBC) with Benjamini-Hochberg adjusted FDR of 0.0108. Thus, diazoxide may be 
repositioned as a treatment for TBNC which is the most aggressive type of breast cancer and cannot 
be effectively treated by any existing targeted therapy. It notes that the FDR of predicted diazoxide-
TNBC association did not show particularly statistically significant. If this prediction can be 
experimentally validated, we will have more confidence in predictions with lower FDRs. 
As discussed in the reference [99], our predicted drug activities of diazoxide were 
experimentally validated by proprietary KinomeScanTM assay and cell proliferation inhibition 
assay. Briefly, diazoxide was found to inhibit multiple kinases, including DRYK1A, IRAK1, and 
TTK, which are associated with multiple cancer drug-resistance, and TNBC, Alzheimer’s disease. 
In cell viability assays, diazoxide showed stronger inhibition for the MDA-MB-368 (TNBC) cell 
line (IC50 = 0.87 ± 0.39	𝜇M) than for the MCF-7 (ER-positive breast cancer) cell line (IC50 = 
130.0 ± 70.0	𝜇M). The inhibition of diazoxide against TNBC cell line is clearly stronger than the 
clinically accepted cutoff value of IC50 = 10	𝜇M, indicating that diazoxide may be a potential 
treatment for TNBC. 
4.5 Conclusions 
In summary, we have developed a reliable and accurate multi-rank, multi-layered 
recommender system ANTENNA. Using ANTENNA, we predicted that an FDA-approved safe 
medicine, diazoxide, could bind to multiple kinases whose malfunction is associated with TNBC, 
a deadly subtype of breast cancer. We outsourced to perform the proprietary KinomeScanTM assay, 
which confirmed the kinase-binding activities of diazoxide. Cell viability assay – also outsourced 
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– further validated that diazoxide is highly potent in inhibiting the proliferation of TNBC cancer 
cells. These findings suggest that diazoxide can be repositioned as an effective targeted therapy 
for TNBC. Furthermore, diazoxide may be effective in the treatment of other diseases such as liver 
cancer and Alzheimer’s disease. We are carrying out experiments to validate these predictions. 
This chapter demonstrates that big data analytics provides new opportunities for accelerating drug 

















Severe side effects or adverse drug reactions are the 2nd leading cause for drug attrition, 
and the 4th leading cause of death in the US. Adverse drug reactions and side effects limit the use 
of the drugs, decrease their value, and negatively affect patients [281, 282]. Despite the importance 
of identifying potential side effects of a drug molecule in advance, it is intimidating and prohibitive 
to experimentally test them. As a result, our knowledge in biological and biomedical associations 
of side effects and adverse drug reactions is biased, sparse and noisy. To tackle the difficulty in 
studying drug-induced side effects, systematic, large-scale methods have been developed to 
computationally predict drug-induced side effects [283-286]. Although these approaches provide 
acceptable performances for predicting common side effects of existing drugs, challenges remain 
to predict rare side effects as well as to systematically predict missing multi-scale drug-protein-
pathway-side effect associations. It is important to computationally model drug actions in multiple 
aspects since the drug responses result from complex interplay among biological pathways that are 
modulated by drug-target interactions.  
It is not trivial for a machine learning method to predict novel drug-protein-pathway-side 
effect associations based on incomplete, biased, and noisy data. In Chapter 2, we proposed 
REMAP to address the challenge of learning from such data. As shown in Chapter 2, REMAP has 
several unique features, making it particularly applicable to predict missing relations from 
incomplete and noisy data sets such as drug-side effect network. First, REMAP does not require 
negative data annotations for training as it utilizes the imputation strategy. The drug-side effect 
association network in existing databases are mainly collections of reported side effects. As a 
result, known negative associations are extremely sparse as they are rarely tested or reported. These 
limitations impose hurdles for most classification methods, which require positive and negative 
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samples. Second, REMAP can handle mislabeling by assigning a confidence score to each label. 
Mislabeling is common in biological and clinical data sets due to systematic and random errors in 
experiments. Finally, by applying neighborhood regularization on drug, protein, and side effect 
information, REMAP partially alleviates the cold start problem, where predicting new protein 
targets or side effects is difficult for ligands without any known target proteins or side effects.  In 
our earlier study, we have showed that REMAP can be successfully applied to predict unknown 
drug-protein interactions [110]. In this chapter, we extend its application to drug side effect 
prediction.  
 
Figure 5.1 A multilayered network view of drugs causing side effects. Drugs may bind protein targets that 
are associated with side effects or relevant biological pathways. Therefore, drugs may cause side effects 
as results of complex interplay of molecules within biological networks. Solid lines: known associations 
used as training sets in this chapter. Dashed lines: no known associations used. 
 
While REMAP shows high accuracy and great potential in understanding drug actions, it 
has limitations. One of the most important limitations is that REMAP can take only two distinct 
types of biological entities (e.g. drugs and proteins) and their relationship as a bipartite graph. As 
mentioned above, however, drug actions involve multiple biological entities that are linked with 
each other on a multi-scale. Therefore, integrating information from more than two types of 
biological entities may be crucial for predicting drug actions and drug-induced side effects. For 
example, a drug often interacts with off-targets. The off-targets are involved in biological 
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pathways, and the pathways may be associated with side effects. These biological entities (e.g. 
drug, target, pathway, and side effect) and their relationships can be modeled as a multilayer 
network (Figure 5.1). To predict missing associations in the multilayer network, most conventional 
methods model multiple pairwise associations independently, and integrate these binary relations 
subsequently. Such an approach ignores the within-layer dependency among the binary 
associations. FASCINATE algorithm was proposed to predict novel missing relationships from 
multilayer networks by jointly optimizing multiple bipartite graphs [287]. In the benchmark, 
FASCINATE outperforms state-of-the-art methods in predicting multilayer associations [287].    
In this chapter, we apply REMAP and FASCIANTE to predict drug-side effect associations 
and identify pathways associated with the side effects, respectively. We first show that REMAP 
outperforms state-of-the-art multi-target learning methods for predicting drug-side effect 
associations. Then, we perform random permutation analysis with the FASCINATE algorithm to 
infer statistically significant protein-side effect associations based on known associations among 
drug-protein, drug-side effect, and protein-side effect associations. The gene overrepresentation 
analysis is carried out to predict associations among biological pathways and side effects. The 
predicted results suggest that the biological pathways associated with cataracts, glaucoma, 
depression, and other side effects. These putative associations are supported by existing clinical 
evidence. Therefore, FASCINATE has demonstrated great potential for identifying novel 
associations between side effects and biological pathways systematically from drug-protein-side 
effect networks. Our method relies on the known associations and node similarity information, 
such as chemical structural similarity between drugs. It is expected that the use of a more accurate 
similarity measurement as well as more complete drug-protein-side effect association datasets can 
discover more novel associations, which may be directly applied to clinical studies.   
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5.2 Related Works 
In this section, we review the existing methods for side effect-pathway association 
prediction, and the core artificial intelligence and statistical machine learning methods that have 
been applied to drug-induced side effect predictions, followed by applications of nonnegative 
matrix factorization methods for association prediction. 
To the best of our knowledge, only a few studies have focused to infer the associations 
between side effects and biological pathways. Using the frequent subgraph discovery method 
Fukuzaki et al. proposed Cooperative Pathway Enumerator, CREPE, to predict associations 
between biological conditions (e.g. heat shock condition) and pathways [288]. Wallach et al. 
presented a method to infer associations between side effect and pathways by a combination of 
protein-ligand docking and logistic regression methods, assuming that drugs affecting the same 
pathway may induce the same side effects [289]. More recently, Shaked et al. developed Array of 
Model-based Phenotype Predictors, AMPP, to infer drug-protein interactions using Support Vector 
Machine, and extended it to connect key metabolic reactions and biomarkers to side effects, by 
applying Random Forest-based feature selection on the biomarker features [104, 290].  
Similarity Ensemble Approach (SEA) is a popular method to predict whether a drug will 
bind to a target protein based on a set of chemical structural similarity scores [56, 291, 292]. 
Lounkine et al. applied SEA to predict drug-induced side effects by connecting the predicted drug-
target associations to the known target-side effect associations [283]. The strength of SEA is that 
it can capture information possibly hidden in sets of weak similarities. 
Multilabel learning is a class of statistical machine learning methods suitable for predicting 
multiple labels that are not necessarily mutually exclusive, and its applications on several domains 
have been developed [293]. Zhang and Zhou developed k-nearest neighbor-based multilabel 
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learning method (MLKNN) [294] and refined it by applying mutual information-based feature 
selection on top of MLKNN (FS-MLKNN) to infer drug-induced side effects [286]. FS-MLKNN 
can be categorized as an ensemble learning method, which combines weak/moderate base learners 
to build a strong predictor. 
Canonical Correlation Analysis (CCA) is used to find the weights that maximize the 
correlation across the feature vectors [295]. Pauwels et al. proposed a chemical substructure-based 
method that applies CCA and refined it to Sparse CCA (SCCA) for easier interpretation [285, 296]. 
In addition to the inference outcomes, SCCA can also return to the optimized importance weights 
for each feature. Liu and Altman applied CCA and found correlations among binding affinities of 
drugs to essential target genes and side effects of drugs. They integrated CCA with singular  value 
decomposition to extract features representative of biological signals, carefully excluding the 
frequency of information in the dataset [297]. 
While these sophisticated computational methods are reasonably accurate, each class of 
methods has clear drawbacks. First, SEA, FS-MLKNN and SCCA only use chemical features from 
drugs. Thus, these methods are incapable of utilizing other side information, such as protein-
protein similarity unless integrating into other methods. Second, these methods are not suitable to 
handle the activity cliff, where a small change in a molecular structure results in a dramatic change 
in the biological outcome [148]. Third, these methods are based on the assumption that the 
unobserved associations are negative. However, the unobserved associations may not necessarily 
be negative, the idea which the weighted imputation-based method tries to adopt. 
Nonnegative matrix factorization (NMF), first introduced by Paatero and Tapper in 1994, 
became a widely adopted method for recommendation tasks with the development of the 
multiplicative update algorithm by Lee and Seung [298, 299]. One of the most successful NMF 
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applications is perhaps the Netflix competition, where the unknown user-video preferences are 
inferred by NMF [225]. To better predict the user-item preferences, advanced NMF algorithms 
take side information, such as user-user and item-item similarities to reflect homophily effect, the 
idea that similar users tend to choose similar items. Advanced NMF methods such as wiZAN-dual 
can also apply weights and imputation strategies to reflect that some of the unknown associations 
may be positive [161]. Based on the mathematical framework of wiZAN-dual, REMAP and its 
variation COSINE were developed to make predictions on unobserved protein-ligand associations 
[110, 300]. FASCINATE is an extension of REMAP on a multilayer network. In this chapter, we 
utilize REMAP and FASCINATE to predict unknown drug-protein-pathway-side effect 
associations. REMAP and its another extension in data-driven, structure-aided computational drug 
repurposing pipeline, 3D-REMAP, are described in detail in Chapter 2. 
 
 
Figure 5.2 Illustration of FASCINATE algorithm for drug-gene(protein)-side effect multilayer network. 
Latent features of drugs, genes, and side effects are calculated based on the observed associations and 
side information. The latent features are utilized to reconstruct the complete association matrices for each 




Overview of REMAP and FASCIANTE algorithms 
As illustrated in Figure 5.2, the hypothesis of FASCINATE algorithm is that the observed 
sparse and noisy drug-gene profiles and drug-side effect profiles rise from the latent features 
(hidden variables) of drugs, genes (proteins), and side effects. Similar drugs, proteins, or side 
effects will have similar latent features as the optimization proceeds. The dot product operation 
between drug and gene latent features will restore the complete drug-gene associations; similarly 
for drug-side effect and gene-side effect associations. Note that when we focus only on one of the 
cross-layer dependencies (e.g. only drug-gene, or only drug-side effect), the application is identical 
to REMAP in Chapter 2. Also, it is important to note that FASCINATE jointly optimizes each 
layer; thus, the result is different from just combining the output matrices after applying REMAP 
separately to the layers. 
Dataset description 
Our method has three distinct types of nodes: drugs, genes (or proteins), and side effects. 
We collected known associations from several publicly available databases. Drug-side effect 
associations for small molecular drugs were obtained from SIDER4.1 database [34]. Drug-protein 
associations are obtained from the combination of three databases: ZINC, ChEMBL, and 
DrugBank as explained in Chapter 2 and Chapter 3 [301-303]. Drug-protein associations were 
excluded if the drug was not found in the SIDER database. Protein-side effect associations were 
obtained from the dataset reported in a publication [283]. The known associations were regarded 
as binary relations (i.e. 1 for observed positive associations, and 0 otherwise). The drug-drug 
similarity scores were calculated based on chemical 2D structure similarity as described in Chapter 
2. We obtained protein-protein interactions from BioGRID database [304] and used as gene-gene 
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similarity matrix. We also have tested semantic similarity-based side effect-side effect similarity 
scores using UMLS-Similarity software [305]. However, our experiments indicated that the 
semantic similarity scores did not improve protein-side effect or drug-side effect prediction 
accuracy. To be specific, the best performance using the semantic similarity was within one 
standard deviation of the performance without it (data not shown). Therefore, we used an identity 
matrix instead, as side effect similarity matrix. The data types and counts are in Table 5.1. 
 
Table 5.1 Data statistics of drug-gene-side effect network 




Side effects (diseases) 4251 
Associations 
Drug-gene 4727 
Drug-side effect 127595 




Side effect-side effect 4251 
 
Description of prediction method, FASCINATE  
REMAP is a variation of nonnegative matrix factorization algorithm for inferring novel 
binary relations, introduced with details in Chapter 2. FASCINATE is an extension of REMAP on 
multi-layered network [287]. The three layers used in this study are drugs, genes (proteins), and 
side effects, and the aim is to find low-rank matrices of latent features for each layer that minimizes 
the following equation: 
min
X8Y;	(ZP2,…,\)
J =iWZ,]⊙7DZ,] + PZ,] − FZF]^9iX








Here, g is the number of total layers (3 in this study), and Fi (e.g. F1, F2, or F3) is the low-
rank feature matrix for the ith layer, Di,j is the cross-layer association matrix between the ith and jth 
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layers (e.g. drug-gene), Ai is the within-layer similarity matrix (e.g. drug-drug or protein-protein), 
Ti is the diagonal degree matrix of Ai, Wi,j is the weight matrix, Pi,j is the imputation matrix, ⊙ is 
an element-wise product operator (Hadamard product), and ‖M‖F3  is the Frobenius norm of matrix 
M. For the sake of algorithmic efficiency, we use global scalar weight and imputation values as 
done in the REMAP in Chapter 2. Once the low-rank feature matrices for each layer are obtained, 
the prediction matrix between the ith and jth layer is the matrix inner product of Fi and Fj. If there 
are only two layers, the objective function in Eq. 5.1 is equivalent to that of REMAP in Chapter 2.  
We evaluated the effectiveness of REMAP based on multiple metrics. For varying degree 
of density in the gene-side effect network, we performed 10-fold cross-validations to evaluate four 
different performance metrics that are frequently used to assess recommender systems algorithms. 
The four metrics include the standard area under the receiver operating characteristic curve 
(AUROC, or AUC), Half-Life Utility (HLU) [306], Mean Average Precision (MAP) [251], and 
Mean Percentage Ranking (MPR) [307]. HLU estimates the likelihood that a user accepts the 
recommended items with an assumption that the likelihood exponentially decreases with the 
ranking of items [308]. MAP is a measure of the average precision over all users in the test dataset 
at different recall levels [251]. MPR is a measure of the average of percentile-ranks of positive 
associations in the test dataset [307]. For example, an MPR of 0% is obtained if all positive samples 
are top-ranked. On the other hand, a 100% MPR indicates that they are ranked to the least. Thus, 
the higher AUC, HLU, MAP and the lower MPR, the better performance. During the cross-
validation, we categorized side effects by the number of known associations with drugs and 
measured performances from rare side effects to frequently observed ones. For comparison, we 
tested feature selection-based multilabel k-nearest neighbor method (MLKNN) [286] under the 
same cross-validation and rarity conditions as those for REMAP.  
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Since FASCINATE takes several tuning parameters, we found the optimal parameters by 
using a grid search and 10-fold cross-validation. For each fold, we randomly selected 
approximately 10% of the associations from both drug-protein and drug-side effect layers as test 
sets and measured the AUC for each layer separately. Then, we took the sample-count weighted 
average to evaluate the performance. In this way, we found the optimal low-rank hyperparameter 
and maximum iteration number to be 770 and 100, respectively, while fixing the other 
hyperparameters to be the default values. Using the optimal rank parameter and iteration number, 
we found the optimal hyperparameters to be α=0.5, β=1.0, and w=0.25.  
Random permutation and overrepresentation analysis 
Next, we conducted random permutation and overrepresentation analysis on the gene-side 
effect layer using the optimal hyperparameters above. We estimated the null distribution of 
prediction scores from random permutations, and using the null distribution, we filtered predicted 
pairs from FASCINATE without permutation. The filtered pairs were then used to search for 
significant pathway-side effect associations by a hypergeometric overrepresentation test. For each 
permutation test, we randomly permutated the drug-protein and drug-side effect associations while 
keeping the total number of observed associations in each layer intact. Using the permutated layers 
and the intact gene-side effect layer as inputs, we ran FASCINATE to obtain the prediction scores 
for gene-side effect pairs. We performed 200 iterations of permutation tests and recorded the 
prediction scores for each gene-side effect pair. Then, we collected raw prediction scores from 
randomly selected 1,000 gene-side effect pairs from unknown associations. With the 200,000 raw 
scores (1,000 pairs with 200 scores from each iteration), Epanechnikov kernel was used to fit the 
distribution (Figure 5.3). Excluding those for known gene-side effect associations, the raw 
prediction scores were converted into p-values by the Epanechnikov kernel probability density 
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function obtained above, followed by the False Discovery Rate adjustment. To predict unknown 
associations among biological pathways and the side effects, the gene sets for each side effect were 
used for KEGG overrepresentation test provided in the Cluster Profiler package [309]. To focus 
on rare associations, the enriched pathway-side effect associations were excluded if the pathway 
is associated with more than 5 side effects, or the side effect is associated with more than 5 
pathways. Also, predicted pairs with q-value (from hypergeometric test) higher than 0.05 were 
filtered out.  
 
Figure 5.3 (A) Epanechnikov kernel fitting on FASCINATE prediction scores from random 




Significantly improved performance of REMAP in predicting rare side effects 
REMAP showed better performances than MLKNN evaluated by the four metrics in all 
tested rarity categories (Table 5.2). The better performance of REMAP over MLKNN is more 
noticeable for rarer side effects. The AUC of REMAP drops from 0.95 to 0.84 as the rarity of side 
effects increases, while that of MLKNN drops from 0.92 to 0.68. This suggests that REMAP can 
be effectively applied for drug-side effect inference tasks from rare to common side effects. It is 
noted that while REMAP shows better AUC and MPR for more common side effects, its 
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performance is not necessarily improving as the rarity decreases, based on HLU and MAP. The 
same trend is observed for MLKNN, suggesting that the use of these four metrics together provides 
more objective evaluations. To summarize, our extensive benchmark studies show that REMAP 
has a great potential to infer novel associations. 
 
Table 5.2 Performances of REMAP and MLKNN predicting drug-side effect associations 
 
 Avg. AUC Avg. HLU Avg. MAP Avg. MPR 
Number of 
drugs per SE* REMAP
 MLKNN REMAP MLKNN REMAP MLKNN REMAP MLKNN 
< 12 0.84 0.68 5.6 3.6 .048 .031 0.26 0.33 
< 25 0.88 0.76 4.9 2.4 .045 .026 0.20 0.24 
< 50 0.90 0.82 4.1 1.6 .044 .026 0.16 0.19 
< 100 0.92 0.85 3.9 1.1 .043 .024 0.13 0.16 
< 200 0.93 0.88 3.5 0.7 .040 .023 0.11 0.13 
< 400 0.94 0.90 3.4 0.4 .042 .024 0.10 0.11 
< 800 0.95 0.91 3.6 0.2 .047 .027 0.08 0.10 
All 0.95 0.92 4.0 0.3 .052 .031 0.08 0.09 
* Side effects having a certain number of associated drugs per side effect. 
 
Literature supports of top ranked predictions 
Furthermore, multiple pieces of clinical evidence support the top ranked predictions from 
REMAP as shown in Table 5.3. Newton et al. investigated a total of 984 patients with generalized 
anxiety disorder to reported that patient groups receiving diazepam showed decreased libido 
compared to other groups including placebo [310]. Although the main cause was unclear, an 
ovarian cancer patient treated with paclitaxel and carboplatin was reported to develop acute 
myeloid leukemia (AML) in 2006 [311]. In 2016, another group of authors reported a case of a 
patient who developed AML after endometrial chemotherapy including paclitaxel, where 
paclitaxel was discussed as the likely cause of AML [312]. Patients treated with lenalidomide 
showed significant dermatologic side effects although indirectly related to ichthyosis and less 
severe [313]. It was reported that one of the most frequent side effect of erlotinib for non-small 
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cell lung cancer (NSCLC) is hypocalcemia when treated with emibetuzumab [314]. Furthermore, 
erlotinib alone was reported to cause hypocalcemia [315]. Two clinical case reports and human 
exposure studies imply that overdosing propranolol may cause cardiac arrest [316, 317]. Although 
rare and limited to the elderly population, ranolazine treatment was reported to cause visual 
hallucinations, which resolved after discontinuation of treatment [318]. In a study of 5,194 males, 
approximately 35% of patients suffered from erectile dysfunction, and it was associated with 
cumulative exposure to zalcitabine or enfuvirtide [319]. Ejaculatory failure was reported from 
oxcarbazepine treatment [320]. In three cases of long-term corticosteroid treatment, including two 
cases with prednisolone, the patients suffered from moderate to severe vision impairment, which 
could have resulted in permanent loss of vision [321]. In a study analyzing more than a million 
cases from September 1999 to April 2012, use of levofloxacin was found to be a great risk for 
patients. Patients who were treated with levofloxacin had higher hazard ratios for serious cardiac 
arrhythmia and death compared to amoxicillin and azithromycin [322]. In a case report, 
Mahendran and Liew suggested that symptoms of depression need to be carefully monitored when 
prescribing alprazolam. They reported a case of a healthy woman in her 20s who developed severe 
depression with suicidal thoughts after taking the prescribed doses of alprazolam for three times 
[323]. 
Table 5.3 Predicted top ranked drug-side effect associations with literature support 
 
Drug Predicted Side Effect Reference Drug 
Predicted Side 
Effect Reference 
Diazepam Libido disorder [310] Zalcitabine Erectile dysfunction [319] 
Paclitaxel Acute myeloid leukemia [311, 312] 
Oxcarbazepin
e Erectile dysfunction [320] 
Lenalidomide Ichthyosis [313] Prednisone Blindness [321] 
Erlotinib Hypocalcemia [314, 315] Levofloxacin Cardiac failure [322] 
Propranolol Cardiac failure [316, 317] Alprazolam Suicide attempt [323] 




Identification of pathway-side effect associations 
By FASCINATE and the subsequent random permutation analysis, a total of 7,572 gene-
side effect pairs for 409 unique genes and 1,150 unique side effects were found with q-values 
lower than 0.001. Then, these genes are statistically linked with biological pathways using gene 
set overrepresentation analysis. The final inferred pathway-side effect associations with their q-
value are listed in Table 5.4. The list of literatures supporting the inferred top-ranked side effect-
pathway associations suggests that our method can reliably infer missing one type of binary 
relations by jointly learning other types of binary relations from a multilayer network (Table 5.4). 
Wirtz and Keller identified mutations and significant up or down regulation in different kinds of 
an interleukin family of cytokines in mice with glaucoma, suggesting that disruption of interleukin-
20 signaling in the eye may be linked to glaucoma [324]. In a more recent study, Gupta et al. 
demonstrated that the concentration of tear film cytokines were significantly lower in patients with 
primary open-angle glaucoma [325]. Liu and Neufeld found that the epidermal growth factor 
receptor (EGFR) is significantly upregulated and tyrosine-phosphorylated in human glaucomatous 
optic nerve head in vivo. They showed that it induces nitric oxide synthase to generate excessive 
nitric oxide, leading to an increased intraocular pressure and potentially glaucoma [326]. In a 
separate study, the authors suggested that EGFR is a common regulatory pathway for neural 
injuries in optic nerves, including glaucoma [327]. Kwon and Tomarev showed that several 
components in integrin-focal adhesion kinase – serine/threonine kinase signaling pathway are 
activated in the eyes of mice expressing high level of myocilin, a protein known to be associated 
with glaucoma [328]. Piotrowska et al. found a significant proportion of patients developed drug-
induced cataracts, including those who had to undergo surgical repair from patients treated with a 
selective EGFR tyrosine kinase inhibitor [329]. Though the association between cataract and focal 
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adhesion pathway seems subtle, Kokkinos et al. demonstrated that the expression and 
phosphorylation pattern of focal adhesion kinase changes as the lens develops in mice [330]. Quite 
obviously, sex steroid hormone deficiency is known to be linked to erectile dysfunction [331]. 
Although we could not find pertinent literature evidence, it may be trivial to validate the predicted 
association between steroid hormone synthesis and decreased libido. An indirect association was 
shown between erectile dysfunction and gastric acid secretion, which is clinically regulated by 
histamine receptor antagonists [332, 333]. In a study involving 55 patients with stage IV NSCLC, 
patients having mutations in EGFR showed milder depression compared to those without EGFR 
mutations, suggesting a mutation-dependent association between depression and EGFR [334]. In 
a review paper, evidence was shown for omega-6 polyunsaturated fatty acid (e.g. linoleic acid) 
affecting the function of leukocytes [335]. Several interesting hypotheses rise from the inferred 
side effect-pathway associations. First, cataract and glaucoma share two common biological 
pathways: EGFR tyrosine kinase inhibitor resistance and focal adhesion pathways. Second, the 
results suggest that erectile dysfunction and decreased libido are linked to the steroid hormone 
biosynthesis pathway. Further studies with broader computational and biological aspects and 
experimental validations are required to refine FASCINATE method for gene-side effect-
biological pathway association prediction. 
Table 5.4 Predicted pathway-side effect associations by random permutation and 
overrepresentation analysis 
Side Effect (disease) KEGG Pathway Q-value Reference 
Glaucoma Cytokine-cytokine receptor interaction 1.1E-2 [324, 325] 
Glaucoma EGFR tyrosine kinase inhibitor resistance 9.2E-4 [326, 327] 
Glaucoma Focal adhesion 6.9E-3 [328] 
Cataract EGFR tyrosine kinase inhibitor resistance 7.3E-3 [329] 
Cataract Focal adhesion 2.2E-2 [330] 
Erectile dysfunction Steroid hormone biosynthesis 5.6E-3 [331] 
Libido decreased Steroid hormone biosynthesis 9.3E-6 Not found 
Erectile dysfunction Gastric acid secretion 8.1E-3 [332, 333] 
Depression EGFR tyrosine kinase inhibitor resistance 1.2E-2 [334] 
Leukopenia Linoleic acid metabolism 1.4E-2 [335] 
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5.5 Conclusions 
In this chapter, we showed that REMAP outperformed state-of-the-art MLKNN on drug-
side effect prediction evaluated by the four metrics (AUC, HLU, MAP, and MPR), especially for 
rare side effects. We apply FASCINATE, a multilayer extension of REMAP, to jointly optimize 
and predict the drug-protein-side effect network and to infer missing pathway-side effect 
associations by integrating with random permutation analysis and the gene set overrepresentation 
analysis. Several of the inferred drug-side effect and pathway-side effect associations are 
supported by existing experimental and clinical evidence (Table 5.3 and Table 5.4). These results 
suggest that network-regularized weighted imputed one-class collaborative filtering is indeed a 
potential tool for inferring missing biological relations on a multi-scale. There are many ways to 
further refine the performance of REMAP and FASCINATE. Their performances are dependent 
on the similarity measure of drug-drug, gene-gene, and side effect-side effect pairs as well as the 
coverage of reconstructed drug-gene-side effect networks.  The side effect-side effect semantic 
similarity used in this study does not improve the predictive power. Therefore, a new side effect-
side effect similarity measurement is necessary.  In earlier studies, it was shown that the structure-
based ligand binding site similarity improves the prediction accuracy for side effects. Furthermore, 
the datasets we used in this chapter are not comprehensive. Only 1,549 unique FDA-approved 
drugs and 4,727 drug-gene interactions are included in the network. Obviously, it is expected that 
more novel relations can be discovered if the reliable chemical-gene network which include 
millions of chemical compounds and thousands of targets genes [110] and more complete drug-













Learning Biochemical Properties from Protein Sequences by ALBERT, a Natural 






Data-driven knowledge discovery has been expanding with the unprecedented amount of 
available data to train and fine-tune models. Computational biology is one of such research areas, 
where the amount of biological and biomedical data is exponentially growing with the 
advancement of laboratory techniques and gradually decreasing costs to conduct high-throughput 
experiments. As introduced in Chapter 1, many large-scale databases provide the outputs from 
such large-scale high-throughput experiments, enabling researchers to perform computational 
experiments to mine concealed pieces of knowledge from the multi-omics data sets. A number of 
computational methodologies have been developed to learn from biomolecules and infer their 
activities that eventually result in drug responses or disease phenotypes.  
Despite the advancements and continued research activities, computational learning 
methods from protein sequences have been largely limited to the collective statistics of individual 
amino acids, termed protein descriptors [73]. The protein descriptors are often based on the 
physicochemical properties of individual amino acids with an assumption that the properties of 
amino acids are static, where the same behaviors are expected for a type of amino acid regardless 
of the position it appears in the protein. For example, an autocorrelation descriptor represents a 
protein as an average of certain amino acid properties, such as the net charge or volume of a type 
of amino acid, where a particular type of amino acid will always have the same contributions to 
the final descriptor. The assumption is unrealistic, however, as the key amino acid residues, 
including catalytic and binding site residues, play more important roles than the others. Thus, 
computational representations of protein sequences need refinements to account for the positional 
differences of amino acids to better model their biological activities, such as enzymatic activities 
or protein-ligand binding. 
 136 
Developing an efficient and effective representation method for proteins is a challenging 
task. Proteins having significant differences in primary sequences may still perform the same 
functions via the shared properties in their binding sites. On the contrary, proteins with globally 
similar structures do not necessarily share the binding partners. Protein primary sequences may 
contain evolutionary information that give rise to the similarities and differences in their biological 
activities, which may not be easily detected by conventional sequence comparison methods, such 
as BLAST [249]. In a sense, proteins may be considered a natural language, where the primary 
sequences are sentences from nature conveying the evolutionary and functional messages through 
the combination of words, the amino acids. Deciphering the natural language of proteins is a 
critical task in computational biology. 
Advanced deep learning architectures have shown promising performances in various 
tasks, including computer vision and natural language processing. In recent advancements in 
natural language processing projects, models are trained to correctly predict missing words based 
on the context [75, 337]. Since the training does not require additional annotations than the text 
itself, the scheme is often called self-supervised learning. In a recent study, Rives et al. showed 
that a deep learning-based natural language processing method, BERT [75], is capable of learning 
biochemical properties from protein sequences via self-supervised learning [76]. 
The protein representation learned by BERT language model has a few drawbacks. First, 
BERT pretraining on the whole 250 million protein sequences is inefficient. As stated in the 
manuscript, it takes several days to train the model with 128 of the NVIDIA V100 GPU, the most 
advanced GPU as of this writing, implying that it is infeasible to reproduce the work in most 
research facilities. Also, it is proposed that BERT architecture itself is suboptimal and can be 
refined to significantly reduce the computational burdens without compromising the accuracy [78]. 
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Second, the size of amino acid vocabulary is suboptimal to be comparable to human languages, 
for which BERT was designed. There are only about 30 distinct amino acids even if rare or 
unnatural amino acids are included, unlike the size of vocabulary in human language, which is 
typically several 10000s. Finally, the pretraining did not consider the evolutionarily conserved 
positions in protein families. Evolutionarily related proteins may exert same functions via 
conserved residues, which can be pre-sorted by comparing multiple protein sequences. 
In this chapter, we attempt to address aforementioned challenges in protein representation 
learning using a natural language processing method. We pretrain ALBERT model, a significantly 
optimized BERT architecture for predicting hidden words in sentences. We consider protein 
sequences as sentences containing words of amino acid triplets. Evolutionarily conserved 
positional information is obtained from Pfam database [338]. Our pretrained ALBERT model is 
capable of learning biochemical properties of amino acids as well as mutational information from 
kinase sequences. Please note that we use the term pretraining interchangeably with training in this 
chapter. Typically, pretraining refers to the self-supervised training of the language models, and 
training refers to the subsequent fine-tuning tasks, such as protein-ligand interaction predictions 
using the pretrained language models. The pretrained ALBERT model is applied to a fine-tuning 
task to de-orphanizing GPCRs, which showed promising results and submitted to a peer-reviewed 
journal for publication and is under review. We will focus on protein kinases in this chapter. 
 
6.2 Materials and Methods 
Protein sequences for kinases and GPCRs are obtained from Pfam database [338]. Pfam is 
a database of protein families, where the families are defined by statistical inference of homology 
using hidden Markov model [339]. Pfam database provides protein sequences grouped by families 
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with multiple sequence alignment within the family. We use the aligned protein sequences as the 
sentences and triplets of amino acids as words for pretraining the natural language model, 
ALBERT [78]. The overall preprocessing and pretraining steps are illustrated in Figure 6.1.  
 
Figure 6.1 Illustration of preprocessing protein sequences and pretraining ALBERT, a natural language 
processing model. From the top, protein sequences are grouped and aligned based on their protein family 
memberships as curated in Pfam database, and the triplet amino acids are extracted. Treating triplet amino 
acids as words and the aligned sequences as sentences, ALBERT pretraining is performed by randomly 
hiding words (red question marks). from sentences and optimize the model to correctly predict the hidden 
words. Once pretraining is complete, all possible amino acid triplets are processed by the pretrained 
ALBERT model to visualize triplet clusters. Similarly, all trained kinases are processed by the ALBERT 
model to cluster and visualize. Asterisks represent the classification token that is prepended to each protein 
sequence and used as the barcodes of the proteins. 
 
The raw sentences often contain substantial amounts of gaps, which makes the model 
training inefficient. On the other hand, each Pfam family contains the consensus sequence from 
the multiple sequence alignment. Thus, we selected evolutionarily conserved positions from the 
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multiple sequence alignment provided in the Pfam database. The alignment consensus sequence 
contains information about positions that are highly conserved, moderately conserved, and 
conservatively substituted. We selected the three different types of conserved positions from the 
consensus sequence of a given Pfam family, and the corresponding amino acid residues in each 
aligned protein sequence are obtained. The selected amino acids in each protein are then 
preprocessed into triplets. The triplets are used to train the ALBERT model with the following 
parameters: sentence batch size = 256, maximum sequence length = 256, maximum predictions 
per sentence = 40, word masking probability = 0.15, and duplication factor = 10. At 50,000 steps 
of pretraining ALBERT, the accuracy of predicting hidden amino acid triplets reached 0.970, 
which is more accurate and efficient than that of using BERT, reaching 0.964 accuracy at 100,000 
steps. We used a single NVIDIA V100 GPU for training, which were able to run approximately 
480 training steps per second. 
After pretraining, each triplet of amino acids was used to pull the triplet feature vectors, 
and the triplet feature vectors were grouped based on the type of amino acid in their third positions. 
The feature vectors were projected onto a 2D space using t-SNE, a popular dimension reduction 
technique, to visualize the clusters of triplets. Also, each sentence starts with a classification token, 
representing the classification features for the whole sentence. The classification tokens for each 
kinase were used to pull the feature vectors for kinases. The kinase feature vectors were visualized 
in a similar manner using t-SNE. The kinases are also grouped by the distinct kinase subfamilies 





6.3 Results and Discussions 
After pretraining ALBERT model with masked triplets of proteins, we extracted the 
pretrained feature vectors for all possible amino acid triplets. We used t-SNE to project the triplet 
vectors onto a 2D space. By grouping the triplets based on the type of amino acid on the third 
position of the triplets, we visualized the clusters of triplets on the t-SNE projection space (Figure 
6.2). Triplets containing an ambiguous or uncommon amino acids, such as amino acid U for 
selenocysteine or X for any unresolved amino acids, formed a large distinct cluster that did not 
belong to a smaller group (the large black clusters), suggesting that the information regarding such 
rare amino acids are scarce and may be insufficient to pretrain the model. When there is no 
ambiguity in triplets, they form clearly separated clusters, meaning that the pretraining process 
indeed allows the model to extract biochemically meaningful feature vectors from the proteins as 
sentences. The same clustering trends were also observed when triplets are grouped by individual 
amino acid types, rather than their physicochemical properties of side chains. 
Next, we also investigated whether the pretrained ALBERT model can efficiently learn a 
higher-level feature from protein sequences. We collected the feature vectors for the classification 
tokens for each kinase (asterisks in Figure 6.1) and projected onto a 2D-space using t-SNE. As 
shown in Figures 6.3 and 6.4, the classification tokens are initially randomly spread out. As 
reaching to more processed ALBERT layers, the kinase classification tokens form distinct clusters, 
noticeably for the tyrosine kinases forming several distinct clusters with gentle separation from 
other kinase classes (Figure 6.3). The distinct clusters of tyrosine kinases are found to be clusters 
of wild-type and mutant kinases, where the wild-type and its mutants are forming distinct clusters. 
Note that the classification tokens are the same “[CLS]” characters in the procedures (asterisks in 
Figure 6.1). These results demonstrate that ALBERT model can differentiate features for the same 
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token or triplets based on the context, and the differentiated features are biologically and 
biochemically meaningful. 
 
Figure 6.2 Visualization of pretrained feature vectors for amino acid triplets, projected onto a 2D-space 
using t-SNE, a dimensionality reduction technique frequently used to visualize high-dimensional features. 
Amino acid triplets are grouped and colored by the properties of the side chain for the third amino acid. 
A. The visualization of vectors from initial embedding that are not trained. B-E. The visualization of 
vectors from the 1st to 4th layers of ALBERT after pretraining. Legends are enlarged and shown separately 
for readability. Standard one-letter or three-letter amino acid codes are used to indicate the type of amino 
acids on the legend. The group “Others” includes triplets containing any nonstandard, ambiguous or 






Figure 6.3 Visualization of pretrained feature vectors for kinases, projected onto a 2D-space using t-SNE, 
a dimensionality reduction technique frequently used to visualize high-dimensional features. Kinases are 
grouped and colored by the Pfam family they belong to. A. The visualization of vectors from initial 
embedding that are not trained. B-E. The visualization of vectors from the 1st to 4th layers of ALBERT 




Figure 6.4 Visualization of pretrained feature vectors for kinases, projected onto a 2D-space using t-SNE, 
a dimensionality reduction technique frequently used to visualize high-dimensional features. Kinases are 
grouped and colored by their mutational status. A. The visualization of vectors from initial embedding that 
are not trained. B-E. The visualization of vectors from the 1st to 4th layers of ALBERT after pretraining. 
Legends are enlarged and shown separately for readability. 
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In this chapter, we demonstrated that ALBERT, a natural language processing model 
originally developed to learn from human languages is also efficient in learning from protein 
sequences. We preprocessed protein sequences to account for the evolutionary conservations in 
protein sequences as well as to reduce computational burden for the pretraining. With the highly 
optimized ALBERT architecture and reduced amount of sequences and triplets by preprocessing, 
we were able to train a highly accurate model within a reasonable computational time. Moreover, 
our pretrained language model were able to capture the biophysical properties and evolutionary 
relationships from protein sequences. When amino acid triplets were visualized, distinct clusters 
of triplets were formed based on the properties of amino acids. When whole kinases were 
visualized, on the other hand, they were grouped by the protein families as well as the mutational 
information. These results demonstrate that the pretrained ALBERT model is indeed an efficient 
strategy to mine biological features from protein sequences. 
The ALBERT pretraining strategy can be utilized for several fine-tuning tasks to predict 
various biological properties of proteins. After the self-supervised pretraining, models may be fine-
tuned using the binding site or active site residue labels. The model tuned with binding site or 
active site can also be further tuned for protein-ligand interaction prediction tasks. For instance, 
the feature vectors from the language model can replace protein descriptors in proteochemometric 
models introduced in Chapter 1. Also, it is plausible to integrate the language model with other 
deep learning architectures, such as Neural Fingerprint [63] for representing ligand molecules and 
predict protein-ligand binding activities. We applied the strategy to predict protein-ligand 
interactions to de-orphanize GPCRs, which showed promising results and is under review. The 
language model can be used for other tasks, such as predictions of protein-protein interactions or 















7.1 Future Directions 
 In this dissertation, we covered machine learning applications for predicting drug actions, 
including protein-ligand interactions and drug-induced side effects via biological pathways. We 
demonstrated that our nonnegative matrix factorization-based methods are highly efficient and 
effective in mining undiscovered drug activities from large-scale biochemical and biomedical data 
sets. Our subsequent studies have experimentally validated the utility of our methods, which are 
discussed in Chapter 2 and Chapter 4. Our results support our hypothesis that the integration of 
data-driven molecular screening methods with structure-based bioinformatics tools can present a 
powerful computational drug discovery pipeline. Our whole genome-scale drug-off-target 
prediction methods showed great scalability and accuracy with promising prediction outcomes, 
which are further enriched by methodological extensions in multiple directions. The 
experimentally validated predictions support that our contributions to the field of computational 
drug discovery are significant. 
 Despite the successful drug repurposing cases using our methods, a few important points 
remain to be refined for optimal outcomes for computational drug discovery. First, the REMAP 
algorithm and its variants introduced in this dissertation can be further improved for scalability. 
Second, the predictive models need to be extended to include molecular interactions across human 
and microbiome to gain better understanding of disease phenotypes. Third, more efficient models 
are needed to capture the necessary information from proteins. Finally, a unified systems structural 
pharmacology pipeline is needed to accurately predict the drug actions by integrating the large-
scale interaction networks with sequence- and structure-based predictive modeling, refined by 




Figure 7.1 An overview of the integrated systems structural pharmacology pipeline. The molecular 
interactions from human and pathogens are integrated with drugs and potential lead compounds. 
Sequence-based and structure-based predictive models prioritize the protein-ligand interactions and 
relevant diseases with the aid of homology modeling when structures are unavailable. The prioritized 
interactions are then further refined using biophysics-based modeling techniques such as protein-ligand 
docking and molecular dynamics simulation with relevant in silico mutational effects in considerations. 
The refined predictions can iteratively feedback the structure-based modeling, and the predictions can be 
experimentally validated.  
 
The REMAP method and its variants can be further improved for its scalability. As shown 
in Chapter 2, current implementation of REMAP is scalable to screen millions of ligands against 
whole human genome. However, the most updated PubChem database alone contains over 96 
million unique ligands [29], and the size of ligand pool can be even greater if stereochemistry is 
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fully considered. The number of potential protein targets can also be larger if all known mutants 
are regarded as separate, unique entities. Moreover, it is an active area of research to understand 
disease phenotypes as a result of host-microbiome molecular interactions [340, 341], which will 
expand the number of unique protein targets to model. With current level of scalability, however, 
it is limited to screening millions of ligands against whole human genome. Moreover, WINTF, a 
tri-factorization extension of REMAP, is not as scalable as REMAP, implying that it cannot be 
applied to projects at similar scales. The sizes of floating-point-valued matrices in such projects 
are often beyond the capability of many modern computing machines. The scalability can be 
partially addressed by using higher performing machines or by improving the update rules. 
Distributed matrix factorization [270] and simultaneous perturbation stochastic approximation 
[271, 272] can improve the algorithmic scalability and potentially find global optimum solution. 
Network-based predictive methods for drug activities need to integrate the interactions 
between human and microbiome, which is known to have multidimensional effects on human 
health. Human-microbiome interactions via proteins, small molecules, nucleic acids and 
metabolites can intervene the biological pathways to exert beneficial or harmful effects, where the 
microbiome can mimic host interactions at sequence, motif, and structural levels [341]. Thus, 
computational models that do not consider human-microbiome interactions cannot fully reveal the 
potential drug activities in the human biological network. Integration of such interaction network 
with protein-ligand-biological pathway-side effect (or disease) associations necessarily form a 
large-scale multilayer network, which is not trivial to deal with traditional methods. The proteins 
in microbiome may not be well understood in terms of their structures and functions, which 
increases the difficulty to accurately model the interaction network. FASCINATE method that is 
introduced in Chapter 5 may be utilized to mine from such a multilayer network. Homology 
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modeling and molecular dynamics simulation methods may enhance the structural and functional 
coverage of the microbiome for better computational modeling. 
To develop better predictive models for biomolecular interactions, it is necessary to refine 
the representations for protein molecules. As discussed earlier in Chapter 1 and Chapter 6, the 
existing molecular descriptors for proteins rely on the static properties of amino acids without 
considering positional dependencies. Proteins are three-dimensional complexes consisting of 
amino acids, whose detailed physicochemical properties dynamically changes upon the changes 
of the environment. An amino acid exposed to the solvent or located near binding pockets may 
have significantly different functions compared to the ones that are buried in the complex. A single 
amino acid mutation in proteins may alter the properties of the binding or active sites either by 
directly modifying the sites or through interactions with neighboring residues that are distant from 
the sites but eventually affect the sites in three-dimensional space. These properties cannot be 
captured by conventional protein descriptors. A position-dependent feature extraction method, 
such as ALBERT-based protein representation introduced in Chapter 6 is necessary to efficiently 
model the activities of proteins from sequences. A similar idea to the molecular dynamics 
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